

Histone deacetylase inhibitors and the promise of epigenetic cancer

Nature Reviews Cancer

6, 38-51

DOI: [10.1038/nrc1779](https://doi.org/10.1038/nrc1779)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Histone deacetylase inhibitors: Apoptotic effects and clinical implications (Review). International Journal of Oncology, 1992, 33, 637.	1.4	36
2	Inhibition of Histone Deacetylases. , 2004, 287, 087-098.		4
3	Emerging Therapies for Multiple Myeloma. American Journal of Cancer, 2006, 5, 141-153.	0.4	2
4	Small-Molecule Inhibitors of Histone Acetyltransferase Activity:Â Identification and Biological Properties. Journal of Medicinal Chemistry, 2006, 49, 6897-6907.	2.9	134
5	Histone Deacetylase Inhibitors in Cancer Therapy. Cancer Investigation, 2006, 24, 521-527.	0.6	44
6	Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Molecular Cancer, 2006, 5, 40.	7.9	40
7	Epigenetic aberrations and cancer. Molecular Cancer, 2006, 5, 60.	7.9	144
8	Contribution of CYP2C9, CYP2A6, and CYP2B6 to Valproic Acid Metabolism in Hepatic Microsomes from Individuals with the CYP2C9*1/*1 Genotype. Toxicological Sciences, 2006, 94, 261-271.	1.4	128
9	Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Letters, 2006, 580, 4353-4356.	1.3	209
10	Selective transcription and cellular proliferation induced by PDGF require histone deacetylase activity. Biochemical and Biophysical Research Communications, 2006, 343, 544-554.	1.0	16
11	Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone. Biochemical and Biophysical Research Communications, 2006, 348, 1429-1435.	1.0	73
12	Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends in Molecular Medicine, 2006, 12, 382-393.	3.5	123
13	Epigenetics of lung cancer. Respirology, 2006, 11, 355-365.	1.3	52
14	Mutational analyses of WNT7A and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumours. Clinical Endocrinology, 2006, 66, 061031010617001-???.	1.2	13
15	New approaches to molecular cancer therapeutics. Nature Chemical Biology, 2006, 2, 689-700.	3.9	361
16	HIF1Î± and ARD1: enemies, friends or neither?. Nature Reviews Cancer, 2006, 6, 250-250.	12.8	1
17	Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery, 2006, 5, 769-784.	21.5	2,578
18	Exploring alternative Zn-binding groups in the design of HDAC inhibitors: Squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4784-4787.	1.0	25

#	ARTICLE	IF	CITATIONS
19	Synthesis of rigid trichostatin A analogs as HDAC inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5339-5344.	1.0	19
20	HC-toxin. <i>Phytochemistry</i> , 2006, 67, 1406-1413.	1.4	186
21	Pharmacological Inhibition of Histone Deacetylases by Suberoylanilide Hydroxamic Acid Specifically Alters Gene Expression and Reduces Ischemic Injury in the Mouse Brain. <i>Molecular Pharmacology</i> , 2006, 70, 1876-1884.	1.0	231
22	AML1/Runx1 as a Versatile Regulator of Hematopoiesis: Regulation of Its Function and a Role in Adult Hematopoiesis. <i>International Journal of Hematology</i> , 2006, 84, 136-142.	0.7	33
23	A series of novel, potent, and selective histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5948-5952.	1.0	68
24	Gene expression regulation and cancer. <i>Clinical and Translational Oncology</i> , 2006, 8, 780-787.	1.2	24
25	The Myc oncoprotein as a therapeutic target for human cancer. <i>Seminars in Cancer Biology</i> , 2006, 16, 318-330.	4.3	486
26	Thioredoxin in cancer—Role of histone deacetylase inhibitors. <i>Seminars in Cancer Biology</i> , 2006, 16, 436-443.	4.3	64
27	Tip60 in DNA damage response and growth control: many tricks in one HAT. <i>Trends in Cell Biology</i> , 2006, 16, 433-442.	3.6	264
28	ARDent about acetylation and deacetylation in hypoxia signalling. <i>Trends in Cell Biology</i> , 2006, 16, 616-621.	3.6	33
29	The Potential of Histone Deacetylase Inhibitors in Lung Cancer. <i>Clinical Lung Cancer</i> , 2006, 7, 309-312.	1.1	6
30	Inhibition of histone deacetylase as a new mechanism of teratogenesis. <i>Birth Defects Research Part C: Embryo Today Reviews</i> , 2006, 78, 345-353.	3.6	71
31	Total Synthesis of Azumamides A and E. <i>Angewandte Chemie - International Edition</i> , 2006, 45, 7557-7560.	7.2	39
32	Azumamides A–E: Histone Deacetylase Inhibitory Cyclic Tetrapeptides from the Marine Sponge <i>Mycale izuensis</i> . <i>Angewandte Chemie - International Edition</i> , 2006, 45, 7553-7557.	7.2	105
33	Structure-Based Organic Synthesis of Drug Prototypes: A Personal Odyssey. <i>ChemMedChem</i> , 2006, 1, 1300-1330.	1.6	42
36	Effects of Histone Deacetylase Inhibitors on HIF-1. <i>Cell Cycle</i> , 2006, 5, 2430-2435.	1.3	80
38	Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis. <i>Epigenetics</i> , 2006, 1, 67-75.	1.3	94
39	Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells. <i>Clinical Cancer Research</i> , 2006, 12, 5869-5878.	3.2	98

#	ARTICLE	IF	CITATIONS
40	SIRT1: Linking Adaptive Cellular Responses to Aging-Associated Changes in Organismal Physiology. <i>Physiology</i> , 2006, 21, 404-410.	1.6	78
41	Epigenetic Regulation of Tumor Endothelial Cell Anergy: Silencing of Intercellular Adhesion Molecule-1 by Histone Modifications. <i>Cancer Research</i> , 2006, 66, 10770-10777.	0.4	139
42	Histone Deacetylase Inhibitors Repress the Transactivation Potential of Hypoxia-inducible Factors Independently of Direct Acetylation of HIF-1 α . <i>Journal of Biological Chemistry</i> , 2006, 281, 13612-13619.	1.6	103
43	A Novel Signal Transduction Cascade Involving Direct Physical Interaction of the Renin/Prorenin Receptor With the Transcription Factor Promyelocytic Zinc Finger Protein. <i>Circulation Research</i> , 2006, 99, 1355-1366.	2.0	287
44	Histone acetylation in gene regulation. <i>Briefings in Functional Genomics & Proteomics</i> , 2006, 5, 209-221.	3.8	190
45	Antitumor Effects of a Novel Phenylbutyrate-Based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 5199-5206.	3.2	93
46	A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 7039-7045.	3.2	108
47	The Histone Deacetylase Inhibitor Trichostatin A Has Genotoxic Effects in Human Lymphoblasts In Vitro. <i>Toxicological Sciences</i> , 2006, 93, 341-347.	1.4	47
48	Histone Deacetylase Inhibitors Suppress the Inducibility of Nuclear Factor- κ B by Tumor Necrosis Factor- α Receptor-1 Down-regulation. <i>Cancer Research</i> , 2006, 66, 5409-5418.	0.4	96
49	Oxidative Stress as a Mechanism of Valproic Acid-Associated Hepatotoxicity. <i>Drug Metabolism Reviews</i> , 2006, 38, 627-639.	1.5	126
50	Challenges of Evaluating the Cardiac Effects of Anticancer Agents. <i>Clinical Cancer Research</i> , 2006, 12, 3871-3874.	3.2	49
51	Histone Deacetylase 2 Modulates p53 Transcriptional Activities through Regulation of p53-DNA Binding Activity. <i>Cancer Research</i> , 2007, 67, 3145-3152.	0.4	132
52	Myc Goes Global: New Tricks for an Old Oncogene: Figure 1.. <i>Cancer Research</i> , 2007, 67, 5061-5063.	0.4	113
53	Elicitation of T Cell Responses to Histologically Unrelated Tumors by Immunization with the Novel Cancer-Testis Antigen, Brother of the Regulator of Imprinted Sites. <i>Journal of Immunology</i> , 2007, 178, 566-573.	0.4	28
54	Histone Deacetylase Inhibitors Suppress TF- κ B-dependent Agonist-driven Tissue Factor Expression in Endothelial Cells and Monocytes. <i>Journal of Biological Chemistry</i> , 2007, 282, 28408-28418.	1.6	64
55	p300 Protein Acetyltransferase Activity Suppresses Systemic Lupus Erythematosus-Like Autoimmune Disease in Mice. <i>Journal of Immunology</i> , 2007, 178, 6941-6948.	0.4	44
56	Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. <i>Genes and Development</i> , 2007, 21, 1790-1802.	2.7	619
57	Valproic Acid Induces Neuroendocrine Differentiation and UGT2B7 Up-Regulation in Human Prostate Carcinoma Cell Line. <i>Drug Metabolism and Disposition</i> , 2007, 35, 968-972.	1.7	40

#	ARTICLE	IF	CITATIONS
58	Activity-based probes for proteomic profiling of histone deacetylase complexes. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1171-1176.	3.3	239
59	Novel small-molecule therapy of Hodgkin lymphoma. Expert Review of Anticancer Therapy, 2007, 7, 735-740.	1.1	11
60	Epigenetic Targeting in Acute Myeloid Leukemia: Use of Flow Cytometry in Monitoring Therapeutic Effects. Current Pharmaceutical Biotechnology, 2007, 8, 401-411.	0.9	7
61	Relationship between Embryonic Histone Hyperacetylation and Axial Skeletal Defects in Mouse Exposed to the Three HDAC Inhibitors Apicidin, MS-275, and Sodium Butyrate. Toxicological Sciences, 2007, 98, 582-588.	1.4	19
62	Platelet-derived growth factor-BB represses smooth muscle cell marker genes via changes in binding of MKL factors and histone deacetylases to their promoters. American Journal of Physiology - Cell Physiology, 2007, 292, C886-C895.	2.1	101
63	Cancer Control by Phytochemicals. Current Pharmaceutical Design, 2007, 13, 3394-3399.	0.9	61
64	Epigenetic Lesions in Malignant Melanoma. Current Pharmaceutical Biotechnology, 2007, 8, 382-387.	0.9	30
65	Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells. Endocrine-Related Cancer, 2007, 14, 1021-1028.	1.6	35
66	Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Molecular Cancer Therapeutics, 2007, 6, 1425-1432.	1.9	76
67	Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Human Reproduction, 2007, 22, 2956-2966.	0.4	52
68	Histone Deacetylase Inhibitors Regulate Retinoic Acid Receptor β Expression in Neuroblastoma Cells by Both Transcriptional and Posttranscriptional Mechanisms. Molecular Endocrinology, 2007, 21, 2416-2426.	3.7	24
69	Histone Deacetylase Inhibitors Stimulate Cell Migration in Human Endometrial Adenocarcinoma Cells through Up-Regulation of Glycodelin. Endocrinology, 2007, 148, 896-902.	1.4	57
70	Heterochromatin and its Relationship to Cell Senescence and Cancer Therapy. Cell Cycle, 2007, 6, 784-789.	1.3	93
71	Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: Implications for therapy. Cancer Biology and Therapy, 2007, 6, 795-801.	1.5	93
72	Targeted Therapy for Inherited GPI Deficiency. New England Journal of Medicine, 2007, 356, 1641-1647.	13.9	82
73	The Cancer-Aging Interface and the Significance of Telomere Dynamics in Cancer Therapy. Rejuvenation Research, 2007, 10, 387-396.	0.9	10
74	v-Src-mediated Down-regulation of SSeCKS Metastasis Suppressor Gene Promoter by the Recruitment of HDAC1 into a USF1-Sp1-Sp3 Complex. Journal of Biological Chemistry, 2007, 282, 26725-26739.	1.6	37
75	Molecular Mechanisms of Spinal Muscular Atrophy. Journal of Child Neurology, 2007, 22, 979-989.	0.7	72

#	ARTICLE	IF	CITATIONS
76	Reduced Body Size and Decreased Intestinal Tumor Rates in HDAC2-Mutant Mice. <i>Cancer Research</i> , 2007, 67, 9047-9054.	0.4	121
77	Inhibition of Histone Deacetylation Does Not Block Resilencing of p16 after 5-Aza-2-Deoxycytidine Treatment. <i>Cancer Research</i> , 2007, 67, 346-353.	0.4	62
78	The Identification of (ETV6)/RUNX1-Regulated Genes in Lymphopoiesis Using Histone Deacetylase Inhibitors in ETV6/RUNX1-Positive Lymphoid Leukemic Cells. <i>Clinical Cancer Research</i> , 2007, 13, 1726-1735.	3.2	19
79	Targeted Disruption of Kaposi's Sarcoma-Associated Herpesvirus ORF57 in the Viral Genome Is Detrimental for the Expression of ORF59, K81, and K8.1 and the Production of Infectious Virus. <i>Journal of Virology</i> , 2007, 81, 1062-1071.	1.5	76
80	Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 70-81.	1.9	74
81	Chromatin-Associated Regulation Of Hiv-1 Transcription. <i>Sub-Cellular Biochemistry</i> , 2007, , 375-398.	1.0	11
82	Identification of Two New Synthetic Histone Deacetylase Inhibitors That Modulate Globin Gene Expression in Erythroid Cells from Healthy Donors and Patients with Thalassemia. <i>Molecular Pharmacology</i> , 2007, 72, 1111-1123.	1.0	30
83	A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17777-17782.	3.3	78
84	The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Growth Inhibition and Enhances Gemcitabine-Induced Cell Death in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 18-26.	3.2	103
85	Immunocell-array for Molecular Dissection of Multiple Signaling Pathways in Mammalian Cells. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 939-947.	2.5	4
86	Epigenetic Silencing of the Candidate Tumor Suppressor Gene Per1 in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1399-1404.	3.2	120
87	Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications. <i>Clinical Cancer Research</i> , 2007, 13, 7237-7242.	3.2	100
88	Histone Deacetylase Inhibitors Affect Dendritic Cell Differentiation and Immunogenicity. <i>Clinical Cancer Research</i> , 2007, 13, 3933-3941.	3.2	144
89	Synergistic <i>in vivo</i> Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 4538-4546.	3.2	82
90	Histone deacetylase inhibitors selectively suppress expression of HDAC7. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2525-2534.	1.9	93
91	Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. <i>Haematologica</i> , 2007, 92, 1615-1622.	1.7	39
92	Diallyl disulfide accelerates adipogenesis in 3T3-L1 cells. <i>International Journal of Molecular Medicine</i> , 2007, 20, 59.	1.8	15
93	An active site tyrosine residue is essential for amidohydrolase but not for esterase activity of a class 2 histone deacetylase-like bacterial enzyme. <i>Biochemical Journal</i> , 2007, 401, 659-665.	1.7	20

#	ARTICLE	IF	CITATIONS
94	Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. <i>Blood</i> , 2007, 109, 1123-1130.	0.6	233
95	Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. <i>Blood</i> , 2007, 109, 4432-4440.	0.6	82
96	Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. <i>Oncology Reports</i> , 0, , .	1.2	8
97	The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. <i>International Journal of Oncology</i> , 0, , .	1.4	13
98	Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 30-39.	1.0	46
99	Utilization of Chromatin Remodeling Agents for Lung Cancer Therapy. <i>Cancer Journal (Sudbury, Mass)</i> Tj ETQq1 1 0,784314 rgBT /Over	1.0	10
100	HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit. <i>Topics in Medicinal Chemistry</i> , 2007, , 293-331.	0.4	9
101	Mechanisms of human β -globin transcriptional induction by apicidin involves p38 signaling to chromatin. <i>Biochemical and Biophysical Research Communications</i> , 2007, 363, 889-894.	1.0	17
102	The Epigenomics of Cancer. <i>Cell</i> , 2007, 128, 683-692.	13.5	4,039
103	Transcription factors in hematopoietic malignancies. <i>Current Opinion in Genetics and Development</i> , 2007, 17, 78-83.	1.5	9
104	MS-275, a potent orally available inhibitor of histone deacetylasesâ€”The development of an anticancer agent. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1388-1405.	1.2	134
105	HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1500-1509.	1.2	44
106	The new frontier in cancer research: Deciphering cancer epigenetics. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1450-1461.	1.2	17
107	Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1510-1522.	1.2	13
108	2-Aroylindoles and 2-Aroylbenzofurans with N-Hydroxyacrylamide Substructures as a Novel Series of Rationally Designed Histone Deacetylase Inhibitorsâ€”. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 4405-4418.	2.9	56
109	Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. <i>FEBS Letters</i> , 2007, 581, 1317-1322.	1.3	96
110	Bispyridinium Dienes:Â Histone Deacetylase Inhibitors with Selective Activities. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 2497-2505.	2.9	48
111	Histone Deacetylase Inhibitors: Overview and Perspectives. <i>Molecular Cancer Research</i> , 2007, 5, 981-989.	1.5	1,025

#	ARTICLE	IF	CITATIONS
115	Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype. This article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products.. Canadian Journal of Physiology and Pharmacology, 2007, 85, 848-855.	0.7	13
116	Depsipeptide (FK228) Preferentially Induces Apoptosis in BCR/ABL-Expressing Cell Lines and Cells from Patients with Chronic Myelogenous Leukemia in Blast Crisis. Stem Cells and Development, 2007, 16, 503-514.	1.1	33
117	Drug Insight: role of the androgen receptor in the development and progression of prostate cancer. Nature Clinical Practice Oncology, 2007, 4, 236-244.	4.3	185
118	Molecular Insights into Azumamide E Histone Deacetylases Inhibitory Activity. Journal of the American Chemical Society, 2007, 129, 3007-3012.	6.6	89
119	Structure-Activity Relationship Studies of a Series of Novel β -Lactam-Based Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 2737-2741.	2.9	29
120	FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. Oncologist, 2007, 12, 1247-1252.	1.9	1,142
121	Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8071-8076.	3.3	195
122	The role of histone deacetylases (HDACs) in human cancer. Molecular Oncology, 2007, 1, 19-25.	2.1	796
123	The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Molecular Cancer, 2007, 6, 24.	7.9	663
124	Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Biochemistry and Cell Biology, 2007, 85, 751-758.	0.9	97
125	Pharmacodynamic markers for histone deacetylase inhibitor development. Drug Discovery Today Disease Mechanisms, 2007, 4, 277-283.	0.8	9
126	Structural Basis for the Inhibition of the LSD1 Histone Demethylase by the Antidepressant trans-2-Phenylcyclopropylamine,. Biochemistry, 2007, 46, 8058-8065.	1.2	213
127	Enzyme Inhibitors from Marine Invertebrates. Journal of Natural Products, 2007, 70, 689-710.	1.5	82
128	Chromatin Structure Regulation in Transforming Growth Factor- β -Directed Epithelial-Mesenchymal Transition. Cells Tissues Organs, 2007, 185, 162-174.	1.3	24
129	Development of histone deacetylase inhibitors for cancer treatment. Expert Review of Anticancer Therapy, 2007, 7, 583-598.	1.1	141
130	Chapter 21 Recent Advances in the Medicinal Chemistry of Histone Deacetylase Inhibitors. Annual Reports in Medicinal Chemistry, 2007, , 337-348.	0.5	12
131	Histone deacetylase inhibitor <i>Helminthosporium carbonum</i> (HC) toxin suppresses the malignant phenotype of neuroblastoma cells. International Journal of Cancer, 2008, 122, 1891-1900.	2.3	38
132	Expression of cyclin D3 through Sp1 sites by histone deacetylase inhibitors is mediated with protein kinase C- β (PKC- β) signal pathway. Journal of Cellular Biochemistry, 2007, 101, 987-995.	1.2	20

#	ARTICLE	IF	CITATIONS
133	Histone deacetylases in control of skeletogenesis. <i>Journal of Cellular Biochemistry</i> , 2007, 102, 332-340.	1.2	28
134	Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. <i>Hepatology</i> , 2007, 46, 1119-1130.	3.6	84
135	Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. <i>Cancer</i> , 2007, 109, 2132-2141.	2.0	97
136	Microsporins A and B: new histone deacetylase inhibitors from the marine-derived fungus <i>Microsporium cf. gypseum</i> and the solid-phase synthesis of microsporin A. <i>Tetrahedron</i> , 2007, 63, 6535-6541.	1.0	71
137	Cyclic disulfides as functional mimics of the histone deacetylase inhibitor FK-228. <i>Tetrahedron Letters</i> , 2007, 48, 4579-4583.	0.7	9
138	Design of novel histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4619-4624.	1.0	46
139	Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4819-4823.	1.0	33
140	γ-Alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: A study of chain-length and stereochemical dependence. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6261-6265.	1.0	29
141	Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6142-6146.	1.0	15
142	N-(2-Amino-phenyl)-4-(heteroarylmethyl)-benzamides as new histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6729-6733.	1.0	17
143	Parthenolide Specifically Depletes Histone Deacetylase 1 Protein and Induces Cell Death through Ataxia Telangiectasia Mutated. <i>Chemistry and Biology</i> , 2007, 14, 813-823.	6.2	100
144	Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer. <i>Analytical Biochemistry</i> , 2007, 362, 136-141.	1.1	29
145	Trithiocarbonates—Exploration of a new head group for HDAC inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4746-4752.	1.0	32
146	HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo. <i>Genetic Vaccines and Therapy</i> , 2007, 5, 10.	1.5	20
147	Discovery and development of SAHA as an anticancer agent. <i>Oncogene</i> , 2007, 26, 1351-1356.	2.6	565
148	HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. <i>Oncogene</i> , 2007, 26, 5310-5318.	2.6	845
149	Histone deacetylase inhibitors: molecular mechanisms of action. <i>Oncogene</i> , 2007, 26, 5541-5552.	2.6	1,379
150	Epigenetic regulation of normal and malignant hematopoiesis. <i>Oncogene</i> , 2007, 26, 6697-6714.	2.6	127

#	ARTICLE	IF	CITATIONS
151	Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. <i>Nature Biotechnology</i> , 2007, 25, 84-90.	9.4	1,097
152	Protein arginine-methyltransferase-dependent oncogenesis. <i>Nature Cell Biology</i> , 2007, 9, 1208-1215.	4.6	270
153	Deacetylase inhibition promotes the generation and function of regulatory T cells. <i>Nature Medicine</i> , 2007, 13, 1299-1307.	15.2	835
154	Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 373-390.	21.5	635
155	Cellular senescence: when bad things happen to good cells. <i>Nature Reviews Molecular Cell Biology</i> , 2007, 8, 729-740.	16.1	3,502
156	HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. <i>Cell Research</i> , 2007, 17, 195-211.	5.7	481
157	Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?. <i>Leukemia</i> , 2007, 21, 61-65.	3.3	96
158	A redundant oncogenic potential of the retinoic receptor (RAR) $\hat{1}\pm$, $\hat{1}^2$ and $\hat{1}^3$ isoforms in acute promyelocytic leukemia. <i>Leukemia</i> , 2007, 21, 647-650.	3.3	22
159	Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. <i>Leukemia</i> , 2007, 21, 1773-1782.	3.3	114
160	Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. <i>Leukemia</i> , 2007, 21, 2344-2353.	3.3	40
161	Histone modifications as markers of cancer prognosis: a cellular view. <i>British Journal of Cancer</i> , 2007, 97, 1-5.	2.9	138
162	Epigenetic events in malignant melanoma. <i>Pigment Cell & Melanoma Research</i> , 2007, 20, 92-111.	4.0	77
163	Epigenetic changes in cancer. <i>Apmis</i> , 2007, 115, 1039-1059.	0.9	320
164	Chromatinâ€modifying proteins in cancer. <i>Apmis</i> , 2007, 115, 1060-1089.	0.9	33
165	Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors. <i>BMC Genomics</i> , 2007, 8, 362.	1.2	57
166	Dual targeting of epigenetic therapy in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2007, 1775, 76-91.	3.3	85
167	HDAC inhibitors: Clinical update and mechanism-based potential. <i>Biochemical Pharmacology</i> , 2007, 74, 659-671.	2.0	339
168	Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. <i>Gynecologic Oncology</i> , 2007, 107, 143-153.	0.6	51

#	ARTICLE	IF	CITATIONS
169	Impact of protein acetylation in inflammatory lung diseases. , 2007, 116, 249-265.		68
170	Effect of the Histone Deacetylase Inhibitor Trichostatin A in Human Peripheral Blood Lymphocytes as a Function of Donor Age. Annals of the New York Academy of Sciences, 2007, 1119, 64-71.	1.8	2
171	Transcription Factors as Therapeutic Targets in Lymphoid Malignancies. International Reviews of Immunology, 2007, 26, 305-332.	1.5	3
172	Histone deacetylasesâ€”an important class of cellular regulators with a variety of functions. Applied Microbiology and Biotechnology, 2007, 75, 487-497.	1.7	168
173	Histone deacetylase inhibitorsâ€”turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Applied Microbiology and Biotechnology, 2007, 75, 499-514.	1.7	49
174	Towards a new age in the treatment of multiple myeloma. Annals of Hematology, 2007, 86, 159-172.	0.8	31
175	Valproic acid induces p21 and topoisomerase-II ($\hat{1}\pm/\hat{1}^2$) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. Journal of Neuro-Oncology, 2007, 85, 159-170.	1.4	100
176	Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2007, 134, 83-91.	1.2	73
177	Investigation of the Drugâ€”Drug Interaction Between $\hat{1}\pm$ -Lipoic Acid and Valproate via Mitochondrial $\hat{1}^2$ -oxidation. Pharmaceutical Research, 2008, 25, 2639-2649.	1.7	6
178	Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. Journal of Neuro-Oncology, 2008, 86, 23-30.	1.4	12
179	Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemotherapy and Pharmacology, 2008, 61, 791-802.	1.1	39
180	PLZF and the (pro)renin receptor. Journal of Molecular Medicine, 2008, 86, 623-627.	1.7	29
181	Breast cancer epigenetics: normal human mammary epithelial cells as a model system. Journal of Molecular Medicine, 2008, 86, 1315-1328.	1.7	77
182	Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clinical and Translational Oncology, 2008, 10, 395-398.	1.2	99
183	Prevention of murine experimental corneal trauma by epigenetic events regulating claudin 6 and claudin 9. Japanese Journal of Ophthalmology, 2008, 52, 195-203.	0.9	9
184	Neuroendocrine transdifferentiation induced by VPA is mediated by PPAR $\hat{1}^3$ activation and confers resistance to antitlastic therapy in prostate carcinoma. Prostate, 2008, 68, 588-598.	1.2	10
185	SAHA induces caspaseâ€”independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. Journal of Pathology, 2008, 216, 495-504.	2.1	90
186	HDAC3 overexpression and colon cancer cell proliferation and differentiation. Molecular Carcinogenesis, 2008, 47, 137-147.	1.3	108

#	ARTICLE	IF	CITATIONS
187	Identification, Synthesis, and Enzymology of Non-natural Glucosinolate Chemopreventive Candidates. <i>ChemBioChem</i> , 2008, 9, 729-747.	1.3	55
188	Synthesis of Benzamides Related to Anacardic Acid and Their Histone Acetyltransferase (HAT) Inhibitory Activities. <i>ChemMedChem</i> , 2008, 3, 1435-1442.	1.6	52
189	Novel 2-step synthetic indole compound 1,1,3-tri(3-indolyl)cyclohexane inhibits cancer cell growth in lung cancer cells and xenograft models. <i>Cancer</i> , 2008, 113, 815-825.	2.0	28
190	Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors. <i>International Journal of Cancer</i> , 2008, 122, 333-341.	2.3	98
191	Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. <i>International Journal of Cancer</i> , 2008, 122, 1400-1410.	2.3	76
192	Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. <i>International Journal of Cancer</i> , 2008, 123, 2774-2781.	2.3	60
193	Chromatin organization and nuclear microenvironments in cancer cells. <i>Journal of Cellular Biochemistry</i> , 2008, 104, 2004-2015.	1.2	51
194	Relationship between the induction of leukemia cell differentiation and the enhancement of reporter gene expression in 3T3 Swiss cells. <i>Leukemia Research</i> , 2008, 32, 89-96.	0.4	4
195	Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor κ B. <i>Leukemia Research</i> , 2008, 32, 287-296.	0.4	49
196	Potential of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. <i>Leukemia Research</i> , 2008, 32, 771-780.	0.4	56
197	MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. <i>Leukemia Research</i> , 2008, 32, 1382-1392.	0.4	78
198	Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7992-8002.	1.4	11
199	Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1067-1071.	1.0	32
200	4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1502-1506.	1.0	14
201	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1893-1897.	1.0	33
202	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1814-1819.	1.0	91
203	2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3456-3461.	1.0	61
204	Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: A cyclic tetrapeptide scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2549-2554.	1.0	21

#	ARTICLE	IF	CITATIONS
205	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: Histone deacetylase inhibition and in-cell activities. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2530-2535.	1.0	22
206	Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2788-2792.	1.0	96
207	Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5071-5074.	1.0	27
208	Optimization of a series of potent and selective ketone histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5528-5532.	1.0	12
209	Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6078-6082.	1.0	25
210	A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression. <i>Analytical Biochemistry</i> , 2008, 375, 237-248.	1.1	35
211	Development of a fluorescence polarization based assay for histone deacetylase ligand discovery. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2809-2812.	1.0	34
212	2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6083-6087.	1.0	48
213	In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. <i>International Journal of Pharmaceutics</i> , 2008, 361, 19-25.	2.6	72
214	Histone Deacetylase Inhibitors through Click Chemistry. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7417-7427.	2.9	80
215	Cancer Epigenetics: Modifications, Screening, and Therapy. <i>Annual Review of Medicine</i> , 2008, 59, 267-280.	5.0	241
216	MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2008, 7, 759-768.	1.9	303
217	Epigenetic Regulation of Vascular Endothelial Gene Expression. <i>Circulation Research</i> , 2008, 102, 873-887.	2.0	194
218	Hypermethylation of <i>CXCR4</i> Promoter in CD34+ Cells from Patients with Primary Myelofibrosis. <i>Stem Cells</i> , 2008, 26, 1920-1930.	1.4	91
219	Histone deacetylase inhibitors and a functional potent inhibitory effect on human uterine contractility. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 167.e1-167.e7.	0.7	32
220	Epigenetic Changes in Cancer as Potential Targets for Prophylaxis and Maintenance Therapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 389-396.	1.2	26
221	Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming. <i>Leukemia</i> , 2008, 22, 1503-1518.	3.3	55
222	C/EBP β , do not forget your TIP60. <i>Leukemia</i> , 2008, 22, 676-677.	3.3	2

#	ARTICLE	IF	CITATIONS
223	Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. <i>Leukemia</i> , 2008, 22, 2159-2168.	3.3	84
224	Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. <i>Oncogene</i> , 2008, 27, 1767-1778.	2.6	44
225	Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells. <i>Oncogene</i> , 2008, 27, 3134-3144.	2.6	63
226	SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins. <i>Oncogene</i> , 2008, 27, 3384-3392.	2.6	59
227	Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. <i>British Journal of Cancer</i> , 2008, 98, 604-610.	2.9	429
228	Transcriptional control of human p53-regulated genes. <i>Nature Reviews Molecular Cell Biology</i> , 2008, 9, 402-412.	16.1	1,669
229	Transcriptional Modulation Using HDACi Depsipeptide Promotes Immune Cell-Mediated Tumor Destruction of Murine B16 Melanoma. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1506-1516.	0.3	84
230	Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. <i>Leukemia</i> , 2008, 22, 1449-1452.	3.3	31
231	Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. <i>Cancer Science</i> , 2008, 99, 376-384.	1.7	79
232	Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera. <i>Cancer Science</i> , 2008, 99, 414-422.	1.7	12
233	Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. <i>Cancer Science</i> , 2008, 99, 1218-1226.	1.7	63
234	Epigenetic silencing of the WNT antagonist DICKKOPF-1 in cervical cancer cell lines. <i>Gynecologic Oncology</i> , 2008, 109, 270-274.	0.6	54
235	Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. <i>BMC Cancer</i> , 2008, 8, 381.	1.1	155
236	BM88/Cend1 is involved in histone deacetylase inhibition-mediated growth arrest and differentiation of neuroblastoma cells. <i>FEBS Letters</i> , 2008, 582, 741-748.	1.3	17
237	Effects of trichostatin A on neuronal mu-opioid receptor gene expression. <i>Brain Research</i> , 2008, 1246, 1-10.	1.1	27
238	5 Histone Deacetylase Inhibitors: A Novel Class of Anti-Cancer Agents on its Way to the Market. <i>Progress in Medicinal Chemistry</i> , 2008, 46, 205-280.	4.1	12
239	Epigenomics and breast cancer. <i>Pharmacogenomics</i> , 2008, 9, 1879-1902.	0.6	153
240	Apoptotic Pathways in Tumor Progression and Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2008, 615, 47-79.	0.8	77

#	ARTICLE	IF	CITATIONS
241	Zinc metalloproteins as medicinal targets. <i>Chemical Society Reviews</i> , 2008, 37, 1629.	18.7	144
242	Isoform-selective histone deacetylase inhibitors. <i>Chemical Society Reviews</i> , 2008, 37, 1402.	18.7	295
243	Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?. <i>Arthritis Research and Therapy</i> , 2008, 10, 226.	1.6	73
244	Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. <i>Molecular Cancer</i> , 2008, 7, 55.	7.9	54
245	Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. <i>Molecular Cancer</i> , 2008, 7, 70.	7.9	34
246	Role of epigenetic therapy in myelodysplastic syndrome. <i>Expert Review of Hematology</i> , 2008, 1, 161-174.	1.0	0
247	Assessment of Histone Acetylation Levels in Relation to Cell Cycle Phase. <i>Current Protocols in Cytometry</i> , 2008, 46, Unit 7.35.	3.7	1
248	Epigenetic Multiple Ligands: Mixed Histone/Protein Methyltransferase, Acetyltransferase, and Class III Deacetylase (Sirtuin) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2279-2290.	2.9	133
249	Determination of Protein Lysine Deacetylation. <i>Current Protocols in Protein Science</i> , 2008, 54, Unit 14.12.	2.8	2
252	Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas. <i>Neoplasia</i> , 2008, 10, 1021-1027.	2.3	158
253	TRANSCRIPTION FACTORS AND HUMAN DISEASE. , 2008, , 373-VII.		4
254	Histone deacetylase inhibition reduces myocardial ischemia/reperfusion injury in mice. <i>FASEB Journal</i> , 2008, 22, 3549-3560.	0.2	248
256	A Novel Series of Potent and Selective Ketone Histone Deacetylase Inhibitors with Antitumor Activity in Vivo. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2350-2353.	2.9	56
257	Chromatin-remodelling mechanisms in cancer. <i>Mutation Research - Reviews in Mutation Research</i> , 2008, 658, 191-214.	2.4	72
258	Valproic acid induces polarization, neuronal-like differentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression. <i>Neuroscience</i> , 2008, 156, 911-920.	1.1	24
259	colgate/hdac1 repression of foxd3 expression is required to permit mitfa-dependent melanogenesis. <i>Developmental Biology</i> , 2008, 313, 568-583.	0.9	74
260	A Series of Potent and Selective, Triazolylphenyl-Based Histone Deacetylases Inhibitors with Activity against Pancreatic Cancer Cells and <i>Plasmodium falciparum</i> . <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3437-3448.	2.9	122
261	A new era of cancer therapy: Cancer cell targeted therapies are coming of age. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 1-8.	1.2	13

#	ARTICLE	IF	CITATIONS
262	Histone deacetylase inhibitors and hemoglobin F induction in β^0 -thalassemia. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 2341-2347.	1.2	14
263	Anti-neuroblastoma activity of <i>Helminthosporium carbonum</i> (HC)-toxin is superior to that of other differentiating compounds in vitro. <i>Cancer Letters</i> , 2008, 264, 21-28.	3.2	27
264	Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. <i>Cancer Letters</i> , 2008, 269, 7-17.	3.2	394
265	Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. <i>Experimental Neurology</i> , 2008, 210, 531-542.	2.0	94
266	Application of activity-based probes to the study of enzymes involved in cancer progression. <i>Current Opinion in Genetics and Development</i> , 2008, 18, 97-106.	1.5	74
267	Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. <i>Current Opinion in Pharmacology</i> , 2008, 8, 57-64.	1.7	444
268	Targeting the androgen receptor pathway in prostate cancer. <i>Current Opinion in Pharmacology</i> , 2008, 8, 440-448.	1.7	371
269	Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. <i>Oncogene</i> , 2008, 27, 3405-3413.	2.6	147
271	Histone deacetylase inhibitors from microorganisms: the Astellas experience. , 2008, 66, 335-359.		13
272	Histone deacetylase inhibition in the treatment of heart disease. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 53-67.	1.0	46
273	Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias. <i>Current Medicinal Chemistry</i> , 2008, 15, 1274-1287.	1.2	42
274	Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. <i>Lancet Oncology</i> , The, 2008, 9, 139-148.	5.1	332
275	Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases <i>in vitro</i> and <i>in vivo</i> . <i>Clinical Cancer Research</i> , 2008, 14, 1669-1677.	3.2	334
276	Targeting Pro-Invasive Oncogenes with Short Chain Fatty Acid-Hexosamine Analogues Inhibits the Mobility of Metastatic MDA-MB-231 Breast Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 8135-8147.	2.9	49
277	Pharmacodynamic Assessment of Histone Deacetylase Inhibitors: Infrared Vibrational Spectroscopic Imaging of Protein Acetylation. <i>Analytical Chemistry</i> , 2008, 80, 6390-6396.	3.2	25
278	Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. <i>Biochemical Journal</i> , 2008, 409, 581-589.	1.7	667
279	Discovery of <i>N</i> -(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4072-4075.	2.9	102
280	Total Synthesis and Biological Mode of Action of Largazole: A Potent Class I Histone Deacetylase Inhibitor. <i>Journal of the American Chemical Society</i> , 2008, 130, 11219-11222.	6.6	165

#	ARTICLE	IF	CITATIONS
281	Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase inhibitor genes to trichostatin A and 1 β ,25-dihydroxyvitamin D 3. <i>Nucleic Acids Research</i> , 2008, 36, 121-132.	6.5	62
282	Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin. <i>Clinical Cancer Research</i> , 2008, 14, 188-198.	3.2	119
283	Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells. <i>Clinical Cancer Research</i> , 2008, 14, 6106-6115.	3.2	69
284	Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2008, 8, 37-46.	0.8	156
285	The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2008, 8, 275-284.	0.8	41
286	A work in progress: The clinical development of histone deacetylase inhibitor. <i>Epigenetics</i> , 2008, 3, 164-171.	1.3	79
287	Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 714-726.	4.3	84
288	Upregulation of Annexin A1 Expression by Butyrate in Human Colon Adenocarcinoma Cells: Role of p53, NF- κ B, and p38 Mitogen-Activated Protein Kinase. <i>Molecular and Cellular Biology</i> , 2008, 28, 4665-4674.	1.1	65
289	OSU-HDAC42, a Histone Deacetylase Inhibitor, Blocks Prostate Tumor Progression in the Transgenic Adenocarcinoma of the Mouse Prostate Model. <i>Cancer Research</i> , 2008, 68, 3999-4009.	0.4	52
290	Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 14981-14986.	3.3	161
291	Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8250-8255.	3.3	63
292	Repression of 15-Hydroxyprostaglandin Dehydrogenase Involves Histone Deacetylase 2 and Snail in Colorectal Cancer. <i>Cancer Research</i> , 2008, 68, 9331-9337.	0.4	50
293	Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1007-1012.	1.9	27
294	Histone Hyperacetylation Occurs on Promoters of Lytic Cycle Regulatory Genes in Epstein-Barr Virus-Infected Cell Lines Which Are Refractory to Disruption of Latency by Histone Deacetylase Inhibitors. <i>Journal of Virology</i> , 2008, 82, 4706-4719.	1.5	87
295	Evaluation of the <i>in vitro</i> and <i>in vivo</i> Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma. <i>Clinical Cancer Research</i> , 2008, 14, 3113-3123.	3.2	70
296	Gene microarray analysis of human renal cell carcinoma: The effects of HDAC inhibition and retinoid treatment. <i>Cancer Biology and Therapy</i> , 2008, 7, 1607-1618.	1.5	32
297	Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 740-748.	1.9	47
298	Drosophila Histone Deacetylase-3 Controls Imaginal Disc Size through Suppression of Apoptosis. <i>PLoS Genetics</i> , 2008, 4, e1000009.	1.5	25

#	ARTICLE	IF	CITATIONS
299	The Inhibition of Embryonic Histone Deacetylases as the Possible Mechanism Accounting for Axial Skeletal Malformations Induced by Sodium Salicylate. <i>Toxicological Sciences</i> , 2008, 104, 397-404.	1.4	20
300	HDAC6 Is Required for Epidermal Growth Factor-induced β -Catenin Nuclear Localization. <i>Journal of Biological Chemistry</i> , 2008, 283, 12686-12690.	1.6	150
301	Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors. <i>Current Cancer Drug Targets</i> , 2008, 8, 132-140.	0.8	67
302	TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels. <i>Nucleic Acids Research</i> , 2008, 36, 4067-4078.	6.5	33
303	KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1054-1065.	1.9	38
304	Statins Increase p21 through Inhibition of Histone Deacetylase Activity and Release of Promoter-Associated HDAC1/2. <i>Cancer Research</i> , 2008, 68, 2375-2383.	0.4	182
305	Androgen receptor: role and novel therapeutic prospects in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1495-1508.	1.1	58
306	Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. <i>Journal of Experimental Medicine</i> , 2008, 205, 1491-1503.	4.2	175
307	Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity. <i>Journal of Biological Chemistry</i> , 2008, 283, 11355-11363.	1.6	239
308	Histone Deacetylase Inhibitors Modify Pancreatic Cell Fate Determination and Amplify Endocrine Progenitors. <i>Molecular and Cellular Biology</i> , 2008, 28, 6373-6383.	1.1	167
309	A New Preclinical 3-Dimensional Agarose Colony Formation Assay. <i>Technology in Cancer Research and Treatment</i> , 2008, 7, 329-334.	0.8	14
310	Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells. <i>Molecular Cancer Research</i> , 2008, 6, 1908-1919.	1.5	95
311	Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. <i>Neuro-Oncology</i> , 2008, 10, 309-319.	0.6	38
312	Role of Acetylation and Extracellular Location of Heat Shock Protein 90 α in Tumor Cell Invasion. <i>Cancer Research</i> , 2008, 68, 4833-4842.	0.4	213
313	The Epigenetics of Cancer in Children. <i>Klinische Padiatrie</i> , 2008, 220, 333-341.	0.2	17
314	Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects. <i>Molecular Therapy</i> , 2008, 16, 1041-1047.	3.7	74
315	Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1247-1254.	1.9	20
316	Novel Epigenetic Targets in Lymphoproliferative Disorders. <i>Current Cancer Drug Targets</i> , 2008, 8, 378-391.	0.8	4

#	ARTICLE	IF	CITATIONS
317	Targeting important pathways in head and neck cancer: from the bench to the clinic. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1819-1835.	1.1	2
318	Histone deacetylase inhibitors in lymphoma and solid malignancies. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 413-432.	1.1	89
319	The role of histone deacetylases in prostate cancer. <i>Epigenetics</i> , 2008, 3, 300-309.	1.3	130
320	CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. <i>Oncology Reports</i> , 2008, 19, 1517-23.	1.2	16
321	Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. <i>Blood</i> , 2008, 112, 2896-2905.	0.6	80
322	The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph ⁺ acute lymphoblastic leukemia cells. <i>Blood</i> , 2008, 111, 5093-5100.	0.6	134
323	YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model. <i>International Journal of Oncology</i> , 2008, , .	1.4	8
324	Chromatin Remodeling Agents for Cancer Therapy. <i>Reviews on Recent Clinical Trials</i> , 2008, 3, 192-203.	0.4	19
325	Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A. <i>Oncology Reports</i> , 2008, , .	1.2	10
326	Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorogenic assay. <i>Biochemical Journal</i> , 2008, 413, 143-150.	1.7	17
327	Histone Deacetylase Inhibitors: New Hope for Rheumatoid Arthritis?. <i>Current Pharmaceutical Design</i> , 2008, 14, 803-820.	0.9	59
328	Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments. <i>Current Drug Targets</i> , 2008, 9, 851-862.	1.0	76
329	Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?. <i>Current Clinical Pharmacology</i> , 2008, 3, 108-117.	0.2	20
330	Epigenetic drugs in the treatment of skeletal muscle atrophy. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2008, 11, 233-241.	1.3	28
331	HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. <i>Anti-Cancer Drugs</i> , 2008, 19, 849-857.	0.7	24
332	Alternative Modes of Binding of Recombinant Human Histone Deacetylase 8 to Colloidal Gold Nanoparticles. <i>Journal of Biomedical Nanotechnology</i> , 2008, 4, 463-468.	0.5	18
333	Posttranscription Regulation of Prostate Cancer Growth. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 46-53.	1.0	16
335	Histone Deacetylase Inhibitors as Novel Anticancer Therapeutics. <i>Current Oncology</i> , 2008, 15, 237-243.	0.9	84

#	ARTICLE	IF	CITATIONS
336	Cholesterylbutyrate Solid Lipid Nanoparticles as a Butyric Acid Prodrug. <i>Molecules</i> , 2008, 13, 230-254.	1.7	42
337	Full PDF of Hematology Reviews 2009, volume 1, issue 1.. <i>Hematology Reports</i> , 2009, 1, 1.	0.3	0
339	Histone deacetylase inhibitors in multiple myeloma. <i>Hematology Reports</i> , 2009, 1, 9.	0.3	1
340	Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions. <i>PLoS ONE</i> , 2009, 4, e7085.	1.1	18
341	Regenerative medicine and tissue engineering in orthopaedic surgery. <i>Frontiers in Bioscience - Elite</i> , 2009, E3, 923.	0.9	1
343	Pharmacoeigenetic aspects of gene polymorphism on drug therapies: effects of DNA methylation on drug response. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 55-65.	1.3	4
344	Chapter 4 Histone Demethylases and Cancer. <i>Advances in Cancer Research</i> , 2009, 102, 103-169.	1.9	57
345	Epigenetically regulated tumor-associated antigens in melanoma. <i>Expert Review of Dermatology</i> , 2009, 4, 145-154.	0.3	1
346	UNC45A Confers Resistance to Histone Deacetylase Inhibitors and Retinoic Acid. <i>Molecular Cancer Research</i> , 2009, 7, 1861-1870.	1.5	23
347	High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. <i>Clinical Cancer Research</i> , 2009, 15, 4066-4076.	3.2	53
348	Epigenetic Modulation of mGlu2 Receptors by Histone Deacetylase Inhibitors in the Treatment of Inflammatory Pain. <i>Molecular Pharmacology</i> , 2009, 75, 1014-1020.	1.0	173
349	Histone Deacetylase Inhibitors Promote Apoptosis and Senescence in Human Mesenchymal Stem Cells. <i>Stem Cells and Development</i> , 2009, 18, 573-582.	1.1	57
350	Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 501-508.	1.9	45
351	Histone deacetylases facilitate sodium/calcium exchanger up-regulation in adult cardiomyocytes. <i>FASEB Journal</i> , 2009, 23, 3851-3864.	0.2	41
352	Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells. <i>Clinical Cancer Research</i> , 2009, 15, 840-850.	3.2	100
353	New patented histone deacetylase inhibitors. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 1727-1757.	2.4	55
354	p53 Acetylation Is Crucial for Its Transcription-independent Proapoptotic Functions. <i>Journal of Biological Chemistry</i> , 2009, 284, 11171-11183.	1.6	111
355	Histone Deacetylase 8 in Neuroblastoma Tumorigenesis. <i>Clinical Cancer Research</i> , 2009, 15, 91-99.	3.2	335

#	ARTICLE	IF	CITATIONS
356	A phase II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. <i>British Journal of Cancer</i> , 2009, 100, 28-36.	2.9	76
357	HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression. <i>Cancer Research</i> , 2009, 69, 8403-8411.	0.4	60
358	Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia. <i>Journal of Leukocyte Biology</i> , 2009, 85, 563-573.	1.5	11
359	Abrogation of TGF- β 1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 297, L864-L870.	1.3	193
360	Epigenetic control of aquaporin 1 expression by the amyloid precursor protein. <i>FASEB Journal</i> , 2009, 23, 4158-4167.	0.2	48
361	HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. <i>Gut</i> , 2009, 58, 1399-1409.	6.1	139
362	Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma. <i>Clinical Cancer Research</i> , 2009, 15, 2818-2828.	3.2	86
363	Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds. <i>Clinical Cancer Research</i> , 2009, 15, 3690-3696.	3.2	41
364	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2009, 15, 5002-5007.	3.2	103
365	Histone Deacetylase Inhibitor, Trichostatin A, Affects Gene Expression Patterns during Morphogenesis of Chicken Limb Buds in vivo. <i>Cells Tissues Organs</i> , 2009, 190, 121-134.	1.3	9
366	Emerging therapies for B-cell non-Hodgkin lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1305-1316.	1.1	9
367	Animal Models of Epigenetic Inheritance. <i>Seminars in Reproductive Medicine</i> , 2009, 27, 369-379.	0.5	26
368	Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 507-519.	0.9	49
369	Targeting Histone Deacetylases in Neuroblastoma. <i>Current Pharmaceutical Design</i> , 2009, 15, 436-447.	0.9	69
370	Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human Mantle Cell Lymphoma (MCL) cells. <i>Cancer Biology and Therapy</i> , 2009, 8, 1273-1280.	1.5	28
371	Directing cell differentiation with small-molecule histone deacetylase inhibitors: The example of promoting pancreatic endocrine cells. <i>Cell Cycle</i> , 2009, 8, 536-544.	1.3	39
372	Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2844-2851.	1.9	23
373	Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 164-170.	1.8	142

#	ARTICLE	IF	CITATIONS
374	Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate. <i>Xenobiotica</i> , 2009, 39, 722-737.	0.5	8
375	Regulation of Epidermal Growth Factor Receptor Trafficking by Lysine Deacetylase HDAC6. <i>Science Signaling</i> , 2009, 2, ra84.	1.6	140
376	The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells <i>in vitro</i> and <i>in vivo</i> with particular efficacy for small cell lung cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2221-2231.	1.9	106
377	Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway. <i>Clinical Cancer Research</i> , 2009, 15, 2829-2839.	3.2	57
378	Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2718-2725.	1.9	30
379	Chromobox Protein Homologue 7 Protein, with Decreased Expression in Human Carcinomas, Positively Regulates E-Cadherin Expression by Interacting with the Histone Deacetylase 2 Protein. <i>Cancer Research</i> , 2009, 69, 7079-7087.	0.4	72
380	Melding a New 3-Dimensional Agarose Colony Assay with the Emax Model to Determine the Effects of Drug Combinations on Cancer Cells. <i>Technology in Cancer Research and Treatment</i> , 2009, 8, 163-175.	0.8	4
381	CCAAT/enhancer-binding protein β : its role in breast cancer and associations with receptor tyrosine kinases. <i>Expert Reviews in Molecular Medicine</i> , 2009, 11, e12.	1.6	147
382	Bone Morphogenic Protein 2 Activates Protein Kinase D to Regulate Histone Deacetylase 7 Localization and Repression of Runx2. <i>Journal of Biological Chemistry</i> , 2009, 284, 2225-2234.	1.6	61
383	Characterization of the HDAC1 Complex That Regulates the Sensitivity of Cancer Cells to Oxidative Stress. <i>Cancer Research</i> , 2009, 69, 3597-3604.	0.4	54
384	Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 6782-6789.	1.6	252
385	Loss of Histone Deacetylase 4 Causes Segregation Defects during Mitosis of p53-Deficient Human Tumor Cells. <i>Cancer Research</i> , 2009, 69, 6074-6082.	0.4	36
386	Regulation of Renal Epithelial Tight Junctions by the von Hippel-Lindau Tumor Suppressor Gene Involves Occludin and Claudin 1 and Is Independent of E-Cadherin. <i>Molecular Biology of the Cell</i> , 2009, 20, 1089-1101.	0.9	70
387	Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response <i>in vitro</i> and <i>in vivo</i> . <i>Neurobiology of Disease</i> , 2009, 36, 269-279.	2.1	123
388	Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. <i>Oral Oncology</i> , 2009, 45, 610-614.	0.8	99
389	Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines <i>in vitro</i> and <i>in vivo</i> . <i>Oral Oncology</i> , 2009, 45, 766-770.	0.8	13
390	High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer <i>in vitro</i> and <i>in vivo</i> . <i>BMC Cancer</i> , 2009, 9, 395.	1.1	75
391	Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2990-3005.	1.6	17

#	ARTICLE	IF	CITATIONS
392	Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity. <i>DNA Repair</i> , 2009, 8, 1411-1423.	1.3	4
393	Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009, 1793, 1749-1758.	1.9	48
394	Transcriptional activation of hypoxia-inducible factor-1 α by HDAC4 and HDAC5 involves differential recruitment of p300 and FIH-1. <i>FEBS Letters</i> , 2009, 583, 55-60.	1.3	55
395	SAHA treatment overcomes the anti-apoptotic effects of Bcl-2 and is associated with the formation of mature PML nuclear bodies in human leukemic U937 cells. <i>Chemico-Biological Interactions</i> , 2009, 181, 61-70.	1.7	3
396	Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis. <i>Cancer Cell</i> , 2009, 15, 57-66.	7.7	120
401	Total Synthesis of the Bicyclic Depsipeptide HDAC Inhibitors Spiruchostatins A and B, 5 α -Spiruchostatin B, FK228 (FR901228) and Preliminary Evaluation of Their Biological Activity. <i>1.7 Chemistry - A European Journal</i> , 2009, 15, 11174-11186.		61
402	Pyridylalanine-Containing Hydroxamic Acids as Selective HDAC6 Inhibitors. <i>ChemMedChem</i> , 2009, 4, 283-290.	1.6	37
403	Studies of Benzamide- and Thiol-Based Histone Deacetylase Inhibitors in Models of Oxidative-Stress-Induced Neuronal Death: Identification of Some HDAC3-Selective Inhibitors. <i>ChemMedChem</i> , 2009, 4, 842-852.	1.6	45
404	Searching for Disease Modifiers - PKC Activation and HDAC Inhibition - A Dual Drug Approach to Alzheimer's Disease that Decreases A β Production while Blocking Oxidative Stress. <i>ChemMedChem</i> , 2009, 4, 1095-1105.	1.6	42
405	Pyrrrole-Based Hydroxamates and 2-Aminoanilides: Histone Deacetylase Inhibition and Cellular Activities. <i>ChemMedChem</i> , 2009, 4, 1411-1415.	1.6	9
406	Azetidinones as Zinc-Binding Groups to Design Selective HDAC8 Inhibitors. <i>ChemMedChem</i> , 2009, 4, 1991-2001.	1.6	49
407	Probing the Bioactive Conformation of an Archetypal Natural Product HDAC Inhibitor with Conformationally Homogeneous Triazole-Modified Cyclic Tetrapeptides. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 4718-4724.	7.2	141
408	Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 879-889.	1.2	14
409	Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). <i>Investigational New Drugs</i> , 2009, 27, 469-475.	1.2	68
410	Emerging treatment options for spinal muscular atrophy. <i>Current Treatment Options in Neurology</i> , 2009, 11, 90-101.	0.7	28
411	Biological activities of substituted trichostatic acid derivatives. <i>Journal of Chemical Sciences</i> , 2009, 121, 471-479.	0.7	5
412	Microarray study of mechanism of trichostatin a inducing apoptosis of Molt-4 cells. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2009, 29, 445-450.	1.0	6
413	Histone post-translational modifications by HPLC-ESI-MS after HT29 cell treatment with histone deacetylase inhibitors. <i>Proteomics</i> , 2009, 9, 5437-5445.	1.3	25

#	ARTICLE	IF	CITATIONS
414	The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. <i>Journal of Pathology</i> , 2009, 218, 467-477.	2.1	46
415	Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. <i>Cancer Science</i> , 2009, 100, 1728-1734.	1.7	39
416	BubR1 acetylation at prometaphase is required for modulating APC/C activity and timing of mitosis. <i>EMBO Journal</i> , 2009, 28, 2077-2089.	3.5	113
417	Escaping the firing squad: acetylation of BubR1 protects it from degradation in checkpoint cells. <i>EMBO Journal</i> , 2009, 28, 1991-1993.	3.5	7
418	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. <i>EMBO Reports</i> , 2009, 10, 776-782.	2.0	125
419	The use of novel agents in the treatment of relapsed and refractory multiple myeloma. <i>Leukemia</i> , 2009, 23, 2222-2232.	3.3	75
420	HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the β -catenin-TCF interaction. <i>Nature Neuroscience</i> , 2009, 12, 829-838.	7.1	517
421	Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 969-981.	21.5	163
422	HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. <i>Oncogene</i> , 2009, 28, 243-256.	2.6	140
423	Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. <i>Oncogene</i> , 2009, 28, 781-791.	2.6	244
424	HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. <i>Oncogene</i> , 2009, 28, 2370-2382.	2.6	107
425	The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies. <i>Cellular Microbiology</i> , 2009, 11, 889-897.	1.1	25
426	The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy. <i>Journal of Neurochemistry</i> , 2009, 109, 1557-1569.	2.1	28
427	HDAC inhibitors in leukemia: Current status and perspectives. <i>Leukemia Research</i> , 2009, 33, 207-208.	0.4	8
428	Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 4470-4476.	2.6	25
429	Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1168-1172.	1.0	21
430	Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1132-1135.	1.0	63
431	Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1866-1870.	1.0	19

#	ARTICLE	IF	CITATIONS
432	Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3081-3084.	1.0	26
433	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3651-3656.	1.0	19
434	Histone deacetylase inhibitors: Potential in cancer therapy. <i>Journal of Cellular Biochemistry</i> , 2009, 107, 600-608.	1.2	641
435	Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-Phosphate. <i>Science</i> , 2009, 325, 1254-1257.	6.0	850
436	Synthesis and Conformational Activity Relationships of the Peptide Isoesters of FK228 and Largazole. <i>Journal of the American Chemical Society</i> , 2009, 131, 2900-2905.	6.6	107
437	Design, Synthesis, Biological Evaluation, and Structural Characterization of Potent Histone Deacetylase Inhibitors Based on Cyclic β -Tetrapeptide Architectures. <i>Journal of the American Chemical Society</i> , 2009, 131, 3033-3041.	6.6	78
438	The rationale and use of hypomethylation agents in adult acute myeloid leukemia. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 195-205.	2.5	1
439	Minireview: Epigenetic Changes in Ovarian Cancer. <i>Endocrinology</i> , 2009, 150, 4003-4011.	1.4	136
440	New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential. <i>Drug Resistance Updates</i> , 2009, 12, 17-27.	6.5	152
441	Epigenetic therapies in haematological malignancies: Searching for true targets. <i>European Journal of Cancer</i> , 2009, 45, 1137-1145.	1.3	45
442	Zn(II)-dependent histone deacetylase inhibitors: Suberoylanilide hydroxamic acid and trichostatin A. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 736-739.	1.2	104
443	Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 16-20.	1.2	19
444	Epigenomic profiling of cancer cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 127-135.	1.2	42
445	Cancer treatment of the future: Inhibitors of histone methyltransferases. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 4-11.	1.2	84
446	Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 225-234.	1.2	48
447	Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 199-213.	1.2	177
448	Acetylation of non-histone proteins modulates cellular signalling at multiple levels. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 185-198.	1.2	613
449	New pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme- and cell-based investigations. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 235-247.	1.2	24

#	ARTICLE	IF	CITATIONS
450	Histone deacetylase inhibitors: Anticancer compounds. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 21-25.	1.2	81
451	HDAC family: What are the cancer relevant targets?. <i>Cancer Letters</i> , 2009, 277, 8-21.	3.2	893
452	HDAC expression and clinical prognosis in human malignancies. <i>Cancer Letters</i> , 2009, 280, 168-176.	3.2	341
453	Development of vorinostat: Current applications and future perspectives for cancer therapy. <i>Cancer Letters</i> , 2009, 280, 201-210.	3.2	149
454	Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. <i>Cancer Letters</i> , 2009, 280, 134-144.	3.2	98
455	HDACi “ Targets beyond chromatin. <i>Cancer Letters</i> , 2009, 280, 160-167.	3.2	146
456	A novel role for methyl CpG-binding domain protein 3, a component of the histone deacetylase complex, in regulation of cell cycle progression and cell death. <i>Biochemical and Biophysical Research Communications</i> , 2009, 378, 332-337.	1.0	11
457	Inhibition of <i>Plasmodium falciparum</i> proliferation in vitro by double-stranded RNA directed against malaria histone deacetylase. <i>Biochemical and Biophysical Research Communications</i> , 2009, 381, 144-147.	1.0	18
458	Sodium valproate: an old drug with new roles. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 509-514.	4.0	88
459	Evaluation of 6-([¹⁸ F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain. <i>Nuclear Medicine and Biology</i> , 2009, 36, 247-258.	0.3	48
460	Antitumour activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2009, 38, 427.	0.7	0
461	Role of epigenetics in liver-specific gene transcription, hepatocyte differentiation and stem cell reprogramming. <i>Journal of Hepatology</i> , 2009, 51, 187-211.	1.8	66
462	Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. <i>Mutation Research - Reviews in Mutation Research</i> , 2009, 682, 39-53.	2.4	289
463	Identification and Characterization of Small Molecule Inhibitors of a Class I Histone Deacetylase from <i>Plasmodium falciparum</i> . <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2185-2187.	2.9	75
464	Pharmacologic and Chemical Adjuvants in Tumor Virotherapy. <i>Chemical Reviews</i> , 2009, 109, 3125-3140.	23.0	52
465	Endoplasmic Reticulum Stress Response. , 2008, , 981-981.		0
466	Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-R ² , and Histone Deacetylases. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2265-2279.	2.9	83
467	Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. <i>Retrovirology</i> , 2009, 6, 111.	0.9	182

#	ARTICLE	IF	CITATIONS
468	Vorinostat in solid and hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2009, 2, 31.	6.9	152
469	Solid lipid nanoparticles for brain tumors therapy. <i>Progress in Brain Research</i> , 2009, 180, 193-223.	0.9	13
470	Targeting of HDAC8 and investigational inhibitors in neuroblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1605-1617.	1.9	64
471	Snail Transcription Factors. , 2008, , 2770-2772.		0
472	Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors. <i>Natural Product Reports</i> , 2009, 26, 1293.	5.2	63
473	Histone Deacetylase Inhibitors in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 5459-5468.	0.8	793
474	Identification of Novel, Selective, and Stable Inhibitors of Class II Histone Deacetylases. Validation Studies of the Inhibition of the Enzymatic Activity of HDAC4 by Small Molecules as a Novel Approach for Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6782-6789.	2.9	53
476	Discovery of Potent and Selective Histone Deacetylase Inhibitors via Focused Combinatorial Libraries of Cyclic β -Trapeptides. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7836-7846.	2.9	73
477	Acetylation of FoxO1 Activates Bim Expression to Induce Apoptosis in Response to Histone Deacetylase Inhibitor Depsipeptide Treatment. <i>Neoplasia</i> , 2009, 11, 313-IN1.	2.3	102
478	A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. <i>Chemical Communications</i> , 2009, , 6735.	2.2	99
479	Molecular dynamics of histone H1This paper is one of a selection of papers published in this Special Issue, entitled CSBM's 51st Annual Meeting "Epigenetics and Chromatin Dynamics, and has undergone the Journal's usual peer review process.. <i>Biochemistry and Cell Biology</i> , 2009, 87, 189-206.	0.9	51
480	Global Levels of Histone Modifications Predict Prognosis in Different Cancers. <i>American Journal of Pathology</i> , 2009, 174, 1619-1628.	1.9	448
481	Severe Combined Immunodeficiency Disease. , 2008, , 2718-2718.		1
482	A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer. <i>Neoplasia</i> , 2009, 11, 552-IN9.	2.3	50
483	A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways. <i>Anti-Cancer Drugs</i> , 2009, 20, 815-821.	0.7	17
485	Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. <i>International Journal of Molecular Medicine</i> , 2009, 24, 45-50.	1.8	55
486	Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4. <i>International Journal of Oncology</i> , 2009, 36, .	1.4	8
487	MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. <i>International Journal of Oncology</i> , 2009, 35, 631-40.	1.4	7

#	ARTICLE	IF	CITATIONS
488	Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. <i>Blood</i> , 2009, 113, 4038-4048.	0.6	50
489	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. <i>Blood</i> , 2009, 114, 2926-2935.	0.6	152
490	Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. <i>Blood</i> , 2009, 114, 5024-5033.	0.6	165
491	Involvement of P-glycoprotein and Multidrug Resistance Associated Protein 1 on the Transepithelial Transport of a Mercaptoacetamide-Based Histone-Deacetylase Inhibitor in Caco-2 Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2009, 32, 74-78.	0.6	11
492	Tumor Cell Growth Inhibition and Cell Differentiation Analysis in a Canine Mammary Tumor Cell Line (MCM-B2) Treated with Four Chemical Reagents. <i>Journal of Veterinary Medical Science</i> , 2009, 71, 1413-1417.	0.3	9
493	Epigenetics in Human Melanoma. <i>Cancer Control</i> , 2009, 16, 200-218.	0.7	87
494	Induction of E-Cadherin in Lung Cancer and Interaction with Growth Suppression by Histone Deacetylase Inhibition. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1455-1465.	0.5	40
495	Systemic cell-cycle suppression by Apicidin, a histone deacetylase inhibitor, in MDA-MB-435 cells. <i>International Journal of Molecular Medicine</i> , 2009, 24, 205-26.	1.8	9
496	Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise. <i>Current Pharmaceutical Design</i> , 2009, 15, 3940-3957.	0.9	74
497	Histone Deacetylase Inhibitors In Inflammatory Disease. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 309-319.	1.0	177
498	Non-Cancer Uses of Histone Deacetylase Inhibitors: Effects on Infectious Diseases and β-Hemoglobinopathies+. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 272-291.	1.0	44
499	Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas. <i>Current Stem Cell Research and Therapy</i> , 2010, 5, 63-73.	0.6	35
500	Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents. <i>Anti-Cancer Drugs</i> , 2010, 21, 759-765.	0.7	6
501	Histone deacetylase inhibitors in lymphoma. <i>Current Opinion in Oncology</i> , 2010, 22, 431-436.	1.1	37
502	Histone deacetylases govern cellular mechanisms underlying behavioral and synaptic plasticity in the developing and adult brain. <i>Behavioural Pharmacology</i> , 2010, 21, 409-419.	0.8	72
503	Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation. <i>Haematologica</i> , 2010, 95, 1052-1060.	1.7	35
504	NF- κ B balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement. <i>Blood</i> , 2010, 116, 475-484.	0.6	76
505	Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. <i>Blood</i> , 2010, 116, 406-417.	0.6	121

#	ARTICLE	IF	CITATIONS
506	Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: Perspectives for therapeutics. <i>International Journal of Oncology</i> , 2010, 36, 999-1005.	1.4	7
507	Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 3336-3343.	0.7	64
508	Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A. <i>Journal of the American Chemical Society</i> , 2010, 132, 10842-10846.	6.6	625
509	Recent advances in histone deacetylase targeted cancer therapy. <i>Surgery Today</i> , 2010, 40, 809-815.	0.7	43
510	Modified Cap Group Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivatives Reveal Improved Selective Antileukemic Activity. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 3038-3047.	2.9	44
511	Histone Deacetylase Inhibitors Suppress Inflammatory Activation of Rheumatoid Arthritis Patient Synovial Macrophages and Tissue. <i>Journal of Immunology</i> , 2010, 184, 2718-2728.	0.4	208
512	Inhibition of Histone Deacetylase Expands the Renal Progenitor Cell Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 794-802.	3.0	104
513	Identification of type-specific anticancer histone deacetylase inhibitors: road to success. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 625-633.	1.1	41
514	Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1901-1913.	1.2	26
515	Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. <i>Clinical Epigenetics</i> , 2010, 1, 117-136.	1.8	357
516	Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung. <i>Tumor Biology</i> , 2010, 31, 533-539.	0.8	42
517	Histone Deacetylase Inhibitors Suppress the Expression of Inflammatory and Innate Immune Response Genes in Human Microglia and Astrocytes. <i>Journal of NeuroImmune Pharmacology</i> , 2010, 5, 521-532.	2.1	80
518	Large-cell neuroendocrine carcinoma of the ampulla of Vater. <i>Medical Oncology</i> , 2010, 27, 1144-1148.	1.2	9
519	Epigenetic modulation of host: new insights into immune evasion by viruses. <i>Journal of Biosciences</i> , 2010, 35, 647-663.	0.5	39
520	Epigenetic therapy of lymphoma using histone deacetylase inhibitors. <i>Clinical and Translational Oncology</i> , 2010, 12, 401-409.	1.2	33
521	Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer. <i>Molecular and Cellular Biochemistry</i> , 2010, 343, 163-171.	1.4	29
522	Histone deacetylase inhibitors in Hodgkin lymphoma. <i>Investigational New Drugs</i> , 2010, 28, 21-27.	1.2	24
523	The DAC system and associations with multiple myeloma. <i>Investigational New Drugs</i> , 2010, 28, 28-35.	1.2	15

#	ARTICLE	IF	CITATIONS
524	Deacetylase inhibition in myeloproliferative neoplasms. <i>Investigational New Drugs</i> , 2010, 28, 50-57.	1.2	18
525	The DAC system and associations with acute leukemias and myelodysplastic syndromes. <i>Investigational New Drugs</i> , 2010, 28, 36-49.	1.2	11
526	Investigating micronutrients and epigenetic mechanisms in relation to inflammatory bowel disease. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2010, 690, 71-80.	0.4	36
527	Quinazolines as novel anti-inflammatory histone deacetylase inhibitors. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2010, 690, 81-88.	0.4	7
528	VPA-related axial skeletal defects and apoptosis: A proposed event cascade. <i>Reproductive Toxicology</i> , 2010, 29, 106-112.	1.3	16
529	Structural insights into histone lysine demethylation. <i>Current Opinion in Structural Biology</i> , 2010, 20, 739-748.	2.6	163
530	New Molecular Targeted Therapies Integrated With Radiation Therapy in Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 91-97.	1.1	56
531	Ferritin H induction by histone deacetylase inhibitors. <i>Biochemical Pharmacology</i> , 2010, 80, 316-324.	2.0	19
532	Examination of the expanding pathways for the regulation of p21 expression and activity. <i>Cellular Signalling</i> , 2010, 22, 1003-1012.	1.7	355
533	Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 116, 195-201.	0.6	95
534	Epigenetic therapy in myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2010, 84, 463-473.	1.1	38
535	New Anacardic Acid-Inspired Benzamides: Histone Lysine Acetyltransferase Activators. <i>ChemMedChem</i> , 2010, 5, 1530-1540.	1.6	18
536	Synthesis and Biological Characterization of Amidopropenyl Hydroxamates as HDAC Inhibitors. <i>ChemMedChem</i> , 2010, 5, 1359-1372.	1.6	13
537	Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. <i>International Journal of Cancer</i> , 2010, 127, 1332-1346.	2.3	134
538	Histone deacetylase inhibitor-induced sensitization to TNF α /TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression. <i>International Journal of Cancer</i> , 2010, 127, 1384-1392.	2.3	24
539	The Identification of a Novel Natural Activator of p300 Histone Acetyltransferase Provides New Insights into the Modulation Mechanism of this Enzyme. <i>ChemBioChem</i> , 2010, 11, 818-827.	1.3	61
541	Probing the Biology of Natural Products: Molecular Editing by Diverted Total Synthesis. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 9592-9628.	7.2	170
542	Strategies in developing promising histone deacetylase inhibitors. <i>Medicinal Research Reviews</i> , 2010, 30, 585-602.	5.0	81

#	ARTICLE	IF	CITATIONS
543	Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A. <i>Leukemia Research</i> , 2010, 34, 786-792.	0.4	9
544	Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery. <i>Journal of Molecular Graphics and Modelling</i> , 2010, 29, 382-395.	1.3	55
545	Histone deacetylase inhibitors: synthesis of cyclic tetrapeptides and their triazole analogs. <i>Tetrahedron Letters</i> , 2010, 51, 4357-4360.	0.7	11
546	Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. <i>Blood Reviews</i> , 2010, 24, 233-238.	2.8	30
547	Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 3252-3260.	1.4	24
548	On the inhibition of histone deacetylase 8. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4103-4110.	1.4	75
549	SeISA, selenium analogs of SAHA as potent histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2044-2047.	1.0	55
550	Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6657-6660.	1.0	7
551	Investigation on the isoform selectivity of histone deacetylase inhibitors using chemical feature based pharmacophore and docking approaches. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 1777-1791.	2.6	18
552	Inside HDAC with HDAC inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 2095-2116.	2.6	306
553	Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Pur1-mediated decrease in androgen receptor levels. <i>Prostate</i> , 2010, 70, 179-189.	1.2	28
554	Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. <i>Proteomics</i> , 2010, 10, 1029-1039.	1.3	43
555	Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies. <i>Journal of Neurochemistry</i> , 2010, 115, 806-813.	2.1	51
556	Global analysis of functional relationships between histone point mutations and the effects of histone deacetylase inhibitors. <i>Genes To Cells</i> , 2010, 15, 553-594.	0.5	6
557	The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. <i>British Journal of Haematology</i> , 2010, 149, 518-528.	1.2	78
558	A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. <i>British Journal of Haematology</i> , 2010, 150, 72-82.	1.2	40
559	research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2010, 150, 665-673.	1.2	168
560	Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. <i>Oncogene</i> , 2010, 29, 105-116.	2.6	73

#	ARTICLE	IF	CITATIONS
561	HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. <i>Oncogene</i> , 2010, 29, 305-312.	2.6	83
562	Histone deacetylases and the immunological network: implications in cancer and inflammation. <i>Oncogene</i> , 2010, 29, 157-173.	2.6	177
563	Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide. <i>Oncogene</i> , 2010, 29, 2192-2204.	2.6	78
564	Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation. <i>Oncogene</i> , 2010, 29, 5619-5629.	2.6	28
565	Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. <i>Oncogene</i> , 2010, 29, 3153-3162.	2.6	117
566	Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. <i>EMBO Journal</i> , 2010, 29, 2586-2597.	3.5	207
567	HDAC1, a novel marker for benign teratomas. <i>EMBO Journal</i> , 2010, 29, 3893-3895.	3.5	4
568	Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation. <i>Leukemia</i> , 2010, 24, 1412-1421.	3.3	57
569	A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia. <i>Leukemia</i> , 2010, 24, 1265-1275.	3.3	21
570	Ubiquitin B: an essential mediator of trichostatin A-induced tumor-selective killing in human cancer cells. <i>Cell Death and Differentiation</i> , 2010, 17, 109-118.	5.0	22
571	Cracking the death code: apoptosis-related histone modifications. <i>Cell Death and Differentiation</i> , 2010, 17, 1238-1243.	5.0	106
572	Histone deacetylase and Cullin3-ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. <i>Nature Cell Biology</i> , 2010, 12, 132-142.	4.6	292
573	Chemical phylogenetics of histone deacetylases. <i>Nature Chemical Biology</i> , 2010, 6, 238-243.	3.9	646
574	Covalent histone modifications are miswritten, misinterpreted and mis-erased in human cancers. <i>Nature Reviews Cancer</i> , 2010, 10, 457-469.	12.8	982
575	Current and Future Pharmacological Treatment Strategies in X-linked Adrenoleukodystrophy. <i>Brain Pathology</i> , 2010, 20, 845-856.	2.1	80
576	Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. <i>Pharmaceuticals</i> , 2010, 3, 2441-2469.	1.7	55
577	Anti-Tumor Effect in Human Lung Cancer by a Combination Treatment of Novel Histone Deacetylase Inhibitors: SL142 or SL325 and Retinoic Acids. <i>PLoS ONE</i> , 2010, 5, e13834.	1.1	25
578	Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2010, 5, e14460.	1.1	101

#	ARTICLE	IF	CITATIONS
579	Signaling Targets in Lymphoid Leukemias. , 2010, , 2831-2835.		0
580	Histone deacetylase 1 and 2 differentially regulate apoptosis by opposing effects on extracellular signal-regulated kinase 1/2. Cell Death and Disease, 2010, 1, e44-e44.	2.7	32
581	Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Experimental Biology and Medicine, 2010, 235, 32-39.	1.1	32
582	Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels. Clinical Cancer Research, 2010, 16, 141-153.	3.2	102
583	Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB. Neoplasma, 2010, 57, 406-414.	0.7	11
584	Distinct roles of HDAC1 and HDAC2 in transcription and recombination at the immunoglobulin loci in the chicken B cell line DT40. Journal of Biochemistry, 2010, 148, 201-207.	0.9	9
585	Trichostatin A-Induced TGF- β 2 Type II Receptor Expression in Retinoblastoma Cell Lines. , 2010, 51, 679.		8
586	A Gold(III) Porphyrin Complex with Antitumor Properties Targets the Wnt/ β -catenin Pathway. Cancer Research, 2010, 70, 329-337.	0.4	92
587	Synergistic Killing Effect between Vorinostat and Target of CD146 in Malignant Cells. Clinical Cancer Research, 2010, 16, 5165-5176.	3.2	10
588	Inhibition of Histone Deacetylase Protects the Retina from Ischemic Injury. , 2010, 51, 3639.		91
589	Transcriptome Remodeling in Hypoxic Inflammation. Journal of Dental Research, 2010, 89, 430-444.	2.5	31
590	Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands. Molecular Cancer Therapeutics, 2010, 9, 246-256.	1.9	57
591	Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes and Development, 2010, 24, 455-469.	2.7	248
592	Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression. Molecular Cancer Therapeutics, 2010, 9, 2309-2321.	1.9	80
593	Marine Invertebrates: Sponges. , 2010, , 327-362.		7
594	Emerging Anticancer Therapeutic Targets and the Cardiovascular System. Circulation Research, 2010, 106, 1022-1034.	2.0	40
595	Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. Expert Opinion on Therapeutic Targets, 2010, 14, 577-584.	1.5	78
596	Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1785-1791.	1.4	21

#	ARTICLE	IF	CITATIONS
597	Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. <i>Journal of Leukocyte Biology</i> , 2010, 87, 1103-1114.	1.5	163
598	Current and emerging molecular targets in glioma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1735-1751.	1.1	31
599	Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1113-1127.	1.9	12
600	Role of epigenomics in ovarian and endometrial cancers. <i>Epigenomics</i> , 2010, 2, 419-447.	1.0	46
601	Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2010, 16, 554-565.	3.2	65
602	Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14639-14644.	3.3	320
603	Epigenomics and ovarian carcinoma. <i>Biomarkers in Medicine</i> , 2010, 4, 543-570.	0.6	38
604	Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report. <i>Journal of Clinical Oncology</i> , 2010, 28, 3623-3629.	0.8	174
605	Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells. <i>Clinical Cancer Research</i> , 2010, 16, 4742-4754.	3.2	49
606	Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study. <i>Journal of Clinical Pathology</i> , 2010, 63, 994-998.	1.0	30
607	SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 642-652.	1.9	119
608	Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2568-2581.	1.9	34
609	Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor. <i>Cancer Biomarkers</i> , 2010, 7, 79-90.	0.8	8
610	Trichostatin A enhances proliferation and migration of vascular smooth muscle cells by downregulating thioredoxin 1. <i>Cardiovascular Research</i> , 2010, 85, 241-249.	1.8	31
611	Molecular and Therapeutic Potential and Toxicity of Valproic Acid. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-18.	3.0	347
612	The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. <i>Cell Cycle</i> , 2010, 9, 2663-2673.	1.3	77
613	Turning off the switch in medulloblastoma: The inhibitory acetylation of an oncogene. <i>Cell Cycle</i> , 2010, 9, 2047-2048.	1.3	7
614	Amphiregulin Promotes Resistance to Gefitinib in NonSmall Cell Lung Cancer Cells by Regulating Ku70 Acetylation. <i>Molecular Therapy</i> , 2010, 18, 536-543.	3.7	38

#	ARTICLE	IF	CITATIONS
615	Molecular Targeting of Aberrant Transcription Factors in Leukemia: Strategies for RUNX1/ETO. <i>Current Drug Targets</i> , 2010, 11, 1181-1191.	1.0	6
616	A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers. <i>Molecular Therapy</i> , 2010, 18, 1123-1129.	3.7	85
617	Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and Tubulin in Hormone Refractory Prostate Cancer Cells. <i>Journal of Urology</i> , 2010, 184, 2557-2564.	0.2	24
618	The epigenome as a therapeutic target in prostate cancer. <i>Nature Reviews Urology</i> , 2010, 7, 668-680.	1.9	118
619	Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays. <i>Journal of Urology</i> , 2010, 183, 2395-2402.	0.2	13
620	Comparative Analysis of Small Molecules and Histone Substrate Analogues as LSD1 Lysine Demethylase Inhibitors. <i>Journal of the American Chemical Society</i> , 2010, 132, 3164-3176.	6.6	149
621	Histone Modification Therapy of Cancer. <i>Advances in Genetics</i> , 2010, 70, 341-386.	0.8	63
622	Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [¹¹ C]MS-275 using Positron Emission Tomography. <i>ACS Chemical Neuroscience</i> , 2010, 1, 65-73.	1.7	85
623	Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes. <i>Epigenomics</i> , 2010, 2, 683-689.	1.0	6
625	Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer. <i>Epigenomics</i> , 2010, 2, 731-742.	1.0	37
626	p21 ^{Waf1} is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate. <i>Cell Cycle</i> , 2010, 9, 3945-3955.	1.3	77
627	Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 8546-8555.	2.9	87
628	Histone deacetylases and epigenetic therapies of hematological malignancies. <i>Pharmacological Research</i> , 2010, 62, 18-34.	3.1	121
629	Targeted therapies for non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 67, 257-274.	0.9	140
630	Increasing CD44 ⁺ /CD24 ⁻ tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. <i>Molecular Cancer</i> , 2010, 9, 288.	7.9	51
631	CDX Transcription Factors Positively Regulate Expression of Solute Carrier Family 5, Member 8 in the Colonic Epithelium. <i>Gastroenterology</i> , 2010, 138, 627-635.	0.6	24
632	Nonhistone protein acetylation as cancer therapy targets. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 935-954.	1.1	257
633	Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF- κ B p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. <i>Rheumatology</i> , 2010, 49, 1447-1460.	0.9	107

#	ARTICLE	IF	CITATIONS
634	Synthesis and Biological Characterization of the Histone Deacetylase Inhibitor Largazole and C7-Modified Analogues. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4654-4667.	2.9	77
635	An Efficient Synthesis of (±)-Trichostatic Acid and Analogues: A New Route to (±)-Trichostatin A. <i>Organic Letters</i> , 2010, 12, 832-834.	2.4	12
636	Dynamic Cyclic Thiopeptide Libraries From Thiol-Thioester Exchange. <i>Organic Letters</i> , 2010, 12, 1860-1863.	2.4	38
637	Mechanism of Binding of the Inhibitor (E)-3-(Furan-2-yl)-N-hydroxyacrylamide to a Histone Deacetylase-like Amidohydrolase. <i>Biochemistry</i> , 2010, 49, 1418-1424.	1.2	8
638	Vorinostat-Like Molecules as Structural, Stereochemical, and Pharmacological Tools. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 70-74.	1.3	16
639	Quantitative Proteomics Analysis Reveals Molecular Networks Regulated by Epidermal Growth Factor Receptor Level in Head and Neck Cancer. <i>Journal of Proteome Research</i> , 2010, 9, 3073-3082.	1.8	26
640	Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 8387-8399.	2.9	58
641	Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells. <i>Human Pathology</i> , 2010, 41, 848-858.	1.1	26
642	Long-term genistein treatment of MCF-7 cells decreases acetylated histone 3 expression and alters growth responses to mitogens and histone deacetylase inhibitors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 120, 164-171.	1.2	36
643	Pharmacologic Resuscitation Promotes Survival and Attenuates Hemorrhage-Induced Activation of Extracellular Signal-Regulated Kinase 1/2. <i>Journal of Surgical Research</i> , 2010, 163, 118-126.	0.8	37
644	HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. <i>Cancer Letters</i> , 2010, 296, 233-240.	3.2	43
645	Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs. <i>Current Opinion in Pharmacology</i> , 2010, 10, 397-404.	1.7	9
646	Nasopharyngeal carcinoma: The next challenges. <i>European Journal of Cancer</i> , 2010, 46, 1967-1978.	1.3	201
647	Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. <i>European Journal of Cancer</i> , 2010, 46, 2771-2780.	1.3	15
648	Induction of TAp63 by histone deacetylase inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 1748-1751.	1.0	8
649	Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. <i>Trends in Pharmacological Sciences</i> , 2010, 31, 153-160.	4.0	80
650	Targeting the correct HDAC(s) to treat cognitive disorders. <i>Trends in Pharmacological Sciences</i> , 2010, 31, 605-617.	4.0	330
651	Chemogenomic profiling of the cellular effects associated with histone H3 acetylation impairment by a quinoline-derived compound. <i>Genomics</i> , 2010, 96, 272-280.	1.3	11

#	ARTICLE	IF	CITATIONS
652	Ultra-High Performance Liquid Chromatography~Mass Spectrometry for the Fast Profiling of Histone Post-Translational Modifications. <i>Journal of Proteome Research</i> , 2010, 9, 5501-5509.	1.8	43
653	Small-molecule chromatin-modifying agents: therapeutic applications. <i>Epigenomics</i> , 2010, 2, 307-324.	1.0	29
654	Epigenome manipulation as a pathway to new natural product scaffolds and their congeners. <i>Natural Product Reports</i> , 2010, 27, 11-22.	5.2	266
655	Intelligent Design: Combination Therapy With Oncolytic Viruses. <i>Molecular Therapy</i> , 2010, 18, 251-263.	3.7	177
656	Antiproliferative and Differentiating Activities of a Novel Series of Histone Deacetylase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 411-415.	1.3	73
657	Epigenetics of Aging. , 2010, , .		10
658	Synthesis and Biological Evaluation of N-Hydroxyphenylacrylamides and N-Hydroxypyridin-2-ylacrylamides as Novel Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 822-839.	2.9	32
659	Trichostatin A enhances acetylation as well as protein stability of ERÎ± through induction of p300 protein. <i>Breast Cancer Research</i> , 2010, 12, R22.	2.2	64
661	Small Molecules as Versatile Tools for Activity-Based Protein Profiling Experiments. , 2010, , 629-674.		7
662	Synthesis of a novel series of benzylether-containing cinnamoyl derivatives as histone deacetylase inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2010, 25, 132-138.	2.5	1
663	Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. <i>Cell Cycle</i> , 2011, 10, 3119-3128.	1.3	45
664	Therapeutic pipeline for soft-tissue sarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2479-2491.	0.9	9
665	In Vivo PET Imaging of Histone Deacetylases by ¹⁸ F-Suberoylanilide Hydroxamic Acid (¹⁸ F-SAHA). <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5576-5582.	2.9	56
666	Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. <i>Neuro-Oncology</i> , 2011, 13, 894-903.	0.6	122
667	Cancer epigenetics: above and beyond. <i>Toxicology Mechanisms and Methods</i> , 2011, 21, 275-288.	1.3	82
668	Identification and Characterization of KCASH2 and KCASH3, 2 Novel Cullin3 Adaptors Suppressing Histone Deacetylase and Hedgehog Activity in Medulloblastoma. <i>Neoplasia</i> , 2011, 13, 374-IN23.	2.3	82
669	Metabolism as a key to histone deacetylase inhibition. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2011, 46, 181-199.	2.3	68
670	HDAC Inhibitors and Cancer Therapy. , 2011, 67, 175-195.		55

#	ARTICLE	IF	CITATIONS
671	Synapse microarray identification of small molecules that enhance synaptogenesis. <i>Nature Communications</i> , 2011, 2, 510.	5.8	84
673	ERK1/2 activation plays important roles in the opposite effects of Trichostatin A in non-cancer and cancer cells. <i>Toxicol</i> , 2011, 57, 932-937.	0.8	12
674	Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. <i>Lung Cancer</i> , 2011, 74, 300-304.	0.9	124
675	Sodium Butyrate Improves Memory Function in an Alzheimer's Disease Mouse Model When Administered at an Advanced Stage of Disease Progression. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 187-197.	1.2	313
676	Histone Deacetylases: the Biology and Clinical Implication. <i>Handbook of Experimental Pharmacology</i> , 2011, , .	0.9	7
677	Stem Cells & Regenerative Medicine. <i>Pancreatic Islet Biology</i> , 2011, , .	0.1	6
678	Hypertrophy. , 2011, , 1791-1791.		0
680	Histone Deacetylase Inhibitors Impair Antibacterial Defenses of Macrophages. <i>Journal of Infectious Diseases</i> , 2011, 204, 1367-1374.	1.9	83
681	Epigenetics and Disease. , 2011, , .		5
682	Complexes Formed in Solution Between Vanadium(IV)/(V) and the Cyclic Dihydroxamic Acid Putrebactin or Linear Suberodihydroxamic Acid. <i>Inorganic Chemistry</i> , 2011, 50, 5978-5989.	1.9	19
684	Heparanase Inhibitors. , 2011, , 1651-1656.		0
685	The role of chromatin, microRNAs, and tumor stem cells in ovarian cancer. <i>Cancer Biomarkers</i> , 2011, 8, 203-221.	0.8	15
687	Clinical development of panobinostat in classical Hodgkin's lymphoma. <i>Expert Review of Hematology</i> , 2011, 4, 245-252.	1.0	18
688	Combinatorial Patterning of Chromatin Regulators Uncovered by Genome-wide Location Analysis in Human Cells. <i>Cell</i> , 2011, 147, 1628-1639.	13.5	303
689	HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. <i>Cancer Letters</i> , 2011, 307, 72-79.	3.2	45
690	Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. <i>Cancer Letters</i> , 2011, 311, 177-186.	3.2	35
692	Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin. <i>Fertility and Sterility</i> , 2011, 95, 1579-1583.	0.5	35
693	p53 in trichostatin A induced C6 glioma cell death. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2011, 1810, 504-513.	1.1	28

#	ARTICLE	IF	CITATIONS
694	The role of class I histone deacetylase (HDAC) on gluconeogenesis in liver. <i>Biochemical and Biophysical Research Communications</i> , 2011, 404, 166-172.	1.0	37
695	Histone Deacetylase Inhibitors from <i>Burkholderia thailandensis</i> . <i>Journal of Natural Products</i> , 2011, 74, 2039-2044.	1.5	27
696	Breaking the histone code with quantitative mass spectrometry. <i>Expert Review of Proteomics</i> , 2011, 8, 631-643.	1.3	105
697	ABPP Methodology: Introduction and Overview. <i>Topics in Current Chemistry</i> , 2011, 324, 1-41.	4.0	29
698	FOXP3 Orchestrates H4K16 Acetylation and H3K4 Trimethylation for Activation of Multiple Genes by Recruiting MOF and Causing Displacement of PLU-1. <i>Molecular Cell</i> , 2011, 44, 770-784.	4.5	67
699	Acetylation-mediated epigenetic regulation of glucocorticoid receptor activity: Circadian rhythm-associated alterations of glucocorticoid actions in target tissues. <i>Molecular and Cellular Endocrinology</i> , 2011, 336, 23-30.	1.6	53
700	The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), A PET radiotracer designed for the delineation of histone deacetylase expression in cancer. <i>Nuclear Medicine and Biology</i> , 2011, 38, 683-696.	0.3	18
701	Zinc Chelation with Hydroxamate in Histone Deacetylases Modulated by Water Access to the Linker Binding Channel. <i>Journal of the American Chemical Society</i> , 2011, 133, 6110-6113.	6.6	91
702	Largazole and Analogues with Modified Metal-Binding Motifs Targeting Histone Deacetylases: Synthesis and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7453-7463.	2.9	41
703	Histone Modifications in Cancer Biology and Prognosis. , 2011, 67, 91-106.		77
704	Natural Products Synthesis: Enabling Tools To Penetrate Nature's Secrets of Biogenesis and Biomechanism. <i>Journal of Organic Chemistry</i> , 2011, 76, 4221-4259.	1.7	28
705	Trichostatin A inhibits collagen synthesis and induces apoptosis in keloid fibroblasts. <i>Archives of Dermatological Research</i> , 2011, 303, 573-580.	1.1	57
706	Epigenetics in breast cancer: what's new?. <i>Breast Cancer Research</i> , 2011, 13, 225.	2.2	114
707	Discovery, Synthesis, and Pharmacological Evaluation of Spiropiperidine Hydroxamic Acid Based Derivatives as Structurally Novel Histone Deacetylase (HDAC) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3051-3064.	2.9	50
708	Preclinical Assessment of Strategies for Enhancement of Metaiodobenzylguanidine Therapy of Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 334-344.	2.5	14
709	Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms. <i>Experimental Neurology</i> , 2011, 229, 214-225.	2.0	51
710	HDAC Inhibition and Graft Versus Host Disease. <i>Molecular Medicine</i> , 2011, 17, 404-416.	1.9	71
711	Epigenetic modulation of gene expression of human leukemia cell lines "induction of cell death and senescence. <i>Neoplasia</i> , 2011, 58, 35-44.	0.7	19

#	ARTICLE	IF	CITATIONS
712	Current Drug Targets and the Druggable Genome. , 2012, , 320-332.		2
713	Epigenetic Changes in Melanoma and the Development of Epigenetic Therapy for Melanoma. , 2011, , .		0
714	Epigenetics: A Possible Link Between Stress and Melanocyte Malignant Transformation. , 0, , .		0
715	Histone Deacetylase Inhibition and Dietary Short-Chain Fatty Acids. ISRN Allergy, 2011, 2011, 1-8.	3.1	72
716	Histone Deacetylase Inhibitors as Therapeutic Agents for Cancer Therapy: Drug Metabolism and Pharmacokinetic Properties. , 2011, , .		2
717	Endosomal Compartments. , 2011, , 1244-1248.		2
718	Regenerative medicine and tissue engineering in orthopaedic surgery. Frontiers in Bioscience - Elite, 2011, E3, 923-944.	0.9	53
719	Synthetic Routes and Biological Evaluation of Largazole and Its Analogues as Potent Histone Deacetylase Inhibitors. Molecules, 2011, 16, 4681-4694.	1.7	23
720	The Therapeutic Potential of HDAC Inhibitors in the Treatment of Multiple Sclerosis. Molecular Medicine, 2011, 17, 442-447.	1.9	68
721	Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. Journal of Medical Investigation, 2011, 58, 106-109.	0.2	38
722	Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells. PLoS ONE, 2011, 6, e22739.	1.1	68
723	Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. Anti-Cancer Drugs, 2011, 22, 494-499.	0.7	31
724	Epigenetic Multiple Modulators. Current Topics in Medicinal Chemistry, 2011, 11, 2749-2787.	1.0	11
725	Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia. Current Cancer Drug Targets, 2011, 11, 882-893.	0.8	14
726	Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions. Recent Patents on Anti-Cancer Drug Discovery, 2011, 6, 131-145.	0.8	28
727	Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood, 2011, 117, 1205-1217.	0.6	311
728	Cell signaling molecules as drug targets in lung cancer: an overview. Current Opinion in Pulmonary Medicine, 2011, 17, 286-291.	1.2	3
729	Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: A special reference to gene-expression microarray analysis. Oncology Reports, 2011, 26, 1057-62.	1.2	11

#	ARTICLE	IF	CITATIONS
730	A novel oncoprotein Pirh2: rising from the shadow of MDM2. <i>Cancer Science</i> , 2011, 102, 909-917.	1.7	23
731	Histone deacetylase inhibitors block nuclear factor- κ B-dependent transcription by interfering with RNA polymerase II recruitment. <i>Cancer Science</i> , 2011, 102, 1081-1087.	1.7	30
732	The significance of strong histone deacetylase 1 expression in the progression of prostate cancer. <i>Histopathology</i> , 2011, 58, 773-780.	1.6	19
733	A role for FoxN3 in the development of cranial cartilages and muscles in <i>Xenopus laevis</i> (Amphibia: Tj ETQq1 1 0.784314 rgBT /Overl... 226-242.	0.9	18
734	Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. <i>Nature Cell Biology</i> , 2011, 13, 292-302.	4.6	294
735	HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. <i>Leukemia</i> , 2011, 25, 161-168.	3.3	84
736	Synergistic induction of PI-PLC β 1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. <i>Leukemia</i> , 2011, 25, 271-280.	3.3	36
737	Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. <i>Leukemia</i> , 2011, 25, 226-235.	3.3	144
738	LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. <i>Leukemia</i> , 2011, 25, 575-587.	3.3	45
739	Synthesis of (S)-2-Boc-Amino-8-(R)-(tert-butyldimethylsilyloxy)decanoic acid, a precursor to the unusual amino acid residue of the anticancer agent microsporin B. <i>Tetrahedron Letters</i> , 2011, 52, 5438-5440.	0.7	5
740	Phenylbutyrate inhibits homologous recombination induced by camptothecin and methyl methanesulfonate. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 713, 64-75.	0.4	11
741	Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus. <i>Virology Journal</i> , 2011, 8, 151.	1.4	7
742	Chromatin modifying agents – the cutting edge of anticancer therapy. <i>Drug Discovery Today</i> , 2011, 16, 543-547.	3.2	32
743	Virus-induced differential expression of nuclear receptors and coregulators in dendritic cells: Implication to interferon production. <i>FEBS Letters</i> , 2011, 585, 1331-1337.	1.3	10
744	Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. <i>Free Radical Biology and Medicine</i> , 2011, 50, 313-322.	1.3	49
745	Protected from the inside: Endogenous histone deacetylase inhibitors and the road to cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011, 1815, 241-252.	3.3	32
746	Valproic acid utilizes the isoleucine breakdown pathway for its complete β -oxidation. <i>Biochemical Pharmacology</i> , 2011, 82, 1740-1746.	2.0	22
747	2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: Design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5735-5738.	1.0	91

#	ARTICLE	IF	CITATIONS
748	The ins and outs of tubulin acetylation: More than just a post-translational modification?. <i>Cellular Signalling</i> , 2011, 23, 763-771.	1.7	186
749	Association of genetic variants in six candidate genes with valproic acid therapy optimization. <i>Pharmacogenomics</i> , 2011, 12, 1107-1117.	0.6	54
750	From bench to bedside: Targeting epigenetics for cancer therapy. <i>Clinical Oncology and Cancer Research</i> , 2011, 8, 191-201.	0.1	1
751	Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 55-63.	1.1	48
752	Chemical biology of Histone acetyltransferase natural compounds modulators. <i>Molecular Diversity</i> , 2011, 15, 401-416.	2.1	28
753	Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon- β on pancreatic cancer cells. <i>International Journal of Clinical Oncology</i> , 2011, 16, 671-678.	1.0	26
755	The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. <i>Journal of Molecular Medicine</i> , 2011, 89, 279-289.	1.7	50
756	Epigenetic aberrations during oncogenesis. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 1681-1702.	2.4	156
757	Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 4101-4114.	2.4	20
758	Discovery of polyoxometalate-based HDAC inhibitors with profound anticancer activity in vitro and in vivo. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2477-2484.	2.6	65
759	The transposon-driven evolutionary origin and basis of histone deacetylase functions and limitations in disease prevention. <i>Clinical Epigenetics</i> , 2011, 2, 97-112.	1.8	1
760	Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. <i>BMC Cancer</i> , 2011, 11, 144.	1.1	141
761	Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. <i>Molecular Cancer</i> , 2011, 10, 68.	7.9	113
762	Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines. <i>Radiation Oncology</i> , 2011, 6, 119.	1.2	14
763	Antiglioma effects of combined use of a baculoviral vector expressing wild-type p53 and sodium butyrate. <i>Journal of Gene Medicine</i> , 2011, 13, 26-36.	1.4	11
764	Novel Cinnamyl Hydroxyamides and α -Aminoanilides as Histone Deacetylase Inhibitors: Apoptotic Induction and Cytodifferentiation Activity. <i>ChemMedChem</i> , 2011, 6, 698-712.	1.6	17
765	Carbamate Prodrug Concept for Hydroxamate HDAC Inhibitors. <i>ChemMedChem</i> , 2011, 6, 1193-1198.	1.6	37
766	Trichostatin A restores Apaf-1 function in chemoresistant ovarian cancer cells. <i>Cancer</i> , 2011, 117, 784-794.	2.0	22

#	ARTICLE	IF	CITATIONS
767	STAT6 activation in ulcerative colitis: A new target for prevention of IL-13-induced colon epithelial cell dysfunction. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2224-2234.	0.9	107
768	Histone deacetylase inhibition as an anticancer telomerase-targeting strategy. <i>International Journal of Cancer</i> , 2011, 129, 2765-2774.	2.3	16
769	Chemical Approaches for the Detection and Synthesis of Acetylated Proteins. <i>ChemBioChem</i> , 2011, 12, 314-322.	1.3	23
770	Adamantanyl-Histone Deacetylase Inhibitor H6CAHA Exhibits Favorable Pharmacokinetics and Augments Prostate Cancer Radiation Sensitivity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1541-1548.	0.4	29
771	Epigenetic profiling of the antitumor natural product psammaplin A and its analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 3637-3649.	1.4	52
772	Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs). <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 3690-3701.	1.4	29
773	Discovery of histone deacetylase 8 selective inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2601-2605.	1.0	82
774	A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4164-4169.	1.0	19
775	Photosensitization by iodinated DNA minor groove binding ligands: Evaluation of DNA double-strand break induction and repair. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2011, 103, 145-152.	1.7	10
776	Suberoylanilide hydroxamic acid, a potent histone deacetylase inhibitor; its X-ray crystal structure and solid state and solution studies of its Zn(II), Ni(II), Cu(II) and Fe(III) complexes. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 763-769.	1.5	66
777	Epigenetic Regulation of Thy-1 by Histone Deacetylase Inhibitor in Rat Lung Fibroblasts. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 16-23.	1.4	96
778	Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. <i>Epigenetics</i> , 2011, 6, 1228-1235.	1.3	22
779	Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics. <i>Current Medicinal Chemistry</i> , 2011, 18, 1658-1671.	1.2	86
780	Abnormal Histone Acetylation and Methylation Levels in Esophageal Squamous Cell Carcinomas. <i>Cancer Investigation</i> , 2011, 29, 548-556.	0.6	33
781	SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. <i>Cell Death and Differentiation</i> , 2011, 18, 1904-1913.	5.0	277
782	Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 823-829.	1.9	98
783	Experiment Specific Expression Patterns. <i>Journal of Computational Biology</i> , 2011, 18, 1423-1435.	0.8	0
784	Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies?. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 393-404.	2.5	35

#	ARTICLE	IF	CITATIONS
785	DAnCER: Disease-Annotated Chromatin Epigenetics Resource. <i>Nucleic Acids Research</i> , 2011, 39, D889-D894.	6.5	19
786	AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. <i>Neuro-Oncology</i> , 2011, 13, 983-999.	0.6	60
787	Deacetylation of Nonhistone Proteins by HDACs and the Implications in Cancer. <i>Handbook of Experimental Pharmacology</i> , 2011, 206, 39-56.	0.9	86
788	Interplay between PKC δ and Sp1 on Histone Deacetylase Inhibitor-Mediated Epstein-Barr Virus Reactivation. <i>Journal of Virology</i> , 2011, 85, 2373-2385.	1.5	35
789	Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. <i>Annals of Oncology</i> , 2011, 22, 2516-2522.	0.6	32
790	Liposomal trichostatin A: therapeutic potential in hormone-dependent and -independent breast cancer xenograft models. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2011, 6, 215-25.	0.3	2
791	Sodium butyrate induces cellular senescence in neuroblastoma and prostate cancer cells. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2011, 7, 265-72.	0.3	15
792	Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-17.	3.0	68
793	The Role of Epigenetic Alterations in Papillary Thyroid Carcinogenesis. <i>Journal of Thyroid Research</i> , 2011, 2011, 1-7.	0.5	15
794	Valproic Acid Antagonizes the Capacity of Other Histone Deacetylase Inhibitors To Activate the Epstein-Barr Virus Lytic Cycle. <i>Journal of Virology</i> , 2011, 85, 5628-5643.	1.5	42
795	Histone Deacetylase Inhibitors Preserve White Matter Structure and Function during Ischemia by Conserving ATP and Reducing Excitotoxicity. <i>Journal of Neuroscience</i> , 2011, 31, 3990-3999.	1.7	102
796	Epigenetic Identity in Cancer Stem Cells. <i>Pancreatic Islet Biology</i> , 2011, , 127-139.	0.1	1
797	The emerging role of epigenetic mechanisms in the etiology of neural tube defects. <i>Epigenetics</i> , 2011, 6, 875-883.	1.3	65
798	SRSF2 is required for sodium butyrate-mediated p21WAF1 induction and premature senescence in human lung carcinoma cell lines. <i>Cell Cycle</i> , 2011, 10, 1968-1977.	1.3	29
799	Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. <i>International Journal of Oncology</i> , 2011, 39, 111-9.	1.4	43
800	Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters. <i>Clinical Cancer Research</i> , 2011, 17, 3956-3968.	3.2	76
801	β Np63, a Target of DEC1 and Histone Deacetylase 2, Modulates the Efficacy of Histone Deacetylase Inhibitors in Growth Suppression and Keratinocyte Differentiation. <i>Journal of Biological Chemistry</i> , 2011, 286, 12033-12041.	1.6	28
802	Diet-induced Lethality Due to Deletion of the Hdac3 Gene in Heart and Skeletal Muscle. <i>Journal of Biological Chemistry</i> , 2011, 286, 33301-33309.	1.6	83

#	ARTICLE	IF	CITATIONS
803	Manipulating Protein Acetylation in Breast Cancer: A Promising Approach in Combination with Hormonal Therapies?. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-15.	3.0	28
805	Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: "To Be or Not to Be Acetylated"? <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-15.	3.0	18
806	The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9.	3.0	24
807	Arabidopsis HDA6 Regulates Locus-Directed Heterochromatin Silencing in Cooperation with MET1. <i>PLoS Genetics</i> , 2011, 7, e1002055.	1.5	148
808	Regulation of Immune Responses by Histone Deacetylase Inhibitors. <i>ISRN Hematology</i> , 2012, 2012, 1-10.	1.6	54
809	Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response. <i>FASEB Journal</i> , 2012, 26, 2437-2445.	0.2	41
810	Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 707-718.	1.5	5
811	HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. <i>Epigenetics</i> , 2012, 7, 1403-1412.	1.3	75
812	Histone Deacetylase Activity Selectively Regulates Notch-Mediated Smooth Muscle Differentiation in Human Vascular Cells. <i>Journal of the American Heart Association</i> , 2012, 1, e000901.	1.6	24
813	Aurora B is regulated by acetylation/deacetylation during mitosis in prostate cancer cells. <i>FASEB Journal</i> , 2012, 26, 4057-4067.	0.2	32
814	CBX7 is a tumor suppressor in mice and humans. <i>Journal of Clinical Investigation</i> , 2012, 122, 612-623.	3.9	133
815	SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection. <i>Cellular and Molecular Immunology</i> , 2012, 9, 390-398.	4.8	30
816	An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors. <i>Current Cancer Drug Targets</i> , 2012, 12, 439-452.	0.8	29
817	Melanoma and Epigenetic Treatment: Past and Future. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 202-209.	0.9	4
818	Downregulation of Hypoxia-related Responses by Novel Antitumor Histone Deacetylase Inhibitors in MDAMB231 Breast Cancer Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 407-413.	0.9	10
819	Infrared spectroscopic studies to understand the effect of drugs at molecular level. , 2012, , .		0
820	Compensatory functions of histone deacetylase 1 (HDAC1) and HDAC2 regulate transcription and apoptosis during mouse oocyte development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E481-9.	3.3	114
821	Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. <i>Leukemia and Lymphoma</i> , 2012, 53, 1077-1083.	0.6	16

#	ARTICLE	IF	CITATIONS
822	Epigenetics, Depression and Antidepressant Treatment. <i>Current Pharmaceutical Design</i> , 2012, 18, 5879-5889.	0.9	62
823	Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2012, 53, 123-129.	0.6	50
825	Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. <i>Immunology and Cell Biology</i> , 2012, 90, 55-65.	1.0	59
826	Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. <i>Leukemia</i> , 2012, 26, 1630-1637.	3.3	48
827	SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. <i>EMBO Journal</i> , 2012, 31, 110-123.	3.5	216
828	Leucine Zipper Domain Is Required for Kaposi Sarcoma-associated Herpesvirus (KSHV) K-bZIP Protein to Interact with Histone Deacetylase and Is Important for KSHV Replication. <i>Journal of Biological Chemistry</i> , 2012, 287, 15622-15634.	1.6	19
829	Histone Deacetylation Inhibition in Pulmonary Hypertension. <i>Circulation</i> , 2012, 126, 455-467.	1.6	222
831	Antimalarial Activity of the Anticancer Histone Deacetylase Inhibitor SB939. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3849-3856.	1.4	74
832	Overview of the Classical Histone Deacetylase Enzymes and Histone Deacetylase Inhibitors. , 2012, 2012, 1-12.		12
833	Controversies Surrounding the Potential Use of Histone Deacetylase Inhibitors for the Treatment of Asthma. <i>ISRN Pulmonology</i> , 2012, 2012, 1-10.	0.3	1
834	Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming. <i>Stem Cells International</i> , 2012, 2012, 1-10.	1.2	103
835	Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors. <i>Lymphoma</i> , 2012, 2012, 1-10.	0.2	13
836	Advances in Induced Pluripotent Stem Cell Technologies. <i>Stem Cells International</i> , 2012, 2012, 1-1.	1.2	0
837	Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2865-74.	3.3	327
838	Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 7765-7769.	3.3	198
839	Loss of Transcription Factor Nuclear Factor-Erythroid 2 (NF-E2) p45-related Factor-2 (Nrf2) Leads to Dysregulation of Immune Functions, Redox Homeostasis, and Intracellular Signaling in Dendritic Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 10556-10564.	1.6	63
840	New Therapeutic Targets in Soft Tissue Sarcoma. <i>Advances in Anatomic Pathology</i> , 2012, 19, 170-180.	2.4	45
841	Epigenetic Control of MIF Expression. , 2012, , 121-137.		0

#	ARTICLE	IF	CITATIONS
842	Valproic acid inhibits proliferation of EB virus-infected natural killer cells. <i>Hematology</i> , 2012, 17, 163-169.	0.7	5
843	Towards Histone Deacetylase Inhibitors as New Antimalarial Drugs. <i>Current Pharmaceutical Design</i> , 2012, , .	0.9	27
844	The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment. <i>Current Medicinal Chemistry</i> , 2012, 19, 4218-4238.	1.2	60
845	Potential of chromatin modifying compounds for the treatment of Alzheimer's disease. <i>Pathobiology of Aging & Age Related Diseases</i> , 2012, 2, 14980.	1.1	20
846	Sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells. <i>International Journal of Oncology</i> , 2012, 41, 1101-1109.	1.4	104
847	Natural chalcones as dual inhibitors of HDACs and NF- κ B. <i>Oncology Reports</i> , 2012, 28, 797-805.	1.2	71
848	Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells. <i>International Journal of Oncology</i> , 2012, 40, 1705-13.	1.4	13
849	Peripheral T-cell lymphoma: pharmacotherapy overview. <i>Clinical Investigation</i> , 2012, 2, 403-416.	0.0	0
850	Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 549-573.	4.2	96
851	HDAC Inhibitors. <i>Advances in Cancer Research</i> , 2012, 116, 87-129.	1.9	114
852	Differentiation of Prostate Cancer Cells Using Flexible Fluorescent Polymers. <i>Analytical Chemistry</i> , 2012, 84, 17-20.	3.2	12
853	A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells. <i>Investigational New Drugs</i> , 2012, 30, 1887-1898.	1.2	32
854	Effects of vitamin U (S-methyl methionine sulphonium chloride) on valproic acid induced liver injury in rats. <i>Food and Chemical Toxicology</i> , 2012, 50, 3562-3566.	1.8	47
855	Trials with "epigenetic"™ drugs: An update. <i>Molecular Oncology</i> , 2012, 6, 657-682.	2.1	208
856	Molecular Dynamics Simulation Study Explaining Inhibitor Selectivity in Different Class of Histone Deacetylases. <i>Journal of Biomolecular Structure and Dynamics</i> , 2012, 29, 677-698.	2.0	26
857	Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells. <i>Investigational New Drugs</i> , 2012, 30, 435-442.	1.2	27
858	Estradiol receptors in breast cancer cells: Associated co-factors as targets for new therapeutic approaches. <i>Steroids</i> , 2012, 77, 1249-1261.	0.8	27
859	Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 433-444.	1.1	28

#	ARTICLE	IF	CITATIONS
860	Impact of HDAC inhibitors on dendritic cell functions. <i>Experimental Hematology</i> , 2012, 40, 783-791.	0.2	29
861	Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression. <i>Experimental Hematology</i> , 2012, 40, 1043-1054.e6.	0.2	13
862	Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. <i>Journal of Leukocyte Biology</i> , 2011, 91, 321-331.	1.5	65
863	Role of Additional Novel Therapies in Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 959-980.	0.9	7
864	Butyrate Histone Deacetylase Inhibitors. <i>BioResearch Open Access</i> , 2012, 1, 192-198.	2.6	138
865	Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. <i>Oncogene</i> , 2012, 31, 537-551.	2.6	120
866	Histone Deacetylases and Their Role in Asthma. <i>Journal of Asthma</i> , 2012, 49, 121-128.	0.9	28
867	The impact of plantâ€‘pathogen studies on medicinal drug discovery. <i>Chemical Society Reviews</i> , 2012, 41, 3168.	18.7	9
868	Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. <i>Oncogene</i> , 2012, 31, 3444-3456.	2.6	112
869	Understanding Histone Deacetylases in the Cancer Development and Treatment: An Epigenetic Perspective of Cancer Chemotherapy. <i>DNA and Cell Biology</i> , 2012, 31, S-62-S-71.	0.9	25
870	A Novel Class of Small Molecule Inhibitors of HDAC6. <i>ACS Chemical Biology</i> , 2012, 7, 331-339.	1.6	88
871	Growing the growth cone: remodeling the cytoskeleton to promote axon regeneration. <i>Trends in Neurosciences</i> , 2012, 35, 164-174.	4.2	99
872	The Inhibitor of Histone Deacetylases Sodium Butyrate Enhances the Cytotoxicity of Mitomycin C. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2116-2126.	1.9	8
873	Enzyme Inhibitors from Marine Invertebrates. , 2012, , 1145-1229.		1
874	Synthesis and Biological Evaluation of 1-Arylsulfonyl-5-(<i>N</i> -hydroxyacrylamide)indoles as Potent Histone Deacetylase Inhibitors with Antitumor Activity in Vivo. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3777-3791.	2.9	52
875	Diversity-oriented synthesis: producing chemical tools for dissecting biology. <i>Chemical Society Reviews</i> , 2012, 41, 4444.	18.7	389
876	Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. <i>British Journal of Pharmacology</i> , 2012, 166, 587-601.	2.7	37
877	Thiazolidinedioneâ€‘dependent activation of sphingosine kinase 1 causes an antiâ€‘fibrotic effect in renal mesangial cells. <i>British Journal of Pharmacology</i> , 2012, 166, 1018-1032.	2.7	23

#	ARTICLE	IF	CITATIONS
878	Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. <i>Blood</i> , 2012, 119, 2346-2357.	0.6	72
879	Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer. <i>Nature Reviews Cancer</i> , 2012, 12, 709-720.	12.8	181
880	Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. <i>Future Medicinal Chemistry</i> , 2012, 4, 505-524.	1.1	330
881	Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications. <i>Pharmaceutical Patent Analyst</i> , 2012, 1, 75-90.	0.4	19
882	Indole-Derived Psammaplin A Analogues as Epigenetic Modulators with Multiple Inhibitory Activities. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9467-9491.	2.9	48
883	Impact of valproic acid on dendritic cells function. <i>Immunobiology</i> , 2012, 217, 704-710.	0.8	34
884	Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma. <i>Journal of Pediatric Surgery</i> , 2012, 47, 1267-1271.	0.8	12
885	Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 104-115.	1.1	45
886	Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 420, 325-330.	1.0	18
887	Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 3865-3872.	1.4	43
888	Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC/EGFR dual inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 4405-4412.	1.4	39
889	Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells. <i>Cancer Letters</i> , 2012, 315, 112-121.	3.2	32
890	Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing Family Tumors. <i>Cancer Letters</i> , 2012, 320, 14-22.	3.2	32
891	Computational identification of novel histone deacetylase inhibitors by docking based QSAR. <i>Computers in Biology and Medicine</i> , 2012, 42, 697-705.	3.9	38
892	Cancer Epigenetics: From Mechanism to Therapy. <i>Cell</i> , 2012, 150, 12-27.	13.5	2,521
893	Inhibition of Histone Deacetylase 3 Protects Beta Cells from Cytokine-Induced Apoptosis. <i>Chemistry and Biology</i> , 2012, 19, 669-673.	6.2	85
894	P38 MAP kinase functions as a switch in MS-275-induced reactive oxygen species-dependent autophagy and apoptosis in Human colon Cancer cells. <i>Free Radical Biology and Medicine</i> , 2012, 53, 532-543.	1.3	65
895	Brazilin Induces Apoptosis and G2/M Arrest via Inactivation of Histone Deacetylase in Multiple Myeloma U266 Cells. <i>Journal of Agricultural and Food Chemistry</i> , 2012, 60, 9882-9889.	2.4	66

#	ARTICLE	IF	CITATIONS
896	Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. <i>Oncogene</i> , 2012, 31, 4677-4688.	2.6	75
897	Glioma Revisited: From Neurogenesis and Cancer Stem Cells to the Epigenetic Regulation of the Niche. <i>Journal of Oncology</i> , 2012, 2012, 1-20.	0.6	40
898	Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1247-1266.	1.9	50
899	n-Butyrate Energized Effector CD4 ⁺ T Cells Independent of Regulatory T cell Generation or Activity. <i>Scandinavian Journal of Immunology</i> , 2012, 76, 457-463.	1.3	23
900	Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. <i>Leukemia</i> , 2012, 26, 1356-1364.	3.3	108
901	Discovery and Extensive in Vitro Evaluations of NK-HDAC-1: A Chiral Histone Deacetylase Inhibitor as a Promising Lead. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3066-3075.	2.9	35
902	7.10 Cell-Extracellular Matrix Mechanobiology in Cancer. , 2012, , 142-167.		0
904	Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells. <i>Gastroenterology</i> , 2012, 143, 811-820.e15.	0.6	178
905	Histone deacetylases inhibitor Trichostatin A ameliorates DNFB-induced allergic contact dermatitis and reduces epidermal Langerhans cells in mice. <i>Journal of Dermatological Science</i> , 2012, 68, 99-107.	1.0	20
906	Chemical and genetic blockade of HDACs enhances osteogenic differentiation of human adipose tissue-derived stem cells by oppositely affecting osteogenic and adipogenic transcription factors. <i>Biochemical and Biophysical Research Communications</i> , 2012, 428, 271-277.	1.0	35
907	Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer. <i>Lung Cancer</i> , 2012, 76, 171-176.	0.9	61
908	Macrocyclic Peptoid ⁺ Peptide Hybrids as Inhibitors of Class I Histone Deacetylases. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 749-753.	1.3	34
909	Influence of Natural and Synthetic Histone Deacetylase Inhibitors on Chromatin. <i>Antioxidants and Redox Signaling</i> , 2012, 17, 340-354.	2.5	15
910	Immune regulation by histone deacetylases: a focus on the alteration of FOXP3 activity. <i>Immunology and Cell Biology</i> , 2012, 90, 95-100.	1.0	40
911	Chromatin regulators with tumor suppressor properties and their alterations in human cancers. <i>Epigenomics</i> , 2012, 4, 537-549.	1.0	19
912	Lactic acid bacteria contribution to gut microbiota complexity: lights and shadows. <i>Frontiers in Cellular and Infection Microbiology</i> , 2012, 2, 86.	1.8	375
913	Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia. <i>Klinische Padiatrie</i> , 2012, 224, 398-403.	0.2	42
914	Acetylation controls Notch3 stability and function in T-cell leukemia. <i>Oncogene</i> , 2012, 31, 3807-3817.	2.6	54

#	ARTICLE	IF	CITATIONS
915	Phosphoinositides and Disease. <i>Current Topics in Microbiology and Immunology</i> , 2012, , .	0.7	2
916	Analytical-scale purification of trichostatin A from bacterial culture in a single step and with high selectivity using immobilised metal affinity chromatography. <i>RSC Advances</i> , 2012, 2, 333-337.	1.7	10
917	SMN-inducing compounds for the treatment of spinal muscular atrophy. <i>Future Medicinal Chemistry</i> , 2012, 4, 2067-2084.	1.1	33
918	Discovery and activity profiling of thailandepsins A through F, potent histone deacetylase inhibitors, from <i>Burkholderia thailandensis</i> E264. <i>MedChemComm</i> , 2012, 3, 976.	3.5	38
919	Emerging New Agents for the Management of Patients with Non-Small Cell Lung Cancer. <i>Drugs</i> , 2012, 72, 37-52.	4.9	23
921	Use and Discovery of Chemical Elicitors That Stimulate Biosynthetic Gene Clusters in <i>Streptomyces</i> Bacteria. <i>Methods in Enzymology</i> , 2012, 517, 367-385.	0.4	60
922	HDAC Inhibitors and Chaperone Function. <i>Advances in Cancer Research</i> , 2012, 116, 239-262.	1.9	40
923	Role of neuroinflammation in morphine tolerance: Effect of tumor necrosis factor- α . <i>Acta Anaesthesiologica Taiwanica</i> , 2012, 50, 178-182.	1.0	33
924	Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors. <i>Archives of Pharmacal Research</i> , 2012, 35, 1723-1732.	2.7	7
925	Epigenetic mechanisms of plant-derived anticancer drugs. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 129.	3.0	46
926	Epigenetic Dysregulation in Laryngeal Squamous Cell Carcinoma. <i>Journal of Oncology</i> , 2012, 2012, 1-10.	0.6	61
927	Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. <i>Cell Death and Differentiation</i> , 2012, 19, 1317-1327.	5.0	99
928	Molecular Pathways: Old Drugs Define New Pathways: Non-Histone Acetylation at the Crossroads of the DNA Damage Response and Autophagy. <i>Clinical Cancer Research</i> , 2012, 18, 2436-2442.	3.2	33
929	Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. <i>Journal of Cellular Physiology</i> , 2012, 227, 3389-3396.	2.0	24
930	Novel molecular targeted therapies for refractory thyroid cancer. <i>Head and Neck</i> , 2012, 34, 736-745.	0.9	23
931	Fourier transform infrared microspectroscopy identifies protein propionylation in histone deacetylase inhibitor treated glioma cells. <i>Journal of Biophotonics</i> , 2012, 5, 230-239.	1.1	8
932	HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 2167-2177.	1.2	98
933	The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. <i>Blood</i> , 2012, 119, 4017-4025.	0.6	79

#	ARTICLE	IF	CITATIONS
935	Discovery of Macrocyclic Peptides Armed with a Mechanism-Based Warhead: Isoform-Selective Inhibition of Human Deacetylase SIRT2. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 3423-3427.	7.2	141
936	Spiro[chromane-2,4'-piperidine]-Based Histone Deacetylase Inhibitors with Improved <i>in vivo</i> Activity. <i>ChemMedChem</i> , 2012, 7, 709-721.	1.6	11
937	Design, Synthesis, and Biological Evaluation of α -Aminobenzanilide Derivatives as Potent and Selective HDAC Inhibitors. <i>ChemMedChem</i> , 2012, 7, 1256-1266.	1.6	16
938	CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. <i>Biochemical Journal</i> , 2012, 443, 735-746.	1.7	108
939	Curcumin Inhibits Histone Deacetylase Leading to Cell Cycle Arrest and Apoptosis via Upregulation of p21 in Breast Cancer Cell Lines. <i>International Journal of Green Nanotechnology</i> , 2012, 4, 183-197.	0.3	9
940	Multiple roles of class I HDACs in proliferation, differentiation, and development. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 2173-2187.	2.4	149
941	A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. <i>Investigational New Drugs</i> , 2012, 30, 1434-1442.	1.2	33
942	Parthenolide, a Sesquiterpene Lactone, Expresses Multiple Anti-cancer and Anti-inflammatory Activities. <i>Inflammation</i> , 2012, 35, 560-565.	1.7	192
943	Dose-dependent effects of R-sulforaphane isothiocyanate on the biology of human mesenchymal stem cells, at dietary amounts, it promotes cell proliferation and reduces senescence and apoptosis, while at anti-cancer drug doses, it has a cytotoxic effect. <i>Age</i> , 2012, 34, 281-293.	3.0	59
944	SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin. <i>Pathology and Oncology Research</i> , 2012, 18, 713-720.	0.9	39
945	Histone deacetylase modulators provided by Mother Nature. <i>Genes and Nutrition</i> , 2012, 7, 357-367.	1.2	60
946	Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 901-909.	1.1	215
947	Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1413-1422.	1.1	90
948	Trichostatin A Ameliorates Myocardial Ischemia/Reperfusion Injury Through Inhibition of Endoplasmic Reticulum Stress-induced Apoptosis. <i>Archives of Medical Research</i> , 2012, 43, 190-196.	1.5	26
949	A novel series of l-2-benzoyloxycarbonylamino-8-(2-pyridyl)-disulfidyoctanoic acid derivatives as histone deacetylase inhibitors: Design, synthesis and molecular modeling study. <i>European Journal of Medicinal Chemistry</i> , 2012, 52, 111-122.	2.6	11
950	Appraisal of GABA and PABA as linker: Design and synthesis of novel benzamide based histone deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2012, 53, 390-397.	2.6	20
951	HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. <i>Leukemia Research</i> , 2012, 36, 1055-1062.	0.4	45
952	HDAC modulation and cell death in the clinic. <i>Experimental Cell Research</i> , 2012, 318, 1229-1244.	1.2	60

#	ARTICLE	IF	CITATIONS
953	A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 773-783.	1.2	19
954	Histone deacetylase inhibitors (HDACIs). Structure-activity relationships: history and new QSAR perspectives. <i>Medicinal Research Reviews</i> , 2012, 32, 1-165.	5.0	69
955	Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. <i>Laryngoscope</i> , 2012, 122, 174-189.	1.1	37
956	The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. <i>American Journal of Hematology</i> , 2012, 87, 354-360.	2.0	61
957	Discovery of a novel histone deacetylase 8 inhibitor by virtual screening. <i>Medicinal Chemistry Research</i> , 2012, 21, 152-156.	1.1	19
958	Suberoylanilide hydroxamic acid affects γ H2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 168-176.	1.0	19
959	RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 439-449.	1.2	7
960	Associations of histone deacetylase 2 and histone deacetylase 3 genes with schizophrenia in a Chinese population. <i>Asia-Pacific Psychiatry</i> , 2013, 5, 11-16.	1.2	9
961	Histone de-acetylase inhibitors: a promising future for cancer treatment?. <i>Infectious Agents and Cancer</i> , 2013, 8, 10.	1.2	1
962	Epigenetic control of HNF-4 α in colon carcinoma cells affects MUC4 expression and malignancy. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 155-167.	2.1	16
963	Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various anti-dedifferentiation strategies. <i>Archives of Toxicology</i> , 2013, 87, 577-610.	1.9	105
964	Expression level of histone deacetylase 2 correlates with occurring of chronic obstructive pulmonary diseases. <i>Molecular Biology Reports</i> , 2013, 40, 3995-4000.	1.0	13
965	Discovery of Potent, Isoform-Selective Inhibitors of Histone Deacetylase Containing Chiral Heterocyclic Capping Groups and a <i>N</i> -(2-Aminophenyl)benzamide Binding Unit. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6156-6174.	2.9	53
966	Total Synthesis and Full Histone Deacetylase Inhibitory Profiling of Azumamides 1 as Well as 2 -Azumamide 1 and 3 -Azumamide 1 . <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6512-6520.	2.9	32
967	Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3295-3299.	1.0	18
968	Histone-Deacetylase-Targeted Fluorescent Ruthenium(II) Polypyridyl Complexes as Potent Anticancer Agents. <i>Chemistry - A European Journal</i> , 2013, 19, 10160-10169.	1.7	69
969	Novel ⁶⁴ Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 858-862.	1.3	20
970	One pot synthesis of dibenzodiazepinones via CuI catalysis in ethylene glycol. <i>Chinese Chemical Letters</i> , 2013, 24, 825-828.	4.8	12

#	ARTICLE	IF	CITATIONS
971	The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. <i>BMC Cancer</i> , 2013, 13, 286.	1.1	41
972	Epigenetic reactivation of estrogen receptor- β (ER β) by genistein enhances hormonal therapy sensitivity in ER β -negative breast cancer. <i>Molecular Cancer</i> , 2013, 12, 9.	7.9	158
973	T-Cell Lymphomas. , 2013, , .		1
974	Androgen receptors in hormone-dependent and castration-resistant prostate cancer. , 2013, 140, 223-238.		273
975	Aberrant histone acetylation and methylation levels in woman with endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 487-494.	0.8	41
976	Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma. <i>Radiation and Environmental Biophysics</i> , 2013, 52, 363-373.	0.6	9
977	Deregulated Chromatin Remodeling in the Pathobiology of Brain Tumors. <i>NeuroMolecular Medicine</i> , 2013, 15, 1-24.	1.8	19
978	Characterization of In Vitro Expanded Bone Marrow-Derived Mesenchymal Stem Cells Isolated from Experimental Autoimmune Encephalomyelitis Mice. <i>Journal of Molecular Neuroscience</i> , 2013, 51, 282-297.	1.1	7
979	HDAC inhibitors in kidney development and disease. <i>Pediatric Nephrology</i> , 2013, 28, 1909-1921.	0.9	52
980	Bioinformatics Analysis Reveals Potential Candidate Drugs for HCC. <i>Pathology and Oncology Research</i> , 2013, 19, 251-258.	0.9	10
981	A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 974-985.	1.2	28
982	Molecular approaches towards development of purified natural products and their structurally known derivatives as efficient anti-cancer drugs: Current trends. <i>European Journal of Pharmacology</i> , 2013, 714, 239-248.	1.7	33
983	Spinal muscular atrophy: An update on therapeutic progress. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 2180-2190.	1.8	62
984	Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery. <i>Oncogene</i> , 2013, 32, 3809-3818.	2.6	7
985	Applicability of Histone Deacetylase Inhibition for the Treatment of Spinal Muscular Atrophy. <i>Neurotherapeutics</i> , 2013, 10, 677-687.	2.1	12
986	Potent Histone Deacetylase Inhibitors Derived from 4-(Aminomethyl)- <i>N</i> -hydroxybenzamide with High Selectivity for the HDAC6 Isoform. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7201-7211.	2.9	41
987	Genetic and epigenetic markers of gliomas. <i>Cell and Tissue Biology</i> , 2013, 7, 303-313.	0.2	3
988	Combating the epigenome: epigenetic drugs against non-Hodgkinâ€™s lymphoma. <i>Epigenomics</i> , 2013, 5, 397-415.	1.0	16

#	ARTICLE	IF	CITATIONS
989	Regulation of fetal gene expression in heart failure. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 2414-2424.	1.8	223
990	Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease. <i>Nature Communications</i> , 2013, 4, 2735.	5.8	76
991	Hydroxamic Acids. , 2013, , .		30
992	Valproic acid promotes neuronal differentiation by induction of neuroprogenitors in human bone-marrow mesenchymal stromal cells. <i>Neuroscience Letters</i> , 2013, 554, 22-27.	1.0	49
993	Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. <i>European Journal of Cancer</i> , 2013, 49, 2791-2797.	1.3	29
994	Acetylation and deacetylation—novel factors in muscle wasting. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1-11.	1.5	58
995	Epigenomic regulation of bile acid metabolism: Emerging role of transcriptional cofactors. <i>Molecular and Cellular Endocrinology</i> , 2013, 368, 59-70.	1.6	24
996	Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting <i>NF2</i> -Deficient Meningioma Growth. <i>Cancer Research</i> , 2013, 73, 792-803.	0.4	44
997	Protocatechualdehyde possesses anti-cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 430, 381-386.	1.0	35
998	Use of diagnostic and therapeutic biomarkers in personalized oncology based on adult T-cell leukemia/lymphoma research. <i>Personalized Medicine Universe</i> , 2013, 2, 7-11.	0.1	0
999	Epigenetic Alterations in Oncogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, v-vii.	0.8	10
1000	Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. <i>Blood</i> , 2013, 122, 684-693.	0.6	109
1001	Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. <i>Leukemia</i> , 2013, 27, 1628-1636.	3.3	123
1002	Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. <i>Experimental Neurology</i> , 2013, 241, 56-66.	2.0	77
1003	Environmental Epigenomics in Health and Disease. <i>Epigenetics and Human Health</i> , 2013, , .	0.2	3
1004	Nutrition, Histone Epigenetic Marks, and Disease. <i>Epigenetics and Human Health</i> , 2013, , 197-217.	0.2	1
1005	Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases. <i>Quarterly Reviews of Biophysics</i> , 2013, 46, 349-373.	2.4	28
1006	Common non-epigenetic drugs as epigenetic modulators. <i>Trends in Molecular Medicine</i> , 2013, 19, 742-753.	3.5	68

#	ARTICLE	IF	CITATIONS
1007	Epigenetic Approaches. , 2013, , 353-372.		1
1008	Methylation Inhibitors and Carcinogens in an Agent-Based Model for Colon Crypt Dynamics during Cancer Development. , 2013, ,		2
1009	Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. Cell Death and Disease, 2013, 4, e951-e951.	2.7	59
1010	Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition. FEBS Journal, 2013, 280, 2042-2055.	2.2	41
1011	The functional interactome landscape of the human histone deacetylase family. Molecular Systems Biology, 2013, 9, 672.	3.2	247
1012	Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma. Cancer, 2013, 119, 4259-4267.	2.0	66
1013	A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene Therapy, 2013, 20, 1-7.	2.2	68
1014	Biological Evaluation of New Largazole Analogues: Alteration of Macrocyclic Scaffold with Click Chemistry. ACS Medicinal Chemistry Letters, 2013, 4, 132-136.	1.3	36
1015	Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Advanced Drug Delivery Reviews, 2013, 65, 880-890.	6.6	308
1016	Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors. Oncogene, 2013, 32, 3184-3197.	2.6	59
1017	Transcriptional Pathways and Potential Therapeutic Targets in the Regulation of Ncx1 Expression in Cardiac Hypertrophy and Failure. Advances in Experimental Medicine and Biology, 2013, 961, 125-135.	0.8	14
1018	Epigenetic Targeting Therapies to Overcome Chemotherapy Resistance. Advances in Experimental Medicine and Biology, 2013, 754, 285-311.	0.8	23
1019	Discovery of Pyridone-Based Histone Deacetylase Inhibitors: Approaches for Metabolic Stability. ChemMedChem, 2013, 8, 272-279.	1.6	19
1020	Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro. Cancer Letters, 2013, 329, 17-26.	3.2	29
1021	Enantioselective apoptosis induction in histiocytic lymphoma cells and acute promyelocytic leukemia cells. Archives of Toxicology, 2013, 87, 303-310.	1.9	1
1022	Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochemical Pharmacology, 2013, 85, 449-465.	2.0	148
1023	Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif. Journal of Medicinal Chemistry, 2013, 56, 1772-1776.	2.9	104
1024	A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. Biomedicine and Pharmacotherapy, 2013, 67, 407-415.	2.5	20

#	ARTICLE	IF	CITATIONS
1025	Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism. <i>Biochemical and Biophysical Research Communications</i> , 2013, 435, 107-112.	1.0	14
1026	C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors. <i>Oncogene</i> , 2013, 32, 3896-3903.	2.6	36
1027	Cancers with wrong HATs: the impact of acetylation. <i>Briefings in Functional Genomics</i> , 2013, 12, 231-243.	1.3	132
1028	Targeting DNA damage response: Threshold, chromatin landscape and beyond. , 2013, 138, 46-52.		5
1029	The one-two punch: Combination treatment in chronic myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 667-679.	2.0	7
1030	Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?. <i>Medical Hypotheses</i> , 2013, 81, 311-315.	0.8	5
1031	Myeloid-cell differentiation redefined in cancer. <i>Nature Immunology</i> , 2013, 14, 197-199.	7.0	28
1032	Changing course by lymphocyte lineage redirection. <i>Nature Immunology</i> , 2013, 14, 199-201.	7.0	6
1033	Histone deacetylase inhibitors in the treatment for multiple myeloma. <i>International Journal of Hematology</i> , 2013, 97, 324-332.	0.7	28
1034	Unique functional roles for class I and class II histone deacetylases in central nervous system development and function. <i>International Journal of Developmental Neuroscience</i> , 2013, 31, 370-381.	0.7	62
1035	Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. <i>Future Oncology</i> , 2013, 9, 255-269.	1.1	119
1036	Interplay between the Cancer Genome and Epigenome. <i>Cell</i> , 2013, 153, 38-55.	13.5	733
1037	Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 4053-4064.	1.1	48
1038	Up-regulation of miR-146b and Down-regulation of miR-200b Contribute to the Cytotoxic Effect of Histone Deacetylase Inhibitors on <i>ras</i> -Transformed Thyroid Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1031-E1040.	1.8	4
1039	Probing Arginine Sideâ€ˆChains and Their Dynamics with Carbonâ€ˆDetected NMR Spectroscopy: Application to the 42â€ˆkDa Human Histone Deacetylaseâ€ˆ8 at High pH. <i>Angewandte Chemie - International Edition</i> , 2013,7.2 52, 3145-3147.		34
1040	Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. <i>Oncogene</i> , 2013, 32, 599-609.	2.6	135
1041	Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4â€ˆ-piperidine] based histone deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2013, 64, 273-284.	2.6	14
1042	Update on Clinical Trials: Genetic Targets in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, 35-54.	0.8	6

#	ARTICLE	IF	CITATIONS
1043	Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. <i>Nature Reviews Cancer</i> , 2013, 13, 497-510.	12.8	490
1044	Simultaneously defining cell phenotypes, cell cycle, and chromatin modifications at single-cell resolution. <i>FASEB Journal</i> , 2013, 27, 2667-2676.	0.2	24
1045	The Histone Deacetylase Inhibitor Sodium Butyrate Promotes Cell Death and Differentiation and Reduces Neurosphere Formation in Human Medulloblastoma Cells. <i>Molecular Neurobiology</i> , 2013, 48, 533-543.	1.9	48
1046	Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 790-799.	1.4	44
1047	Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models. <i>Biochemical and Biophysical Research Communications</i> , 2013, 433, 456-462.	1.0	15
1048	Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?. , 2013, 140, 34-52.		193
1049	Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. <i>Biologics: Targets and Therapy</i> , 2013, 7, 47.	3.0	220
1050	1-(Arylsulfonyl)-N-(hydroxyacrylamide)indolines Histone Deacetylase Inhibitors Are Potent Cytokine Release Suppressors. <i>ChemBioChem</i> , 2013, 14, 1248-1254.	1.3	21
1051	Storage of Hydrogen Spin Polarization in Long-Lived ¹³ C Singlet Order and Implications for Hyperpolarized Magnetic Resonance Imaging. <i>Journal of the American Chemical Society</i> , 2013, 135, 9632-9635.	6.6	65
1052	Different effect of sodium butyrate on cancer and normal prostate cells. <i>Toxicology in Vitro</i> , 2013, 27, 1489-1495.	1.1	19
1053	HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. <i>Cell Death and Disease</i> , 2013, 4, e519-e519.	2.7	150
1054	Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells <i>in vitro</i> and <i>in vivo</i> models. <i>British Journal of Pharmacology</i> , 2013, 170, 233-244.	2.7	12
1055	Tropolones As Lead-Like Natural Products: The Development of Potent and Selective Histone Deacetylase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 757-761.	1.3	82
1056	The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 114-120.	1.8	25
1057	Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with 18F-FAHA. <i>NeuroImage</i> , 2013, 64, 630-639.	2.1	42
1058	Metabolic reprogramming by class I and II histone deacetylases. <i>Trends in Endocrinology and Metabolism</i> , 2013, 24, 48-57.	3.1	81
1059	Loop Interactions and Dynamics Tune the Enzymatic Activity of the Human Histone Deacetylase 8. <i>Journal of the American Chemical Society</i> , 2013, 135, 17862-17868.	6.6	35
1060	Lithium Down-regulates Histone Deacetylase 1 (HDAC1) and Induces Degradation of Mutant Huntingtin. <i>Journal of Biological Chemistry</i> , 2013, 288, 35500-35510.	1.6	42

#	ARTICLE	IF	CITATIONS
1061	Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential. <i>International Journal of Hematology</i> , 2013, 97, 198-209.	0.7	14
1062	Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. <i>International Journal of Clinical Oncology</i> , 2013, 18, 87-95.	1.0	31
1063	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , 2013, 19, 734-744.	0.9	38
1064	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 994-999.	1.3	42
1065	The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low <i>Xist</i> Expression. <i>Clinical Cancer Research</i> , 2013, 19, 6520-6531.	3.2	122
1066	SAHA Treatment Reveals the Link between Histone Lysine Acetylation and Proteome in Nonsmall Cell Lung Cancer A549 Cells. <i>Journal of Proteome Research</i> , 2013, 12, 4064-4073.	1.8	37
1067	Synthesis and Structure-Activity Relationship of 3-Hydroxypyridine-2-thione-Based Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9969-9981.	2.9	34
1068	Loss of histone deacetylases 1 and 2 in hepatocytes impairs murine liver regeneration through Ki67 depletion. <i>Hepatology</i> , 2013, 58, 2089-2098.	3.6	37
1070	A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1091-1094.	0.5	51
1071	Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data. <i>Clinical Investigation</i> , 2013, 3, 557-569.	0.0	3
1072	Inhibition of Class I Histone Deacetylases Unveils a Mitochondrial Signature and Enhances Oxidative Metabolism in Skeletal Muscle and Adipose Tissue. <i>Diabetes</i> , 2013, 62, 732-742.	0.3	196
1073	A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. <i>Cell Death and Differentiation</i> , 2013, 20, 1306-1316.	5.0	38
1074	Romidepsin for the treatment of T-cell lymphomas. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1115-1122.	0.5	27
1075	p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. <i>Nucleic Acids Research</i> , 2013, 41, 2267-2283.	6.5	19
1076	MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. <i>Nucleic Acids Research</i> , 2013, 41, 6018-6033.	6.5	87
1077	Histone Deacetylase Inhibitors and Epigenetic Modifications as a Novel Strategy in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 333-340.	1.0	25
1078	Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma. <i>Cancer Discovery</i> , 2013, 3, 324-337.	7.7	60
1079	HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy. <i>Molecular Therapy</i> , 2013, 21, 887-894.	3.7	98

#	ARTICLE	IF	CITATIONS
1080	Survival factor NFIL3 restricts FOXO-induced gene expression in cancer. <i>Genes and Development</i> , 2013, 27, 916-927.	2.7	42
1081	Targeting of histone deacetylases in brain tumors. <i>CNS Oncology</i> , 2013, 2, 359-376.	1.2	22
1082	Strategies To Modulate Heritable Epigenetic Defects in Cellular Machinery: Lessons from Nature. <i>Pharmaceuticals</i> , 2013, 6, 1-24.	1.7	27
1083	Expression of Acetylated and Dimethylated Histone H3 in Colorectal Cancer. <i>Digestive Surgery</i> , 2013, 30, 249-258.	0.6	14
1084	Synergistic combination of valproic acid and oncolytic parvovirus H Δ 1 <sc>PV</sc> as a potential therapy against cervical and pancreatic carcinomas. <i>EMBO Molecular Medicine</i> , 2013, 5, 1537-1555.	3.3	55
1085	Epigenetic Contributions to Hormonally Mediated Sexual Differentiation of the Brain. <i>Journal of Neuroendocrinology</i> , 2013, 25, 1133-1140.	1.2	87
1086	Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2709-2721.	1.9	45
1087	Inactivating mutation in histone deacetylase 3 stabilizes its active conformation. <i>Protein Science</i> , 2013, 22, 1306-1312.	3.1	7
1088	Epigenetic Regulation of Sensory Axon Regeneration after Spinal Cord Injury. <i>Journal of Neuroscience</i> , 2013, 33, 19664-19676.	1.7	128
1089	Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches. <i>Clinical Investigation</i> , 2013, 3, 571-594.	0.0	2
1090	Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. <i>Cell Death and Disease</i> , 2013, 4, e738-e738.	2.7	30
1091	Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. <i>Cell Death and Disease</i> , 2013, 4, e556-e556.	2.7	113
1092	The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. <i>Cell Death and Disease</i> , 2013, 4, e810-e810.	2.7	67
1093	Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 10747-10752.	3.3	82
1094	Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. <i>Blood</i> , 2013, 121, 2038-2050.	0.6	80
1095	- Vitamin B12. , 2013, , 460-503.		0
1096	A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. <i>Blood</i> , 2013, 121, 3459-3468.	0.6	106
1097	Treatment of relapsed/refractory myeloma. , 0, , 144-166.		0

#	ARTICLE	IF	CITATIONS
1099	Preparation of Small-Molecule Microarrays by <i>trans</i> -Cyclooctene Tetrazine Ligation and Their Application in the High-Throughput Screening of Protein-Protein Interaction Inhibitors of Bromodomains. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 14060-14064.	7.2	38
1100	SAHA, an HDAC Inhibitor, Attenuates Antibody-Mediated Allograft Rejection. <i>Transplantation</i> , 2013, 96, 529-537.	0.5	5
1101	The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expression of specificity protein 1 in oral squamous cell carcinoma. <i>International Journal of Molecular Medicine</i> , 2013, 32, 860-866.	1.8	22
1102	Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells. <i>Oncology Reports</i> , 2013, 29, 1238-1244.	1.2	10
1103	Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA. <i>Oncology Reports</i> , 2013, 30, 961-967.	1.2	11
1104	Improved Therapeutic Effect against Leukemia by a Combination of the Histone Methyltransferase Inhibitor Chaetocin and the Histone Deacetylase Inhibitor Trichostatin A. <i>Journal of Korean Medical Science</i> , 2013, 28, 237.	1.1	31
1105	Targeting Epigenetics in Nervous System Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 126-141.	0.8	11
1106	RuvBL2 Is Involved in Histone Deacetylase Inhibitor PCI-24781-Induced Cell Death in SK-N-DZ Neuroblastoma Cells. <i>PLoS ONE</i> , 2013, 8, e71663.	1.1	11
1107	The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation. <i>PLoS ONE</i> , 2013, 8, e73401.	1.1	41
1108	Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment. <i>PLoS ONE</i> , 2013, 8, e77684.	1.1	35
1109	Trichostatin A Promotes the Generation and Suppressive Functions of Regulatory T Cells. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	19
1110	Profile of panobinostat and its potential for treatment in solid tumors: an update. <i>OncoTargets and Therapy</i> , 2013, 6, 1613.	1.0	58
1111	Histone deacetylase inhibitors. , 0 , 912-920.		0
1112	Roles of Histone Deacetylases in Angiogenic Cellular Processes. <i>Current Angiogenesis</i> , 2013, 2, 60-66.	0.1	2
1114	Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 249.	1.0	31
1115	(+)-Vitisin A Inhibits Osteoclast Differentiation by Preventing TRAF6 Ubiquitination and TRAF6-TAK1 Formation to Suppress NFATc1 Activation. <i>PLoS ONE</i> , 2014, 9, e89159.	1.1	21
1116	An Intelligent System for Identifying Acetylated Lysine on Histones and Nonhistone Proteins. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	20
1117	Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast. <i>Journal of Breast Cancer</i> , 2014, 17, 323.	0.8	72

#	ARTICLE	IF	CITATIONS
1118	Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications. <i>International Journal of Biological Sciences</i> , 2014, 10, 757-770.	2.6	133
1119	Extrahepatic Metabolism may Complicate the IVVC in Rats. <i>Drug Metabolism Letters</i> , 2014, 8, 51-66.	0.5	1
1120	Modulation of Butyrate Anticancer Activity by Solid Lipid Nanoparticle Delivery: An in Vitro Investigation on Human Breast Cancer and Leukemia Cell Lines. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2014, 17, 231.	0.9	27
1121	Histone deacetylase inhibitor treatment induces β -BRCAness TM and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. <i>Oncotarget</i> , 2014, 5, 5637-5650.	0.8	131
1122	Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. <i>Oncotarget</i> , 2014, 5, 4516-4528.	0.8	29
1123	HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process. <i>Cancer Biology and Therapy</i> , 2014, 15, 1561-1570.	1.5	22
1124	EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells. <i>Cancer Biology and Therapy</i> , 2014, 15, 1677-1687.	1.5	49
1125	Chemopreventive Effects of an HDAC2-Selective Inhibitor on Rat Colon Carcinogenesis and APC ^{min/+} Mouse Intestinal Tumorigenesis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 59-68.	1.3	13
1126	Context-Selective Death of Acute Myeloid Leukemia Cells Triggered by the Novel Hybrid Retinoid-HDAC Inhibitor MC2392. <i>Cancer Research</i> , 2014, 74, 2328-2339.	0.4	33
1127	Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 245-252.	0.8	37
1128	Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study. <i>Xenobiotica</i> , 2014, 44, 849-854.	0.5	8
1129	Histone deacetylase inhibitors in cancer therapy. A review. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2014, 158, 161-169.	0.2	53
1130	MTA family of proteins in prostate cancer: biology, significance, and therapeutic opportunities. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 929-942.	2.7	25
1131	Co-administration of ABT-737 and SAHA induces apoptosis, mediated by Noxa upregulation, Bax activation and mitochondrial dysfunction in PTEN-intact malignant human glioma cell lines. <i>Journal of Neuro-Oncology</i> , 2014, 120, 459-472.	1.4	13
1132	Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21 WAF1 expression and cell cycle arrest. <i>Anti-Cancer Drugs</i> , 2014, 25, 767-777.	0.7	3
1133	Molecular Pathways: Targeting ETS Gene Fusions in Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4442-4448.	3.2	54
1134	Acetylation Preserves Retinal Ganglion Cell Structure and Function in a Chronic Model of Ocular Hypertension. , 2014, 55, 7486.		29
1135	Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 287-299.	1.4	34

#	ARTICLE	IF	CITATIONS
1136	Current Status of Healthy Human Skin Models: Can Histone Deacetylase Inhibitors Potentially Improve the Present Replacement Models?. <i>Skin Pharmacology and Physiology</i> , 2014, 27, 36-46.	1.1	3
1137	Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 964, 212-221.	1.2	14
1138	Histone deacetylase inhibitor valproic acid affects plasmacytoid dendritic cells phenotype and function. <i>Immunobiology</i> , 2014, 219, 637-643.	0.8	19
1139	Epigenetic Mechanisms of Cancer Metastasis. <i>Cancer Drug Discovery and Development</i> , 2014, , 87-104.	0.2	0
1141	Pubertal supplementation of lipotropes in female rats reduces mammary cancer risk by suppressing histone deacetylase 1. <i>European Journal of Nutrition</i> , 2014, 53, 1139-1143.	1.8	1
1142	Targeting tumour-supportive cellular machineries in anticancer drug development. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 179-196.	21.5	202
1143	Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. <i>Cancer Letters</i> , 2014, 347, 183-190.	3.2	45
1144	Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013). <i>Expert Opinion on Therapeutic Patents</i> , 2014, 24, 401-415.	2.4	40
1145	Class II HDACs and Neuronal Regeneration. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 1225-1233.	1.2	11
1146	Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2014, 131, 104-112.	1.7	14
1147	Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights. , 2014, 143, 323-336.		219
1148	Epigenetics and Oncology. <i>Pharmacotherapy</i> , 2014, 34, 495-505.	1.2	47
1150	Cylindromatosis gene CYLD regulates hepatocyte growth factor expression in hepatic stellate cells through interaction with histone deacetylase 7. <i>Hepatology</i> , 2014, 60, 1066-1081.	3.6	35
1151	Lysine Deacetylase (KDAC) Regulatory Pathways: an Alternative Approach to Selective Modulation. <i>ChemMedChem</i> , 2014, 9, 511-522.	1.6	29
1152	Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next. <i>ChemMedChem</i> , 2014, 9, 523-536.	1.6	83
1153	Histone Deacetylase Inhibitor Sensitizes Apoptosis-Resistant Melanomas to Cytotoxic Human T Lymphocytes through Regulation of TRAIL/DR5 Pathway. <i>Journal of Immunology</i> , 2014, 192, 3981-3989.	0.4	21
1154	Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 721-732.	1.7	12
1155	Vascular histone deacetylation by pharmacological HDAC inhibition. <i>Genome Research</i> , 2014, 24, 1271-1284.	2.4	79

#	ARTICLE	IF	CITATIONS
1156	The return of the nucleus: transcriptional and epigenetic control of autophagy. <i>Nature Reviews Molecular Cell Biology</i> , 2014, 15, 65-74.	16.1	393
1157	Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. <i>Leukemia</i> , 2014, 28, 577-588.	3.3	112
1158	The Effect of Various Zinc Binding Groups on Inhibition of Histone Deacetylases 11. <i>ChemMedChem</i> , 2014, 9, 614-626.	1.6	52
1159	3D QSAR and docking studies of a series of histone deacetylase inhibitors. <i>Medicinal Chemistry Research</i> , 2014, 23, 2229-2241.	1.1	3
1160	Inhibition of histone deacetylases protects septic mice from lung and splenic apoptosis. <i>Journal of Surgical Research</i> , 2014, 187, 559-570.	0.8	34
1161	Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells. <i>Toxicology Letters</i> , 2014, 224, 225-232.	0.4	25
1162	Phenotypic Screens Targeting Neurodegenerative Diseases. <i>Journal of Biomolecular Screening</i> , 2014, 19, 1-16.	2.6	26
1163	Epigenetic drugs as immunomodulators for combination therapies in solid tumors. , 2014, 142, 339-350.		92
1164	Histone Deacetylases. <i>Journal of Histochemistry and Cytochemistry</i> , 2014, 62, 11-33.	1.3	126
1165	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2014, 86, 639-652.	2.6	48
1166	Design and Optimization of Novel Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides Bearing Potent Activities against Tumor Growth and Metastasis. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9357-9369.	2.9	30
1167	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5450-5454.	1.0	16
1168	Structure-Function Analysis of the Conserved Tyrosine and Diverse π -Stacking among Class I Histone Deacetylases: A QM (DFT)/MM MD Study. <i>Journal of Chemical Information and Modeling</i> , 2014, 54, 3162-3171.	2.5	14
1169	Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 524-538.	3.3	57
1170	Largazole, an inhibitor of class I histone deacetylases, attenuates inflammatory corneal neovascularization. <i>European Journal of Pharmacology</i> , 2014, 740, 619-626.	1.7	21
1171	Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 8966-8976.	1.5	9
1172	Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell proliferation and migration. <i>Biochemical Pharmacology</i> , 2014, 91, 181-190.	2.0	24
1173	A Chemical Strategy for the Cell-Based Detection of HDAC Activity. <i>ACS Chemical Biology</i> , 2014, 9, 1257-1262.	1.6	6

#	ARTICLE	IF	CITATIONS
1174	A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs. <i>Journal of Immunology</i> , 2014, 193, 2850-2862.	0.4	106
1175	Inhibition and Mechanism of HDAC8 Revisited. <i>Journal of the American Chemical Society</i> , 2014, 136, 11636-11643.	6.6	51
1176	Management of Castration Resistant Prostate Cancer. <i>Current Clinical Urology</i> , 2014, , .	0.0	2
1177	Efforts towards the synthesis of microsporin B: ready access to both the enantiomers of the key amino acid fragment. <i>Tetrahedron Letters</i> , 2014, 55, 4777-4779.	0.7	7
1178	The growing landscape of lysine acetylation links metabolism and cell signalling. <i>Nature Reviews Molecular Cell Biology</i> , 2014, 15, 536-550.	16.1	1,153
1179	Cyclometalated Ir(III) complexes as targeted theranostic anticancer therapeutics: combining HDAC inhibition with photodynamic therapy. <i>Chemical Communications</i> , 2014, 50, 10945.	2.2	114
1180	Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 673-691.	21.5	1,277
1181	Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment. <i>MedChemComm</i> , 2014, 5, 1789-1796.	3.5	41
1182	The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells. , 2014, 2, 8.		42
1183	Exploring the Potential binding Sites of Some Known HDAC Inhibitors on Some HDAC8 Conformers by Docking Studies. <i>Applied Biochemistry and Biotechnology</i> , 2014, 173, 1907-1926.	1.4	24
1184	Tunable diblock copolypeptide hydrogel depots for local delivery of hydrophobic molecules in healthy and injured central nervous system. <i>Biomaterials</i> , 2014, 35, 1989-2000.	5.7	45
1185	Development of a Fluorogenic Probe Based on a DNA Staining Dye for Continuous Monitoring of the Histone Deacetylase Reaction. <i>Analytical Chemistry</i> , 2014, 86, 7925-7930.	3.2	26
1186	Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP. <i>Molecular Cancer Research</i> , 2014, 12, 1755-1766.	1.5	74
1187	Natural compounds in epigenetics: A current view. <i>Food and Chemical Toxicology</i> , 2014, 73, 71-83.	1.8	35
1188	Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 5766-5775.	1.4	33
1189	RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells. <i>Oncogene</i> , 2014, 33, 1527-1537.	2.6	29
1190	Identification of a Novel Aminotetralin Class of HDAC6 and HDAC8 Selective Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8026-8034.	2.9	54
1191	Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo. <i>Clinical Immunology</i> , 2014, 151, 29-42.	1.4	63

#	ARTICLE	IF	CITATIONS
1192	Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 445, 320-326.	1.0	21
1193	Posttranslational modifications of histone deacetylases: Implications for cardiovascular diseases. , 2014, 143, 168-180.		75
1194	Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells. <i>Journal of Dermatological Science</i> , 2014, 75, 140-147.	1.0	19
1195	β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update. <i>European Journal of Medicinal Chemistry</i> , 2014, 74, 302-313.	2.6	86
1196	Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activity. <i>Biochemical and Biophysical Research Communications</i> , 2014, 447, 616-620.	1.0	4
1197	A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies. <i>Cancer Letters</i> , 2014, 346, 84-93.	3.2	21
1198	Molecular mechanisms and physiology of disease. , 2014, , .		1
1199	Design, synthesis, and biological evaluation of largazole derivatives: alteration of the zinc-binding domain. <i>Tetrahedron</i> , 2014, 70, 7763-7769.	1.0	14
1200	Early-Stage Ovarian Cancer. , 2014, , 1461-1466.		0
1201	Antitumour effect of valproic acid against salivary gland cancer in vitro and in vivo. <i>Oncology Reports</i> , 2014, 31, 1453-1458.	1.2	2
1202	Synthesis and Biological Evaluation of Raddeanin A, a Triterpene Saponin Isolated from <i>Anemone raddeana</i> . <i>Chemical and Pharmaceutical Bulletin</i> , 2014, 62, 779-785.	0.6	9
1203	Design, Synthesis and Biological Evaluation of Nitro Oxide Donating <i>N</i> -Hydroxycinnamamide Derivatives as Histone Deacetylase Inhibitors. <i>Chemical and Pharmaceutical Bulletin</i> , 2014, 62, 1185-1191.	0.6	12
1204	In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: A paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma. <i>Oncology Reports</i> , 2014, 31, 955-968.	1.2	22
1205	Oncolytic Viruses and Histone Deacetylase Inhibitors. , 2014, , 437-466.		0
1206	Epigenetic alterations in acute myeloid leukemias. <i>FEBS Journal</i> , 2015, 282, 1786-1800.	2.2	36
1207	Suberoylanilide Hydroxamic Acid Treatment Reveals Crosstalks among Proteome, Ubiquitylome and Acetylome in Non-Small Cell Lung Cancer A549 Cell Line. <i>Scientific Reports</i> , 2015, 5, 9520.	1.6	78
1208	Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines. <i>Molecular Medicine Reports</i> , 2015, 11, 4525-4531.	1.1	41
1209	The effects of a novel aliphatic-chain hydroxamate derivative WMJ-S-001 in HCT116 colorectal cancer cell death. <i>Scientific Reports</i> , 2015, 5, 15900.	1.6	9

#	ARTICLE	IF	CITATIONS
1210	Valproic Acid Limits Pancreatic Recovery after Pancreatitis by Inhibiting Histone Deacetylases and Preventing Acinar Redifferentiation Programs. <i>American Journal of Pathology</i> , 2015, 185, 3304-3315.	1.9	29
1212	Remodeling of retrotransposon elements during epigenetic induction of adult visual cortical plasticity by HDAC inhibitors. <i>Epigenetics and Chromatin</i> , 2015, 8, 55.	1.8	32
1213	Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia. <i>Clinical Epigenetics</i> , 2015, 7, 117.	1.8	35
1214	Epigenetic treatment of solid tumours: a review of clinical trials. <i>Clinical Epigenetics</i> , 2015, 7, 127.	1.8	183
1215	Light-Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy. <i>Chemistry - A European Journal</i> , 2015, 21, 16517-16524.	1.7	117
1216	Selective inhibition of histone deacetylase 6 promotes survival in a rat model of hemorrhagic shock. <i>Journal of Trauma and Acute Care Surgery</i> , 2015, 79, 905-910.	1.1	13
1217	Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression. <i>British Journal of Pharmacology</i> , 2015, 172, 3817-3830.	2.7	13
1218	Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer. <i>Journal of Breast Cancer</i> , 2015, 18, 249.	0.8	13
1219	Identification of potent histone deacetylase 8 inhibitors using pharmacophore-based virtual screening, three-dimensional quantitative structure-activity relationship, and docking study. <i>Research and Reports in Medicinal Chemistry</i> , 0, , 21.	0.3	6
1220	The Role of Histone Deacetylase (HDAC) as a Biomarker in Cancer. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2015, 06, .	0.4	3
1221	Role of polyphenolic acetates and calreticulin induced hyperacetylation via epigenetic modulation on apoptosis in Ehrlich Ascites tumour mice model. <i>Asian Journal of Medical Sciences</i> , 2015, 7, 13-20.	0.0	0
1222	The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. <i>International Journal of Molecular Sciences</i> , 2015, 16, 18252-18269.	1.8	9
1223	Molecular Targeted Therapies of Aggressive Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2015, 6, 176.	1.5	54
1224	Cabozantinib in Thyroid Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2015, 10, 259-269.	0.8	29
1225	Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays. <i>PLoS ONE</i> , 2015, 10, e0139588.	1.1	16
1226	Selective use of vandetanib in the treatment of thyroid cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3459.	2.0	23
1227	Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma. <i>Molecular Medicine</i> , 2015, 21, 824-832.	1.9	3
1228	Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 31767-31779.	0.8	28

#	ARTICLE	IF	CITATIONS
1229	A novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells. <i>Oncotarget</i> , 2015, 6, 20121-20131.	0.8	17
1230	Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers. <i>Chemical Science</i> , 2015, 6, 804-815.	3.7	93
1231	Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. <i>British Journal of Haematology</i> , 2015, 169, 506-519.	1.2	39
1232	Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 15-29.	2.5	13
1233	New Therapies for Dedifferentiated Papillary Thyroid Cancer. <i>International Journal of Molecular Sciences</i> , 2015, 16, 6153-6182.	1.8	49
1234	Treatment of chronic kidney diseases with histone deacetylase inhibitors. <i>Frontiers in Physiology</i> , 2015, 6, 121.	1.3	58
1235	Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 308, H1391-H1401.	1.5	39
1236	The State of the Art of Epigenetic Technologies. , 2015, , 1-18.		1
1237	Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. <i>Molecular Oncology</i> , 2015, 9, 1447-1457.	2.1	111
1238	Chemical and Genetic Approaches to Study Histone Modifications. , 2015, , 149-168.		2
1239	Analysis of class I and II histone deacetylase gene expression in human leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3426-3433.	0.6	20
1240	Characterization of <i>Trypanosoma cruzi</i> Sirtuins as Possible Drug Targets for Chagas Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4669-4679.	1.4	36
1241	A miniaturized readout strategy for endogenous histone deacetylase activity. <i>Molecular BioSystems</i> , 2015, 11, 1820-1823.	2.9	5
1242	Vorinostat Enhance TRAIL-Induced Apoptosis Via DR5 in Anaplastic Thyroid Cancer Cells. , 2015, , .		2
1243	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2492-2499.	0.8	394
1244	Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease. <i>Clinical Epigenetics</i> , 2015, 7, 108.	1.8	52
1245	Radiosensitization of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays. <i>International Journal of Radiation Biology</i> , 2015, 91, 90-98.	1.0	26
1246	Metabolic modulation of cancer: a new frontier with great translational potential. <i>Journal of Molecular Medicine</i> , 2015, 93, 127-142.	1.7	27

#	ARTICLE	IF	CITATIONS
1247	Synthesis and characterization of valproic acid ester pro-drug micelles via an amphiphilic polycaprolactone block copolymer design. <i>Polymer Chemistry</i> , 2015, 6, 2386-2389.	1.9	13
1248	Molecular mechanisms of synaptic remodeling in alcoholism. <i>Neuroscience Letters</i> , 2015, 601, 11-19.	1.0	61
1249	Selective class IIa HDAC inhibitors: myth or reality. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 73-86.	2.4	44
1250	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5151-5155.	1.4	35
1251	Epigenetics of Reproduction. , 2015, , 2439-2501.		2
1252	Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. <i>Cancer</i> , 2015, 121, 1654-1661.	2.0	39
1253	Comparative Modeling and Benchmarking Data Sets for Human Histone Deacetylases and Sirtuin Families. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 374-388.	2.5	25
1254	Belinostat for the treatment of T-cell lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 219-227.	0.5	0
1255	Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. <i>Cell Death and Disease</i> , 2015, 6, e1657-e1657.	2.7	137
1256	Epigenetics of Melanoma. , 2015, , 339-361.		1
1257	Trichostatin a modulates intracellular reactive oxygen species through SOD2 and FOXO1 in human bone marrow-mesenchymal stem cells. <i>Cell Biochemistry and Function</i> , 2015, 33, 37-43.	1.4	17
1258	Textbook of Cell Signalling in Cancer. , 2015, , .		6
1259	Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 691-700.	1.1	11
1260	Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma microenvironment via xCT equilibration. <i>Scientific Reports</i> , 2014, 4, 6226.	1.6	20
1261	Transcription factors and chromatin proteins as therapeutic targets in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 183-192.	3.3	24
1262	A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2793-2802.	0.6	33
1263	HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review). <i>Oncology Letters</i> , 2015, 9, 515-521.	0.8	32
1264	The epigenetics of aging and neurodegeneration. <i>Progress in Neurobiology</i> , 2015, 131, 21-64.	2.8	334

#	ARTICLE	IF	CITATIONS
1265	Genetic analysis of common variants in the HDAC2 gene with schizophrenia susceptibility in Han Chinese. <i>Journal of Human Genetics</i> , 2015, 60, 479-484.	1.1	40
1266	An HDAC-Targeted Imaging Probe LBH589- ⁶⁴ Cy5.5 for Tumor Detection and Therapy Evaluation. <i>Molecular Pharmaceutics</i> , 2015, 12, 2469-2476.	2.3	23
1267	Revisit dietary fiber on colorectal cancer: butyrate and its role on prevention and treatment. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 465-478.	2.7	91
1268	Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 1000, 181-186.	1.2	23
1269	Galactosylated magnetic nanovectors for regulation of lipid metabolism based on biomarker-specific RNAi and MR imaging. <i>Nanotechnology</i> , 2015, 26, 335101.	1.3	1
1270	Tumor necrosis factor- α -related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotype. <i>Molecular Biology of the Cell</i> , 2015, 26, 3178-3189.	0.9	44
1271	Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation. <i>Cancer Gene Therapy</i> , 2015, 22, 410-416.	2.2	22
1272	Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis. <i>Experimental Hematology</i> , 2015, 43, 609-624.	0.2	47
1273	Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?. <i>Current Oncology Reports</i> , 2015, 17, 40.	1.8	11
1274	4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation. <i>Experimental Cell Research</i> , 2015, 336, 263-275.	1.2	9
1275	Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. <i>Oncogene</i> , 2015, 34, 5960-5970.	2.6	67
1276	Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5881-5890.	1.4	17
1277	Triazine as a promising scaffold for its versatile biological behavior. <i>European Journal of Medicinal Chemistry</i> , 2015, 102, 39-57.	2.6	97
1278	ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias. <i>Epigenetics</i> , 2015, 10, 6-18.	1.3	29
1279	Novel therapeutic strategies for multiple myeloma. <i>Experimental Hematology</i> , 2015, 43, 732-741.	0.2	98
1280	Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. <i>Epigenomics</i> , 2015, 7, 641-652.	1.0	46
1281	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 3457-3471.	1.4	28
1282	A phosphorescent rhenium(^{III}) histone deacetylase inhibitor: mitochondrial targeting and paraptosis induction. <i>Chemical Communications</i> , 2015, 51, 8353-8356.	2.2	49

#	ARTICLE	IF	CITATIONS
1283	Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteric acids. <i>European Journal of Medicinal Chemistry</i> , 2015, 96, 340-359.	2.6	28
1284	Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. <i>Leukemia Research</i> , 2015, 39, 371-379.	0.4	16
1285	Emerging approaches for histone deacetylase inhibitor drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 599-613.	2.5	63
1286	Histone deacetylase inhibitor attenuates neurotoxicity of clioquinol in PC12 cells. <i>Toxicology</i> , 2015, 331, 112-118.	2.0	13
1287	Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor. <i>Biochemical Pharmacology</i> , 2015, 94, 79-90.	2.0	22
1288	Redox regulation of cardiomyocyte cell cycling via an ERK1/2 and c-Myc-dependent activation of cyclin D2 transcription. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 79, 54-68.	0.9	31
1289	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. <i>Modern Pathology</i> , 2015, 28, 884-894.	2.9	37
1290	Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1 α destabilization. <i>Molecular Cancer</i> , 2015, 14, 4.	7.9	60
1291	Epigenetic therapy for solid tumors: from bench science to clinical trials. <i>Epigenomics</i> , 2015, 7, 215-235.	1.0	59
1292	Ten years of subproteome investigations in lactic acid bacteria: A key for food starter and probiotic typing. <i>Journal of Proteomics</i> , 2015, 127, 332-339.	1.2	17
1293	Luotonin-A based quinazolinones cause apoptosis and senescence via HDAC inhibition and activation of tumor suppressor proteins in HeLa cells. <i>European Journal of Medicinal Chemistry</i> , 2015, 94, 87-101.	2.6	28
1294	Nanostructured delivery system for Suberoylanilide hydroxamic acid against lung cancer cells. <i>Materials Science and Engineering C</i> , 2015, 51, 362-368.	3.8	14
1295	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 96, 1-13.	2.6	42
1296	Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5061-5074.	1.4	32
1297	Distinct novel quinazolinone exhibits selective inhibition in MGC-803 cancer cells by dictating mutant p53 function. <i>European Journal of Medicinal Chemistry</i> , 2015, 95, 377-387.	2.6	27
1298	Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors. <i>Cancer Letters</i> , 2015, 361, 197-206.	3.2	11
1299	Invasive Cell Fate Requires G1 Cell-Cycle Arrest and Histone Deacetylase-Mediated Changes in Gene Expression. <i>Developmental Cell</i> , 2015, 35, 162-174.	3.1	120
1300	Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. <i>Cancer Biology and Therapy</i> , 2015, 16, 1784-1793.	1.5	32

#	ARTICLE	IF	CITATIONS
1301	Targeting epigenetic regulations in cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 97-109.	0.9	60
1302	Reprogramming cancer cells: A novel approach for cancer therapy or a tool for disease-modeling?. <i>Cancer Letters</i> , 2015, 369, 1-8.	3.2	16
1303	Gold-Catalyzed Intramolecular Cyclization of α -Propargylic β -Enaminones for the Synthesis of 1,4-Oxazepine Derivatives. <i>Journal of Organic Chemistry</i> , 2015, 80, 11162-11168.	1.7	82
1304	Inhibition mechanism of SAHA in HDAC: a revisit. <i>Physical Chemistry Chemical Physics</i> , 2015, 17, 29483-29488.	1.3	10
1305	Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 10226-10235.	1.5	12
1306	Lung cancer: Biology and treatment options. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 189-210.	3.3	526
1307	Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a α -(2-Aminophenyl)-benzamide Binding Unit. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6803-6818.	2.9	48
1308	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7672-7680.	2.9	49
1309	Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). <i>Pharmaceutical Patent Analyst</i> , 2015, 4, 261-284.	0.4	36
1310	Direct trifluoroacetylation of mono- and disubstituted thiophene derivatives. <i>Journal of Fluorine Chemistry</i> , 2015, 180, 272-275.	0.9	5
1311	Identification of Structural Features of α,β -Alkylidene- γ -Dicarbonyl Derivatives that Induce Inhibition and/or Activation of Histone Acetyltransferases KAT3B/p300 and KAT2B/PCAF. <i>ChemMedChem</i> , 2015, 10, 144-157.	1.6	21
1312	The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR-T790M mutated lung cancer. <i>International Journal of Cancer</i> , 2015, 136, 2717-2729.	2.3	55
1313	New Insights into the Connection Between Histone Deacetylases, Cell Metabolism, and Cancer. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 30-50.	2.5	11
1314	(α)-Epigallocatechin-3-gallate induces cancer cell apoptosis via acetylation of amyloid precursor protein. <i>Medical Oncology</i> , 2015, 32, 390.	1.2	29
1315	Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells. <i>Tumor Biology</i> , 2015, 36, 1471-1476.	0.8	4
1316	4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents. <i>Investigational New Drugs</i> , 2015, 33, 104-108.	1.2	5
1317	Targeting Histone Deacetylases in Diseases: Where Are We?. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 99-126.	2.5	101
1318	The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 1425-1462.	2.5	9

#	ARTICLE	IF	CITATIONS
1319	Epigenetic therapy as a novel approach in hepatocellular carcinoma. , 2015, 145, 103-119.		59
1320	Inverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases. International Journal of Medical Sciences, 2016, 13, 48-59.	1.1	27
1321	Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials. OncoTargets and Therapy, 2016, 9, 1167.	1.0	5
1322	Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases. International Journal of Molecular Sciences, 2016, 17, 26.	1.8	7
1323	Personalized Epigenetics. , 2016, , 843-858.		2
1324	The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches. Journal of Clinical and Experimental Hematopathology: JCEH, 2016, 56, 20-27.	0.3	10
1325	Synthesis and Preclinical Evaluation of a Highly Improved Anticancer Prodrug Activated by Histone Deacetylases and Cathepsin L. Theranostics, 2016, 6, 808-816.	4.6	22
1326	Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn- β and chemoresistance in acute myeloid leukemia. Cancer Biomarkers, 2016, 16, 81-88.	0.8	7
1327	The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation. Biomolecules, 2016, 6, 45.	1.8	22
1328	Epigenetics in Brain Tumors: HDACs Take Center Stage. Current Neuropharmacology, 2016, 14, 48-54.	1.4	21
1329	Saffron-Based Crocin Prevents Early Lesions of Liver Cancer: In vivo, In vitro and Network Analyses. Recent Patents on Anti-Cancer Drug Discovery, 2016, 11, 121-133.	0.8	70
1330	Discovery and Development of Small Molecules Targeting Epigenetic Enzymes with Computational Methods. , 2016, , 75-112.		4
1331	In β -Bead Screening of Hydroxamic Acids for the Identification of HDAC Inhibitors. Angewandte Chemie - International Edition, 2016, 55, 4472-4475.	7.2	15
1332	Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid. Archiv Der Pharmazie, 2016, 349, 373-382.	2.1	9
1333	Design, synthesis, inhibiting HDACs ability and antitumor activity of pyrimidin-4(3H)-one hydroxamate derivatives. Chemical Research in Chinese Universities, 2016, 32, 576-580.	1.3	1
1334	Loss of histone deacetylase HDAC1 induces cell death in Drosophila epithelial cells through JNK and Hippo signaling. Mechanisms of Development, 2016, 141, 4-13.	1.7	7
1335	In β -Bead Screening of Hydroxamic Acids for the Identification of HDAC Inhibitors. Angewandte Chemie, 2016, 128, 4548-4551.	1.6	0
1336	Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach. International Journal of Oncology, 2016, 48, 2591-2607.	1.4	26

#	ARTICLE	IF	CITATIONS
1338	Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade. <i>Scientific Reports</i> , 2016, 6, 25082.	1.6	20
1339	Histone deacetylase enzyme silencing using shRNAs enhances radiosensitivity of SW579 thyroid cancer cells. <i>Molecular Medicine Reports</i> , 2016, 14, 3509-3516.	1.1	5
1340	HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. <i>Oncology Reports</i> , 2016, 36, 589-597.	1.2	45
1342	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells. <i>Oncology Reports</i> , 2016, 36, 1875-1885.	1.2	32
1343	Plant Isoquinoline Alkaloid Berberine Exhibits Chromatin Remodeling by Modulation of Histone Deacetylase To Induce Growth Arrest and Apoptosis in the A549 Cell Line. <i>Journal of Agricultural and Food Chemistry</i> , 2016, 64, 9542-9550.	2.4	52
1344	Sequencing of nontransplant treatments in multiple myeloma patients with active disease. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 495-503.	0.9	6
1345	Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. <i>Journal of Hematology and Oncology</i> , 2016, 9, 49.	6.9	124
1346	Histone Modifications and Cancer. <i>Cold Spring Harbor Perspectives in Biology</i> , 2016, 8, a019521.	2.3	626
1347	<i>Anaplasma phagocytophilum</i> increases the levels of histone modifying enzymes to inhibit cell apoptosis and facilitate pathogen infection in the tick vector <i>Ixodes scapularis</i> . <i>Epigenetics</i> , 2016, 11, 303-319.	1.3	73
1348	Inside HDACs with more selective HDAC inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 451-483.	2.6	259
1349	Inhibitors of histone deacetylase as antitumor agents: A critical review. <i>Bioorganic Chemistry</i> , 2016, 67, 18-42.	2.0	170
1350	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5488-5504.	2.9	53
1351	Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. <i>Immunotherapy</i> , 2016, 8, 705-719.	1.0	61
1352	Histone deacetylase inhibitor sulforaphane: The phytochemical with vibrant activity against prostate cancer. <i>Biomedicine and Pharmacotherapy</i> , 2016, 81, 250-257.	2.5	35
1353	Epigenetic Advancements in Cancer. , 2016, , .		1
1354	Epigenesis in Colorectal Cancer: A Lethal Change in the Cell. , 2016, , 123-144.		0
1355	Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 541-52.	1.2	42
1356	Disubstituted naphthyl Î²-D-xylopyranosides: Synthesis, GAG priming, and histone acetyltransferase (HAT) inhibition. <i>Glycoconjugate Journal</i> , 2016, 33, 245-257.	1.4	3

#	ARTICLE	IF	CITATIONS
1357	Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors. <i>Oncogene</i> , 2016, 35, 5515-5526.	2.6	24
1358	Histone deacetylase inhibition enhances antimicrobial peptide but not inflammatory cytokine expression upon bacterial challenge. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E2993-3001.	3.3	55
1359	Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile. <i>ACS Chemical Biology</i> , 2016, 11, 1844-1851.	1.6	21
1360	Repurposing strategies for tropical disease drug discovery. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2569-2576.	1.0	83
1361	Tcf1 and Lef1 transcription factors establish CD8+ T cell identity through intrinsic HDAC activity. <i>Nature Immunology</i> , 2016, 17, 695-703.	7.0	188
1362	Therapeutic Effect of Histone Deacetylase Inhibitor, Sodium Butyrate, on Allergic Rhinitis <i>In Vivo</i> . <i>DNA and Cell Biology</i> , 2016, 35, 203-208.	0.9	40
1363	DNA binding modes of leukemia oncoproteins. <i>Blood</i> , 2016, 127, 177-178.	0.6	2
1364	Design, synthesis and in vitro evaluation of amidoximes as histone deacetylase inhibitors for cancer therapy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4679-4683.	1.0	6
1365	Chemical epigenetics to assess the role of HDAC1 ^{Δ3} inhibition in macrophage pro-inflammatory gene expression. <i>MedChemComm</i> , 2016, 7, 2184-2190.	3.5	7
1366	Loss of HDAC-Mediated Repression and Gain of NF- κ B Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer. <i>Cell Reports</i> , 2016, 17, 275-288.	2.9	37
1367	Preparation and Biochemical Analysis of Classical Histone Deacetylases. <i>Methods in Enzymology</i> , 2016, 573, 161-181.	0.4	3
1368	Epigenetic Library Screen Identifies Abexinostat as Novel Regulator of Adipocytic and Osteoblastic Differentiation of Human Skeletal (Mesenchymal) Stem Cells. <i>Stem Cells Translational Medicine</i> , 2016, 5, 1036-1047.	1.6	27
1369	TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types. <i>Bioinformatics</i> , 2016, 32, i413-i420.	1.8	64
1370	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5183-5196.	1.4	15
1371	Histone deacetylase inhibitors suppress RSV infection and alleviate virus-induced airway inflammation. <i>International Journal of Molecular Medicine</i> , 2016, 38, 812-822.	1.8	33
1372	Panobinostat for the treatment of acute myelogenous leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1117-1131.	1.9	23
1373	The Endothelium-Dependent Nitric Oxide-cGMP Pathway. <i>Advances in Pharmacology</i> , 2016, 77, 1-27.	1.2	71
1374	Review structure- and dynamics-based computational design of anticancer drugs. <i>Biopolymers</i> , 2016, 105, 2-9.	1.2	11

#	ARTICLE	IF	CITATIONS
1375	Superparamagnetic Copper Ferrite Nanoparticles Catalyzed One Step Regioselective Synthesis of Dibenzodiazepinones via Ligand and Base Free Ullmann Type Coupling Reaction. <i>ChemistrySelect</i> , 2016, 1, 852-860.	0.7	14
1376	Development of a Potent and Selective HDAC8 Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 929-932.	1.3	59
1377	A novel combinatorial strategy using Seliciclib® and Belinostat® for eradication of non-small cell lung cancer via apoptosis induction and BID activation. <i>Cancer Letters</i> , 2016, 381, 49-57.	3.2	41
1378	HDAC inhibition in the <i>cpfl1</i> mouse protects degenerating cone photoreceptors <i>in vivo</i> . <i>Human Molecular Genetics</i> , 2016, 25, dww275.	1.4	39
1379	Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6. <i>Cell Death Discovery</i> , 2016, 2, 16036.	2.0	32
1380	Cancer Stem Cells as New Therapeutic Targets for Ovarian Cancer. , 2016, , 231-259.		0
1382	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 1569-1578.	5.1	164
1383	Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma. <i>Cancer Biology and Therapy</i> , 2016, 17, 1168-1176.	1.5	16
1384	Integrative Genomic Analysis Identifies the Core Transcriptional Hallmarks of Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2016, 76, 6374-6381.	0.4	48
1385	The Emerging Role of Epigenetics in Pulmonary Arterial Hypertension: An Important Avenue for Clinical Trials (2015 Grover Conference Series). <i>Pulmonary Circulation</i> , 2016, 6, 274-284.	0.8	17
1386	Design and synthesis of novel dual-target agents for HDAC1 and CK2 inhibition. <i>RSC Advances</i> , 2016, 6, 66595-66608.	1.7	20
1387	Activation of AMP-activated Protein Kinase by Metformin Induces Protein Acetylation in Prostate and Ovarian Cancer Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 25154-25166.	1.6	71
1388	Quantitative Analysis of Global Proteome and Lysine Acetylome Reveal the Differential Impacts of VPA and SAHA on HL60 Cells. <i>Scientific Reports</i> , 2016, 6, 19926.	1.6	34
1389	Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. <i>BMC Cancer</i> , 2016, 16, 857.	1.1	37
1390	Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C. <i>Journal of Cellular Physiology</i> , 2016, 231, 1645-1655.	2.0	48
1391	Is there any therapeutic value for the use of histone deacetylase inhibitors for chronic pain?. <i>Brain Research Bulletin</i> , 2016, 125, 44-52.	1.4	17
1392	Epigenetic regulation of soluble guanylate cyclase (sGC) β_1 in breast cancer cells. <i>FASEB Journal</i> , 2016, 30, 3171-3180.	0.2	11
1393	Searching Histone Deacetylase Inhibitors under Computational Procedures. , 2016, , 213-229.		0

#	ARTICLE	IF	CITATIONS
1394	2-(Phenylsulfonyl)quinoline N -hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 92-101.	2.6	28
1395	Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: A systematic review and meta-analysis. <i>Transplantation Reviews</i> , 2016, 30, 171-177.	1.2	22
1396	The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines. <i>Cancer Cell International</i> , 2016, 16, 31.	1.8	11
1397	Epigenetics and Angiogenesis in Cancer. , 2016, , 145-176.		1
1398	HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma. <i>Cancer Letters</i> , 2016, 379, 134-142.	3.2	71
1399	DNA methylation signatures of mood stabilizers and antipsychotics in bipolar disorder. <i>Epigenomics</i> , 2016, 8, 197-208.	1.0	70
1400	Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 307-317.	1.9	45
1401	Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms. <i>Cell Death and Disease</i> , 2016, 7, e2063-e2063.	2.7	69
1402	An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β -Cell Protection. <i>ACS Chemical Biology</i> , 2016, 11, 363-374.	1.6	78
1403	PEG based anti-cancer drug conjugated prodrug micelles for the delivery of anti-cancer agents. <i>Journal of Materials Chemistry B</i> , 2016, 4, 360-370.	2.9	60
1404	Improving cancer immunotherapy with DNA methyltransferase inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 787-796.	2.0	37
1405	Investigating the Sensitivity of NAD ⁺ -dependent Sirtuin Deacylation Activities to NADH. <i>Journal of Biological Chemistry</i> , 2016, 291, 7128-7141.	1.6	91
1406	Toward dissecting the etiology of schizophrenia: HDAC1 and DAXX regulate GAD67 expression in an in vitro hippocampal GABA neuron model. <i>Translational Psychiatry</i> , 2016, 6, e723-e723.	2.4	18
1407	Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 613-621.	1.1	28
1408	MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification. <i>Nature Communications</i> , 2016, 7, 10492.	5.8	72
1409	Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. <i>British Journal of Cancer</i> , 2016, 114, 605-611.	2.9	210
1410	Selective Photorelease of an Organometallic-Containing Enzyme Inhibitor. <i>Organometallics</i> , 2016, 35, 851-854.	1.1	28
1411	Histone deacetylase inhibitor trichostatin A resensitizes gemcitabine resistant urothelial carcinoma cells via suppression of TG-interacting factor. <i>Toxicology and Applied Pharmacology</i> , 2016, 290, 98-106.	1.3	11

#	ARTICLE	IF	CITATIONS
1412	Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1521-1529.	1.4	48
1413	A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 1727-1735.	1.5	17
1414	A potent trifluoromethyl ketone histone deacetylase inhibitor exhibits class-dependent mechanism of action. <i>MedChemComm</i> , 2016, 7, 464-470.	3.5	22
1415	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 53-67.	2.6	26
1416	Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease. <i>ACS Chemical Neuroscience</i> , 2016, 7, 240-258.	1.7	60
1417	NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. <i>Leukemia</i> , 2016, 30, 182-189.	3.3	74
1418	Assessment of Tissue Level of Histone Deacetylase-2 (HDAC-2) in Patients With Mycosis Fungoides. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 40-43.	0.6	1
1419	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1455-1470.	2.9	83
1420	TrkB blockade in the hippocampus after training or retrieval impairs memory: protection from consolidation impairment by histone deacetylase inhibition. <i>Journal of Neural Transmission</i> , 2016, 123, 159-165.	1.4	18
1421	Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer. <i>Oncogene</i> , 2016, 35, 1517-1528.	2.6	61
1422	Living long and ageing well: is epigenomics the missing link between nature and nurture?. <i>Biogerontology</i> , 2016, 17, 33-54.	2.0	25
1423	Short-term memory of danger signals or environmental stimuli in mesenchymal stem cells: implications for therapeutic potential. <i>Cellular and Molecular Immunology</i> , 2016, 13, 369-378.	4.8	63
1424	Impact of Phytochemicals and Dietary Patterns on Epigenome and Cancer. <i>Nutrition and Cancer</i> , 2017, 69, 184-200.	0.9	15
1425	HDAC10 as a potential therapeutic target in ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 144, 613-620.	0.6	39
1426	Ion mobility-mass spectrometry reveals evidence of specific complex formation between human histone deacetylase 8 and poly-r(C)-binding protein 1. <i>International Journal of Mass Spectrometry</i> , 2017, 420, 9-15.	0.7	2
1427	Cisplatin and valproate released from the bifunctional [Pt ^(IV) Cl ₂ (NH ₃) ₂ (valproato) ₂] antitumor prodrug or from liposome formulations: who does what?. <i>Dalton Transactions</i> , 2017, 46, 1559-1566.	1.6	27
1428	Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 167-180.	2.1	70
1429	Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 551-560.	2.8	19

#	ARTICLE	IF	CITATIONS
1430	Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?. <i>Gut</i> , 2017, 66, 168-179.	6.1	103
1431	Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: Selective Class I Histone Deacetylase Inhibitors. <i>Israel Journal of Chemistry</i> , 2017, 57, 319-330.	1.0	3
1432	Epigenetics: a link between addiction and social environment. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 2735-2747.	2.4	50
1433	Low-Intensity Ultrasound Enhances Histone Acetylation and Inhibition of Interleukin 6 Messenger RNA Expression by the Histone Deacetylase Inhibitor Sodium Butyrate in Fibroblasts. <i>Journal of Ultrasound in Medicine</i> , 2017, 36, 879-885.	0.8	8
1434	Copper(I)-Mediated Denitrogenative Macrocyclization for the Synthesis of Cyclic Tripeptide Analogues. <i>Chemistry - an Asian Journal</i> , 2017, 12, 1326-1337.	1.7	7
1435	Asbestos and Mesothelioma. <i>Current Cancer Research</i> , 2017, , .	0.2	5
1436	An Olefin Cross-Metathesis Approach to Depudecin and Stereoisomeric Analogues. <i>Journal of Organic Chemistry</i> , 2017, 82, 4744-4757.	1.7	9
1437	Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma. <i>Molecular Oncology</i> , 2017, 11, 965-980.	2.1	31
1438	A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Suppresses Cell Migration and Invasion in Monomorphic Malignant Human Glioma Cells by Inhibiting FAK/STAT3 Signaling. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 4672-4685.	1.2	17
1439	The Functional Genome. , 2017, , 21-44.		1
1440	In vitro and in vivo anti-veal melanoma activity of JSL-1, a novel HDAC inhibitor. <i>Cancer Letters</i> , 2017, 400, 47-60.	3.2	31
1441	Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat. <i>Lung Cancer</i> , 2017, 103, 58-65.	0.9	39
1442	Plant-derived flavone Apigenin: The small-molecule with promising activity against therapeutically resistant prostate cancer. <i>Biomedicine and Pharmacotherapy</i> , 2017, 85, 47-56.	2.5	44
1443	The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 88, 124-132.	1.2	13
1444	Solvent-Controlled Chemoselectivity in the Photolytic Release of Hydroxamic Acids and Carboxamides from Solid Support. <i>Organic Letters</i> , 2017, 19, 3263-3266.	2.4	10
1445	Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo. <i>Oncology Letters</i> , 2017, 13, 4868-4874.	0.8	15
1446	Exploring Derivatives of Quinazoline Alkaloid Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3484-3497.	2.9	18
1447	Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 510-515.	1.3	30

#	ARTICLE	IF	CITATIONS
1448	Histone deacetylase inhibitors suppress immature dendritic cell's migration by regulating CC chemokine receptor 1 expression. <i>Cellular Immunology</i> , 2017, 316, 11-20.	1.4	5
1449	The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis. <i>Clinical and Translational Oncology</i> , 2017, 19, 1045-1054.	1.2	26
1450	A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer. <i>International Journal of Cancer</i> , 2017, 140, 2375-2386.	2.3	22
1451	Ring-opened tetrahydro- β -carbolines display cytotoxicity and selectivity with histone deacetylase isoforms. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 115-127.	2.6	20
1452	Selective histone deacetylase small molecule inhibitors: recent progress and perspectives. <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 621-636.	2.4	73
1453	Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 1202-1218.	1.4	26
1454	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 531-553.	2.6	17
1455	Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors. <i>ChemMedChem</i> , 2017, 12, 2030-2043.	1.6	9
1456	A Brain-Derived Neurotrophic Factor Mimetic Is Sufficient to Restore Cone Photoreceptor Visual Function in an Inherited Blindness Model. <i>Scientific Reports</i> , 2017, 7, 11320.	1.6	35
1457	Histone Deacetylase Is Required for GA-Induced Programmed Cell Death in Maize Aleurone Layers. <i>Plant Physiology</i> , 2017, 175, 1484-1496.	2.3	21
1458	MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 229-237.	2.5	43
1459	Recent development of luminescent rhenium(^{III}) tricarbonyl polypyridine complexes as cellular imaging reagents, anticancer drugs, and antibacterial agents. <i>Dalton Transactions</i> , 2017, 46, 16357-16380.	1.6	142
1460	Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. <i>Cancer</i> , 2017, 123, 4851-4859.	2.0	45
1461	Sodium phenylbutyrate abrogates African swine fever virus replication by disrupting the virus-induced hypoacetylation status of histone H3K9/K14. <i>Virus Research</i> , 2017, 242, 24-29.	1.1	15
1462	The transformation of the nuclear nanoarchitecture in human field carcinogenesis. <i>Future Science OA</i> , 2017, 3, FSO206.	0.9	8
1463	An unsymmetric cisplatin-based Pt(IV) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate. <i>Dalton Transactions</i> , 2017, 46, 14174-14185.	1.6	39
1464	Memantine-derived drugs as potential antitumor agents for the treatment of glioblastoma. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, 402-411.	1.9	31
1465	Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes. <i>Journal of Biological Chemistry</i> , 2017, 292, 17598-17608.	1.6	43

#	ARTICLE	IF	CITATIONS
1466	The Effectiveness of Cyclic Hydroxamic Acid CHA-5 against Drug-Resistant P388 Leukemia Strains. <i>Bulletin of Experimental Biology and Medicine</i> , 2017, 163, 385-388.	0.3	1
1467	The Wnt/ β -catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation. <i>Tumor Biology</i> , 2017, 39, 101042831771261.	0.8	56
1468	Inhibition of histone deacetylases sensitizes EGF receptor- TK inhibitor-resistant non-small cell lung cancer cells to erlotinib <i>in vitro</i> and <i>in vivo</i> . <i>British Journal of Pharmacology</i> , 2017, 174, 3608-3622.	2.7	34
1469	Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. <i>Cancer Letters</i> , 2017, 405, 100-110.	3.2	90
1470	Design, Synthesis, and Biological Evaluation of Tetrahydroisoquinoline-Based Histone Deacetylase 8 Selective Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 824-829.	1.3	29
1471	Synthesis, characterization, and evaluation of Cd[L-proline] ₂ , a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells. <i>Investigational New Drugs</i> , 2017, 35, 691-705.	1.2	9
1472	Trichostatin A induces bladder cancer cell death via intrinsic apoptosis at the early phase and Sp1-survivin downregulation at the late phase of treatment. <i>Oncology Reports</i> , 2017, 38, 1587-1596.	1.2	13
1473	Intrinsic Dynamics of the Binding Rail and Its Allosteric Effect in the Class I Histone Deacetylases. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 2309-2320.	2.5	9
1474	Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation. <i>Clinical Cancer Research</i> , 2017, 23, 6541-6554.	3.2	27
1475	Modulations of DNMT1 and HDAC1 are involved in the OTA-induced cytotoxicity and apoptosis <i>in vitro</i> . <i>Chemico-Biological Interactions</i> , 2017, 278, 170-178.	1.7	16
1476	New targets and therapies for gastrointestinal stromal tumors. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1117-1129.	1.1	18
1477	Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4614-4619.	1.4	4
1478	Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an <i>in Silico</i> Virtual Screening Approach. <i>Scientific Reports</i> , 2017, 7, 3228.	1.6	36
1479	Scriptaid cause histone deacetylase inhibition and cell cycle arrest in HeLa cancer cells: A study on structural and functional aspects. <i>Gene</i> , 2017, 627, 379-386.	1.0	14
1480	Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation. <i>Molecular Cancer</i> , 2017, 16, 88.	7.9	27
1481	From profiles to function in epigenomics. <i>Nature Reviews Genetics</i> , 2017, 18, 51-66.	7.7	233
1482	Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. <i>Hepatology</i> , 2017, 65, 515-528.	3.6	200
1483	Overexpression of Histone Deacetylase and Amyloid Precursor Protein in Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 586-594.	0.8	8

#	ARTICLE	IF	CITATIONS
1484	Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis. <i>International Immunopharmacology</i> , 2017, 42, 25-31.	1.7	14
1485	Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2017, 57, 87-97.	0.3	26
1486	HDAC inhibition potentiates immunotherapy in triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 114156-114172.	0.8	139
1488	Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 6503-6520.	3.3	33
1489	Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer. <i>Diseases (Basel)</i> , 2017, 7, 50-58.	1.0	54
1490	Histone Deacetylase Inhibitors as Anticancer Drugs. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1414.	1.8	890
1491	Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1. <i>PLoS ONE</i> , 2017, 12, e0170301.	1.1	12
1492	Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. <i>PLoS Medicine</i> , 2017, 14, e1002382.	3.9	107
1493	Three Combined Treatments, a Novel HDAC Inhibitor OBP-801/YM753, 5-Fluorouracil, and Paclitaxel, Induce G ₂ Phase Arrest Through the p38 Pathway in Human Ovarian Cancer Cells. <i>Oncology Research</i> , 2017, 25, 1245-1252.	0.6	12
1494	YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor. <i>Oncotarget</i> , 2017, 8, 40583-40593.	0.8	20
1495	HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?. <i>Oncotarget</i> , 2017, 8, 28187-28202.	0.8	8
1496	Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells. <i>Journal of Nutritional Biochemistry</i> , 2018, 56, 183-192.	1.9	56
1497	A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment. <i>Cell Death and Differentiation</i> , 2018, 25, 2053-2070.	5.0	22
1498	Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2018, 53, 1434-1444.	1.3	8
1499	Computational analysis for selectivity of histone deacetylase inhibitor by replica-exchange umbrella sampling molecular dynamics simulations. <i>Journal of Chemical Physics</i> , 2018, 148, 125102.	1.2	7
1500	Activatable Fluorescence Probe via Self-Immolative Intramolecular Cyclization for Histone Deacetylase Imaging in Live Cells and Tissues. <i>Analytical Chemistry</i> , 2018, 90, 5534-5539.	3.2	43
1501	Anti-plasmodial activity of sodium acetate in <i>Plasmodium berghei</i> infected mice. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2018, 29, 493-498.	0.7	2
1502	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. <i>Neuro-Oncology</i> , 2018, 20, 546-556.	0.6	93

#	ARTICLE	IF	CITATIONS
1503	Panobinostat and Multiple Myeloma in 2018. <i>Oncologist</i> , 2018, 23, 516-517.	1.9	51
1504	New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death. <i>Scientific Reports</i> , 2018, 8, 1400.	1.6	18
1505	2,4-Di-tert-butylphenol, a potential HDAC6 inhibitor, induces senescence and mitotic catastrophe in human gastric adenocarcinoma AGS cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018, 1865, 675-683.	1.9	33
1506	Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo. <i>Anti-Cancer Drugs</i> , 2018, 29, 262-270.	0.7	8
1507	HDAC6 interacts with PTPN1 to enhance melanoma cells progression. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 2630-2636.	1.0	23
1508	HDACis (class I), cancer stem cell, and phytochemicals: Cancer therapy and prevention implications. <i>Biomedicine and Pharmacotherapy</i> , 2018, 97, 1445-1453.	2.5	35
1509	Spirohydantoin and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2018, 146, 79-92.	2.6	26
1510	Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. <i>Nucleic Acids Research</i> , 2018, 46, 1756-1776.	6.5	58
1511	The long noncoding RNA lncZic2 drives the self-renewal of liver tumor-initiating cells via the protein kinase C substrates MARCKS and MARCKSL1. <i>Journal of Biological Chemistry</i> , 2018, 293, 7982-7992.	1.6	36
1512	HDAC inhibitors as epigenetic regulators for cancer immunotherapy. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 98, 65-74.	1.2	61
1513	Histone and RNA-binding protein interaction creates crosstalk network for regulation of alternative splicing. <i>Biochemical and Biophysical Research Communications</i> , 2018, 499, 30-36.	1.0	16
1514	Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma. <i>Medicine (United States)</i> , 2018, 97, e9611.	0.4	5
1515	The B7 Family Member B7-H6: a New Bane of Tumor. <i>Pathology and Oncology Research</i> , 2018, 24, 717-721.	0.9	35
1517	Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer. <i>Gene</i> , 2018, 641, 248-258.	1.0	44
1518	Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 1288-1299.	1.9	37
1519	Natural Agents-Mediated Targeting of Histone Deacetylases. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 31-44.	1.0	5
1520	CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance. <i>Investigational New Drugs</i> , 2018, 36, 10-19.	1.2	17
1521	Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1418-1425.	1.4	15

#	ARTICLE	IF	CITATIONS
1522	Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay. <i>Journal of Biomolecular Structure and Dynamics</i> , 2018, 36, 3231-3245.	2.0	29
1523	Differentiation therapy revisited. <i>Nature Reviews Cancer</i> , 2018, 18, 117-127.	12.8	320
1524	Treatment of Patients in First or Second Relapse. , 2018, , 77-102.		0
1525	Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2018, 36, 195-205.	1.2	19
1526	Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 469-478.	1.1	19
1527	Epigenetics in ovarian cancer. <i>Seminars in Cancer Biology</i> , 2018, 51, 160-169.	4.3	86
1528	Ultimate Precision: Targeting Cancer but Not Normal Self-replication. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 950-963.	1.8	13
1529	Noxa: Role in Cancer Pathogenesis and Treatment. <i>Current Cancer Drug Targets</i> , 2018, 18, 914-928.	0.8	34
1530	Oncogenic IL7R is downregulated by histone deacetylase inhibitor in esophageal squamous cell carcinoma via modulation of acetylated FOXO1. <i>International Journal of Oncology</i> , 2018, 53, 395-403.	1.4	18
1531	Computational QSAR model combined molecular descriptors and fingerprints to predict HDAC1 inhibitors. <i>Medecine/Sciences</i> , 2018, 34, 52-58.	0.0	15
1532	Alpha-tubulin acetyltransferase/MEC-17 regulates cancer cell migration and invasion through epithelialâ€mesenchymal transition suppression and cell polarity disruption. <i>Scientific Reports</i> , 2018, 8, 17477.	1.6	37
1533	Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 329-336.	1.0	7
1534	OBPâ€801, a novel histone deacetylase inhibitor, induces Mâ€phase arrest and apoptosis in rhabdomyosarcoma cells. <i>Oncology Reports</i> , 2019, 41, 643-649.	1.2	4
1535	Vorinostat enhances gefitinibâ€induced cell death through reactive oxygen speciesâ€dependent cleavage of HSP90 and its clients in nonâ€small cell lung cancer with the EGFR mutation. <i>Oncology Reports</i> , 2019, 41, 525-533.	1.2	14
1536	Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients. <i>Journal of Cancer</i> , 2018, 9, 4547-4555.	1.2	31
1537	Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3952.	1.8	35
1538	Histone deacetylases as targets for antitrypanosomal drugs. <i>Future Science OA</i> , 2018, 4, FSO325.	0.9	19
1539	A novel long noncoding RNA HOXC-AS3 mediates tumorigenesis of gastric cancer by binding to YBX1. <i>Genome Biology</i> , 2018, 19, 154.	3.8	216

#	ARTICLE	IF	CITATIONS
1540	Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma. <i>Cell Death and Disease</i> , 2018, 9, 1032.	2.7	45
1541	Relative Transcription Expression Level of SIRT1, SIRT2 and SIRT3 in Correlation to the Expression of a Set of Selected Cancer Related Genes in Human Breast Cancer. <i>OnLine Journal of Biological Sciences</i> , 2018, 18, 147-157.	0.2	0
1542	Trichostatin A inhibits proliferation of triple negative breast cancer cells by inducing cell cycle arrest and apoptosis. <i>Neoplasma</i> , 2018, 65, 898-906.	0.7	15
1543	MGCD0103 induces apoptosis and simultaneously increases the expression of NF- κ B and PD-L1 in classical Hodgkin's lymphoma. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 3827-3834.	0.8	4
1544	Structural basis of the specific interaction of SMRT corepressor with histone deacetylase 4. <i>Nucleic Acids Research</i> , 2018, 46, 11776-11788.	6.5	21
1545	4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 812-819.	1.0	37
1546	Epigenome-Based Precision Medicine in Lung Cancer. <i>Methods in Molecular Biology</i> , 2018, 1856, 57-85.	0.4	5
1547	Innovative DNA-Targeted Metallo-prodrug Strategy Combining Histone Deacetylase Inhibition with Oxidative Stress. <i>Molecular Pharmaceutics</i> , 2018, 15, 5058-5071.	2.3	22
1548	Molecular testing in the diagnosis of differentiated thyroid carcinomas. <i>Gland Surgery</i> , 2018, 7, S19-S29.	0.5	44
1549	The latest evidence for possible HIV-1 curative strategies. <i>Drugs in Context</i> , 2018, 7, 1-14.	1.0	26
1550	Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy. <i>ACS Infectious Diseases</i> , 2018, 4, 1448-1467.	1.8	27
1551	Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma. <i>Child's Nervous System</i> , 2018, 34, 1497-1509.	0.6	4
1552	Fetal Hemoglobin Induction by Epigenetic Drugs. <i>Seminars in Hematology</i> , 2018, 55, 60-67.	1.8	35
1553	Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer. <i>EBioMedicine</i> , 2018, 31, 276-286.	2.7	24
1554	The Benefits of Dietary Fiber Intake on Reducing the Risk of Cancer: An Umbrella Review of Meta-analyses. <i>Journal of Chiropractic Medicine</i> , 2018, 17, 90-96.	0.3	48
1556	<i>In Vivo</i> 6- ¹⁸ F-Fluoroacetamido-1-hexanoicanilide PET Imaging of Altered Histone Deacetylase Activity in Chemotherapy-Induced Neurotoxicity. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-12.	0.4	7
1557	Type 1 Diabetes and Epigenetics. , 2018, , 187-205.		3
1558	Epigenetic Modulations in Ovarian Cancer. , 2018, , 169-193.		1

#	ARTICLE	IF	CITATIONS
1559	Checkpoint Blockade Rescues the Repressive Effect of Histone Deacetylases Inhibitors on $\hat{\beta}$ T Cell Function. <i>Frontiers in Immunology</i> , 2018, 9, 1615.	2.2	21
1561	Development of hydroxamic acid derivatives as anticancer agent with the application of 3D-QSAR, docking and molecular dynamics simulations studies. <i>Medicinal Chemistry Research</i> , 2018, 27, 2100-2115.	1.1	6
1562	Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state. <i>British Journal of Pharmacology</i> , 2018, 175, 4209-4217.	2.7	17
1563	Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway. <i>Oncogene</i> , 2018, 37, 5952-5966.	2.6	57
1564	Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention. <i>Current Drug Targets</i> , 2018, 19, 593-601.	1.0	30
1565	HDAC Inhibition Improves the Sarcoendoplasmic Reticulum Ca ²⁺ -ATPase Activity in Cardiac Myocytes. <i>International Journal of Molecular Sciences</i> , 2018, 19, 419.	1.8	21
1566	Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy. <i>Nutrients</i> , 2018, 10, 731.	1.7	173
1567	Neutralizing negative epigenetic regulation by HDAC5 enhances human haematopoietic stem cell homing and engraftment. <i>Nature Communications</i> , 2018, 9, 2741.	5.8	56
1568	<i>in silico</i> approaches for investigating the binding propensity of apigenin and luteolin against class I HDAC isoforms. <i>Future Medicinal Chemistry</i> , 2018, 10, 1925-1945.	1.1	30
1569	Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents. <i>Current Protein and Peptide Science</i> , 2018, 19, 333-340.	0.7	10
1570	Multiple functions of p27 in cell cycle, apoptosis, epigenetic modification and transcriptional regulation for the control of cell growth: A double-edged sword protein. <i>DNA Repair</i> , 2018, 69, 63-72.	1.3	140
1571	Clinical Interventions in HIV Cure Research. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 285-318.	0.8	16
1572	Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. <i>Biochemical Pharmacology</i> , 2018, 155, 316-325.	2.0	16
1573	Computer-Aided Drug Design in Epigenetics. <i>Frontiers in Chemistry</i> , 2018, 6, 57.	1.8	51
1574	Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 171-179.	1.0	18
1575	The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2337.	1.8	67
1576	Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-12.	3.2	84
1577	Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma. <i>Journal of Pathology</i> , 2018, 246, 141-153.	2.1	18

#	ARTICLE	IF	CITATIONS
1578	Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies. <i>Leukemia Research</i> , 2018, 71, 13-24.	0.4	9
1579	DNA-dependent protein kinase: Epigenetic alterations and the role in genomic stability of cancer. <i>Mutation Research - Reviews in Mutation Research</i> , 2019, 780, 92-105.	2.4	11
1580	Epigenetic Dysregulation at the Crossroad of Women's Cancer. <i>Cancers</i> , 2019, 11, 1193.	1.7	11
1581	MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat. <i>Nature Communications</i> , 2019, 10, 3623.	5.8	71
1582	Current state of melanoma diagnosis and treatment. <i>Cancer Biology and Therapy</i> , 2019, 20, 1366-1379.	1.5	462
1583	HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells. <i>Oncogene</i> , 2019, 38, 6599-6614.	2.6	82
1584	Divergent Access to Histone Deacetylase Inhibitory Cyclopeptides via a Late-Stage Cyclopropane Ring Cleavage Strategy. <i>Short Synthesis of Chlamydocin</i> . <i>Organic Letters</i> , 2019, 21, 8473-8478.	2.4	16
1585	Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma. <i>Frontiers in Genetics</i> , 2019, 10, 986.	1.1	22
1586	Novel Targets for the Treatment of Melanoma. <i>Current Oncology Reports</i> , 2019, 21, 97.	1.8	15
1587	Suppressing Hedgehog signaling reverses drug resistance of refractory acute myeloid leukemia. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7477-7488.	1.0	12
1588	Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-15.	3.2	32
1589	Indole: A privileged scaffold for the design of anti-cancer agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111691.	2.6	291
1591	Comprehensive Exploration to Identify Predictive DNA Markers of p53/SOX2 in Drug Resistance in Human Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 4814-4825.	0.7	2
1592	Trends and Challenges in Tumor Anti-Angiogenic Therapies. <i>Cells</i> , 2019, 8, 1102.	1.8	150
1593	Recent advances in class IIa histone deacetylases research. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 115087.	1.4	37
1594	A fluorine scan on the Zn ²⁺ -binding thiolate side chain of HDAC inhibitor largazole: Synthesis, biological evaluation, and molecular modeling. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111672.	2.6	7
1595	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6992-7014.	2.9	58
1596	H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future. <i>Viruses</i> , 2019, 11, 562.	1.5	40

#	ARTICLE	IF	CITATIONS
1597	Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy. <i>Cancers</i> , 2019, 11, 850.	1.7	31
1598	Pharmacoeugenetics of Histone Deacetylase Inhibitors in Cancer. , 2019, , 501-521.		2
1599	Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells. <i>Cancers</i> , 2019, 11, 747.	1.7	36
1600	Trichostatin A inhibits proliferation of PC3 prostate cancer cells by disrupting the EGFR pathway. <i>Oncology Letters</i> , 2019, 18, 687-693.	0.8	9
1601	p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2415.	1.8	67
1602	Cend1, a Story with Many Tales: From Regulation of Cell Cycle Progression/Exit of Neural Stem Cells to Brain Structure and Function. <i>Stem Cells International</i> , 2019, 2019, 1-16.	1.2	21
1603	NK cells to cure cancer. <i>Seminars in Immunology</i> , 2019, 41, 101272.	2.7	70
1604	Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1436-1447.	2.8	30
1605	Pd-Catalyzed C(sp ²)-H Imidoylative Annulation: A General Approach To Construct Dibenzo(diazepines). <i>Journal of Organic Chemistry</i> , 2019, 84, 6524-6535.	1.7	31
1606	Design, synthesis and biological evaluation of 4-piperidin-4-yl-triazole derivatives as novel histone deacetylase inhibitors. <i>BioScience Trends</i> , 2019, 13, 197-203.	1.1	8
1607	A view on multi-action Pt(IV) antitumor prodrugs. <i>Inorganica Chimica Acta</i> , 2019, 492, 32-47.	1.2	71
1608	Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e613.	0.6	11
1609	Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 2225-2240.	1.7	53
1610	Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway. <i>FEBS Open Bio</i> , 2019, 9, 478-489.	1.0	18
1611	Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1291.	1.8	47
1612	Nrf2-miR-129-3p-mTOR Axis Controls an miRNA Regulatory Network Involved in HDACi-Induced Autophagy. <i>Molecular Therapy</i> , 2019, 27, 1039-1050.	3.7	39
1613	Targeting transcriptional machinery to inhibit enhancer-driven gene expression in heart failure. <i>Heart Failure Reviews</i> , 2019, 24, 725-741.	1.7	6
1614	Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 150.	3.5	25

#	ARTICLE	IF	CITATIONS
1615	Palladium-catalysed regioselective <i>N</i> -arylation of anthranilamides: a tandem route for dibenzodiazepinone synthesis. <i>New Journal of Chemistry</i> , 2019, 43, 7339-7343.	1.4	10
1616	Apoptosis Induction by Histone Deacetylase Inhibitors in Cancer Cells: Role of Ku70. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1601.	1.8	41
1617	Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome. <i>EBioMedicine</i> , 2019, 43, 253-260.	2.7	37
1618	HDAC inhibition as a therapeutic strategy in myocardial ischemia/reperfusion injury. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 129, 188-192.	0.9	19
1619	How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2467-2480.	1.7	86
1620	Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 168, 110-122.	2.6	37
1621	Targeting sickle cell disease root-cause pathophysiology with small molecules. <i>Haematologica</i> , 2019, 104, 1720-1730.	1.7	15
1622	Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5654.	1.8	16
1623	HDAC Inhibitors in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1794.	1.7	118
1624	Autophagy Machinery as a Promising Therapeutic Target in Endometrial Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1326.	1.3	27
1625	Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells. <i>Cells</i> , 2019, 8, 1480.	1.8	11
1626	Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 649-654.	0.6	21
1627	Targeting Metalloenzymes for Therapeutic Intervention. <i>Chemical Reviews</i> , 2019, 119, 1323-1455.	23.0	181
1628	Histone deacetylase 2 is essential for LPS-induced inflammatory responses in macrophages. <i>Immunology and Cell Biology</i> , 2019, 97, 72-84.	1.0	36
1629	Fluorogenic probes for disease-relevant enzymes. <i>Chemical Society Reviews</i> , 2019, 48, 683-722.	18.7	451
1630	Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 139-149.	1.1	16
1631	Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF7 breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 9172-9180.	1.2	35
1632	Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1577-1592.	2.9	31

#	ARTICLE	IF	CITATIONS
1633	The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma. <i>Cancer Biology and Therapy</i> , 2019, 20, 272-283.	1.5	11
1634	Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer. <i>Chemical Biology and Drug Design</i> , 2019, 93, 232-241.	1.5	18
1635	An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 38, 48-65.	2.0	15
1636	Expression of Adenoviral E1A in Transformed Cells as an Additional Factor of HDACi-Dependent FoxO Regulation. <i>Cells</i> , 2020, 9, 97.	1.8	2
1637	Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of Cap group. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3162-3172.	1.2	9
1638	Utility of histone H3K27me3 and H4K20me as diagnostic indicators of melanoma. <i>Melanoma Research</i> , 2020, 30, 159-165.	0.6	6
1639	Importance of the Microbiota Inhibitory Mechanism on the Warburg Effect in Colorectal Cancer Cells. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 738-747.	0.6	43
1640	Hypomethylating agent based combinations in higher risk myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2020, 61, 1012-1027.	0.6	2
1641	Histone Deacetylase Modifications by Probiotics in Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 754-764.	0.6	24
1642	Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity. <i>European Journal of Medicinal Chemistry</i> , 2020, 187, 111950.	2.6	27
1643	Epigenetic control of tumor angiogenesis. <i>Microcirculation</i> , 2020, 27, e12602.	1.0	11
1644	Genome-wide identification and transcriptional modulation of histone variants and modification related genes in the low pH-exposed marine rotifer <i>Brachionus koreanus</i> . <i>Comparative Biochemistry and Physiology Part D: Genomics and Proteomics</i> , 2020, 36, 100748.	0.4	3
1645	The application of histone deacetylases inhibitors in glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 138.	3.5	59
1646	Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. <i>Cancers</i> , 2020, 12, 1872.	1.7	18
1647	Present and future perspectives for targeting histone modifications in therapy. , 2020, , 415-457.		1
1648	Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 577784.	1.8	7
1649	Molecular targets of tyrosine kinase inhibitors in thyroid cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 180-196.	4.3	64
1650	Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth <i>in vitro</i> and <i>in vivo</i> partially through acetylation of p53. <i>International Journal of Biological Sciences</i> , 2020, 16, 3184-3199.	2.6	15

#	ARTICLE	IF	CITATIONS
1651	A distal regulatory region of a class I human histone deacetylase. <i>Nature Communications</i> , 2020, 11, 3841.	5.8	25
1652	Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. <i>Cancer Medicine</i> , 2020, 9, 8086-8121.	1.3	95
1653	Epigenetic-based cancer therapeutics: new potential HDAC8 inhibitors. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 297-311.	2.0	5
1654	<p>Novel HDAC/Tubulin Dual Inhibitor: Design, Synthesis and Docking Studies of Î±-Phthalimido-Chalcone Hybrids as Potential Anticancer Agents with Apoptosis-Inducing Activity</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3111-3130.	2.0	21
1655	Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 278.	3.5	27
1656	Identification of Novel MeCP2 Cancer-Associated Target Genes and Post-Translational Modifications. <i>Frontiers in Oncology</i> , 2020, 10, 576362.	1.3	7
1657	A Translational Study of a Silicon Phthalocyanine Substituted with a Histone Deacetylase Inhibitor for Photodynamic Therapy. <i>ACS Omega</i> , 2020, 5, 25854-25867.	1.6	21
1658	Gold-Catalyzed Regioselective Synthesis of Pyrazolo[1,4]oxazepines via Intramolecular 7-endo-Ëdig Cyclization. <i>European Journal of Organic Chemistry</i> , 2020, 2020, 3560-3567.	1.2	9
1659	Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. <i>Seminars in Cancer Biology</i> , 2022, 79, 203-216.	4.3	12
1660	Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression. <i>Journal of Nutritional Biochemistry</i> , 2020, 84, 108444.	1.9	37
1661	Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 600.	1.3	62
1662	A Synthetic Cell-Penetrating Heparin-Binding Peptide Derived from BMP4 with Anti-Inflammatory and Chondrogenic Functions for the Treatment of Arthritis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4251.	1.8	6
1663	A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110390.	2.5	17
1664	Transient receptor potential vanilloid 1 antagonism in neuroinflammation, neuroprotection and epigenetic regulation: potential therapeutic implications for severe psychiatric disorders treatment. <i>Psychiatric Genetics</i> , 2020, 30, 39-48.	0.6	16
1665	Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 175-184.	1.6	9
1666	Expression of Stromal Progesterone Receptor and Differential Methylation Patterns in the Endometrium May Correlate with Response to Progesterone Therapy in Endometrial Complex Atypical Hyperplasia. <i>Reproductive Sciences</i> , 2020, 27, 1778-1790.	1.1	7
1667	The design of a novel near-infrared fluorescent HDAC inhibitor and image of tumor cells. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115639.	1.4	6
1668	Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines. <i>Scientific Reports</i> , 2020, 10, 10462.	1.6	28

#	ARTICLE	IF	CITATIONS
1669	In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2020, 241, 118669.	2.0	6
1670	Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors. <i>Computers in Biology and Medicine</i> , 2020, 123, 103850.	3.9	9
1671	Epigenetic Therapy as a Putative Molecular Target to Modulate B Cell Biology and Behavior in the Context of Immunological Disorders. <i>Journal of Immunology Research</i> , 2020, 2020, 1-19.	0.9	5
1672	HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN/AKT/mTOR pathway. <i>Scientific Reports</i> , 2020, 10, 3576.	1.6	26
1673	A short guide to histone deacetylases including recent progress on class II enzymes. <i>Experimental and Molecular Medicine</i> , 2020, 52, 204-212.	3.2	221
1674	Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo. <i>European Journal of Medicinal Chemistry</i> , 2020, 190, 112086.	2.6	25
1675	MicroRNA-mediated regulation of Nrf2 signaling pathway: Implications in disease therapy and protection against oxidative stress. <i>Life Sciences</i> , 2020, 244, 117329.	2.0	41
1676	Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures. <i>Nanomaterials</i> , 2020, 10, 158.	1.9	17
1677	Potent non-hydroxamate inhibitors of histone deacetylase-8: Role and scope of an isoindolin-2-yl linker with an α -amino amide as the zinc-binding unit. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126926.	1.0	10
1678	Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders. <i>Life Sciences</i> , 2020, 243, 117278.	2.0	50
1679	Hybrid inhibitors of DNA and HDACs remarkably enhance cytotoxicity in leukaemia cells. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 1069-1079.	2.5	5
1680	Discovery of 1,3-Disubstituted 2,5-Diketopiperazine Derivatives as Potent Class I HDACs Inhibitors. <i>Chemical and Pharmaceutical Bulletin</i> , 2020, 68, 466-472.	0.6	9
1681	Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 196, 112291.	2.6	33
1682	Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors. <i>Molecules</i> , 2020, 25, 1497.	1.7	21
1683	Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors. <i>Molecules</i> , 2020, 25, 1952.	1.7	15
1684	Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 8977-9002.	2.9	95
1685	Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. <i>Nature Communications</i> , 2020, 11, 1792.	5.8	25
1686	Epigenetic Mechanisms Underlying Organic Solute Transporter β 1 Repression in Colorectal Cancer. <i>Molecular Pharmacology</i> , 2020, 97, 259-266.	1.0	6

#	ARTICLE	IF	CITATIONS
1687	Pattern-recognition-based Sensor Arrays for Cell Characterization: From Materials and Data Analyses to Biomedical Applications. <i>Analytical Sciences</i> , 2020, 36, 923-934.	0.8	12
1688	DUSP16 is a regulator of human hematopoietic stem and progenitor cells and promotes their expansion <i>ex vivo</i> . <i>Leukemia</i> , 2021, 35, 1516-1520.	3.3	3
1689	Drive to organoruthenium and organoiridium complexes from organoplatinum: Next-generation anticancer metallothertapeutics. <i>Inorganic Chemistry Communication</i> , 2021, 124, 108364.	1.8	12
1690	Novel Pyridine-Based Hydroxamates and 2-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. <i>ChemMedChem</i> , 2021, 16, 989-999.	1.6	8
1691	Implantable HDAC-inhibiting chemotherapeutics derived from hydrophobic amino acids for localized anticancer therapy. <i>Biomaterials Science</i> , 2021, 9, 261-271.	2.6	4
1692	Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 773-779.	1.0	13
1693	Neuregulin Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1270, 1-29.	0.8	1
1694	Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma. <i>Journal of Cellular Physiology</i> , 2021, 236, 549-560.	2.0	12
1695	Pt(IV) complexes based on cyclohexanediamines and the histone deacetylase inhibitor 2-(2-propynyl)octanoic acid: synthesis, characterization, cell penetration properties and antitumor activity. <i>Dalton Transactions</i> , 2021, 50, 4663-4672.	1.6	11
1696	Integration of epigenomics and metabolomics: From biomarkers discovery to personalized medicine. , 2021, , 31-73.		3
1697	Recent advances in activity-based probes (ABPs) and affinity-based probes (AFBPs) for profiling of enzymes. <i>Chemical Science</i> , 2021, 12, 8288-8310.	3.7	75
1698	Parvovirus-Based Combinatorial Immunotherapy: A Reinforced Therapeutic Strategy against Poor-Prognosis Solid Cancers. <i>Cancers</i> , 2021, 13, 342.	1.7	15
1699	Borinostats: solid-phase synthesis of carborane-capped histone deacetylase inhibitors with a tailor-made selectivity profile. <i>Chemical Science</i> , 2021, 12, 11873-11881.	3.7	8
1700	Long Noncoding RNA LncPGCR Mediated by TCF7L2 Regulates Primordial Germ Cell Formation in Chickens. <i>Animals</i> , 2021, 11, 292.	1.0	4
1701	Epigenetic modulators combination with chemotherapy in breast cancer cells. <i>Cell Biochemistry and Function</i> , 2021, 39, 571-583.	1.4	2
1702	HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. <i>Oncogene</i> , 2021, 40, 1836-1850.	2.6	78
1703	Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies. <i>Cancers</i> , 2021, 13, 612.	1.7	6
1704	CUL4B Promotes Breast Carcinogenesis by Coordinating with Transcriptional Repressor Complexes in Response to Hypoxia Signaling Pathway. <i>Advanced Science</i> , 2021, 8, 2001515.	5.6	16

#	ARTICLE	IF	CITATIONS
1705	In Vivo Evaluation of the Combined Anticancer Effects of Cisplatin and SAHA in Nonsmall Cell Lung Carcinoma Using [18F]FAHA and [18F]FDG PET/CT Imaging. <i>Molecular Imaging</i> , 2021, 2021, 1-11.	0.7	3
1706	Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors. <i>SLAS Discovery</i> , 2021, 26, 628-641.	1.4	1
1707	Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2592.	1.8	9
1708	Do histone deacetylase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 665-673.	1.9	2
1709	Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents. <i>Bioorganic Chemistry</i> , 2021, 109, 104754.	2.0	4
1710	Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. <i>Journal of Biomedical Science</i> , 2021, 28, 27.	2.6	103
1711	Mechanistic Exploration of Methionine 274 Acting as a "Switch" of the Selective Pocket Involved in HDAC8 Inhibition: An in Silico Study. <i>ChemMedChem</i> , 2021, 16, 1933-1944.	1.6	3
1712	Engineered synthetic cell penetrating peptide with intracellular anti-inflammatory bioactivity: An in vitro and in vivo study. <i>Journal of Biomedical Materials Research - Part A</i> , 2021, 109, 2001-2016.	2.1	5
1713	P300/CBP-associated factor (PCAF) attenuated M1 macrophage inflammatory responses possibly through KLF2 and KLF4. <i>Immunology and Cell Biology</i> , 2021, 99, 724-736.	1.0	10
1714	Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 9587.	1.6	10
1715	Posttranslational Modifications of the Mineralocorticoid Receptor and Cardiovascular Aging. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 667990.	1.6	7
1716	Identification of potential histone deacetylase inhibitory biflavonoids from <i>Garcinia kola</i> (Guttiferae) using in silico protein-ligand interaction. <i>ChemistrySelect</i> , 2023, 8, 2127-2141.	0.7	1
1717	Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma. <i>European Journal of Medicinal Chemistry</i> , 2021, 217, 113338.	2.6	13
1718	Latency Reversing Agents: Kick and Kill of HTLV-1?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5545.	1.8	10
1719	Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPAR β and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6949-6971.	2.9	20
1720	Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 395-409.	1.1	3
1721	Risk of carcinogenesis in the biliary epithelium of children with congenital biliary dilatation through epigenetic and genetic regulation. <i>Surgery Today</i> , 2022, 52, 215-223.	0.7	5
1722	Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells. <i>Frontiers in Immunology</i> , 2021, 12, 690207.	2.2	13

#	ARTICLE	IF	CITATIONS
1723	Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7963-7990.	2.9	69
1724	Leveraging NKG2D Ligands in Immuno-Oncology. <i>Frontiers in Immunology</i> , 2021, 12, 713158.	2.2	56
1725	Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. <i>Life Sciences</i> , 2021, 277, 119504.	2.0	113
1726	A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. <i>Blood Advances</i> , 2021, 5, 2740-2750.	2.5	6
1727	Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 219, 113419.	2.6	8
1728	SNP rs4971059 predisposes to breast carcinogenesis and chemoresistance via TRIM46-mediated HDAC1 degradation. <i>EMBO Journal</i> , 2021, 40, e107974.	3.5	12
1729	Drug Discovery of Spinal Muscular Atrophy (SMA) from the Computational Perspective: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8962.	1.8	6
1730	Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy. <i>Chemical Reviews</i> , 2021, 121, 13454-13619.	23.0	657
1731	An <i>In-Silico</i> Approach to Evaluate the Inhibitory Potency of Selected Hydroxamic Acid Derivatives on Zinc-Dependent Histone Deacetylase Enzyme. <i>Journal of Computational Biophysics and Chemistry</i> , 2021, 20, 603-618.	1.0	6
1732	Comprehensive Analysis of HDAC Family Identifies HDAC1 as a Prognostic and Immune Infiltration Indicator and HDAC1-Related Signature for Prognosis in Glioma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 720020.	1.6	13
1733	A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors In Vitro and In Vivo. <i>Frontiers in Pharmacology</i> , 2021, 12, 741697.	1.6	7
1734	Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening. <i>Computers in Biology and Medicine</i> , 2021, 137, 104808.	3.9	22
1735	Double-edged Swords: Diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis. <i>Bioorganic Chemistry</i> , 2021, 116, 105350.	2.0	7
1736	Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1540-1554.	1.7	12
1737	HDAC2/3 inhibitor MI192 mitigates oligodendrocyte loss and reduces microglial activation upon injury: a potential role of epigenetics. <i>Open Veterinary Journal</i> , 2021, 11, 447.	0.3	0
1738	Aromatic side-chain flips orchestrate the conformational sampling of functional loops in human histone deacetylase 8. <i>Chemical Science</i> , 2021, 12, 9318-9327.	3.7	5
1743	Defective Apoptosis Underlies Chemoresistance in Ovarian Cancer. , 2008, 622, 197-208.		20
1744	The Cancer Degradome. , 2008, , .		17

#	ARTICLE	IF	CITATIONS
1745	The Future of Discoveries in Breast and Reproductive Cancers: The Genome and Epigenetics. , 2009, , 315-332.		1
1746	Combination Therapy for Cancer: Phototherapy and HDAC Inhibition. , 2014, , 445-470.		1
1747	Role of Epigenetics in Neural Differentiation: Implications for Health and Disease. , 2014, , 63-79.		2
1748	Use of Epigenetic Modulators as a Powerful Adjuvant for Breast Cancer Therapies. Methods in Molecular Biology, 2015, 1238, 487-509.	0.4	13
1749	The Cancer Epigenome. , 2008, , 97-113.		1
1750	Inhibition of Histone Deacetylases. Methods in Molecular Biology, 2011, 791, 297-311.	0.4	5
1751	Current Epigenetic Therapy for T-Cell Lymphoma. , 2013, , 279-296.		2
1752	Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 87-110.	0.1	1
1753	Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma. Current Cancer Research, 2017, , 313-345.	0.2	1
1754	Sirtuins. , 2011, , 3416-3418.		1
1755	Nuclear PI-PLC \hat{I}^21 and Myelodysplastic Syndromes: From Bench to Clinics. Current Topics in Microbiology and Immunology, 2012, 362, 235-245.	0.7	9
1756	Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy. European Journal of Medicinal Chemistry, 2020, 201, 112446.	2.6	22
1757	Chapter 10. The Design and Development of Polyamine-Based Analogs with Epigenetic Targets. RSC Drug Discovery Series, 2011, , 238-256.	0.2	1
1758	Podocyte histone deacetylase activity regulates murine and human glomerular diseases. Journal of Clinical Investigation, 2019, 129, 1295-1313.	3.9	42
1759	Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. Journal of Clinical Investigation, 2007, 117, 659-671.	3.9	308
1760	Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Journal of Clinical Oncology, 2009, 27, 3529-3529.	0.8	11
1761	Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection. PLoS ONE, 2009, 4, e6093.	1.1	222
1762	A Novel Histone Deacetylase Inhibitor Exhibits Antitumor Activity via Apoptosis Induction, F-Actin Disruption and Gene Acetylation in Lung Cancer. PLoS ONE, 2010, 5, e12417.	1.1	45

#	ARTICLE	IF	CITATIONS
1763	Pre-Clinical Drug Prioritization via Prognosis-Guided Genetic Interaction Networks. PLoS ONE, 2010, 5, e13937.	1.1	9
1764	Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors. PLoS ONE, 2010, 5, e14462.	1.1	63
1765	PRL-3, a Metastasis Associated Tyrosine Phosphatase, Is Involved in FLT3-ITD Signaling and Implicated in Anti-AML Therapy. PLoS ONE, 2011, 6, e19798.	1.1	59
1766	Mitochondrial Apoptosis and FAK Signaling Disruption by a Novel Histone Deacetylase Inhibitor, HTPB, in Antitumor and Antimetastatic Mouse Models. PLoS ONE, 2012, 7, e30240.	1.1	21
1767	Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer. PLoS ONE, 2012, 7, e52095.	1.1	41
1768	Distinct Functional and Temporal Requirements for Zebrafish Hdac1 during Neural Crest-Derived Craniofacial and Peripheral Neuron Development. PLoS ONE, 2013, 8, e63218.	1.1	44
1769	HDAC Up-Regulation in Early Colon Field Carcinogenesis Is Involved in Cell Tumorigenicity through Regulation of Chromatin Structure. PLoS ONE, 2013, 8, e64600.	1.1	114
1770	Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells. PLoS ONE, 2013, 8, e76662.	1.1	32
1771	Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51. PLoS ONE, 2013, 8, e79106.	1.1	76
1772	Mutagenesis Study Reveals the Rim of Catalytic Entry Site of HDAC4 and -5 as the Major Binding Surface of SMRT Corepressor. PLoS ONE, 2015, 10, e0132680.	1.1	6
1773	Effects of β -carotene on Expression of Selected MicroRNAs, Histone Acetylation, and DNA Methylation in Colon Cancer Stem Cells. Journal of Cancer Prevention, 2019, 24, 224-232.	0.8	36
1774	Histone Deacetylases and Cancer-Associated Angiogenesis: Current Understanding of the Biology and Clinical Perspectives. Critical Reviews in Oncogenesis, 2015, 20, 119-137.	0.2	18
1775	In vitro and in vivo anticancer studies of 2'-hydroxy chalcone derivatives exhibit apoptosis in colon cancer cells by HDAC inhibition and cell cycle arrest. EXCLI Journal, 2017, 16, 448-463.	0.5	21
1776	Deregulated expression of HDAC3 in colorectal cancer and its clinical significance. Advances in Clinical and Experimental Medicine, 2018, 27, 305-311.	0.6	33
1777	Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI. Tomography, 2019, 5, 53-60.	0.8	23
1778	Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging, 2010, 2, 659-668.	1.4	42
1779	Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget, 2016, 7, 57327-57350.	0.8	24
1780	Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells. Oncotarget, 2016, 7, 68768-68780.	0.8	6

#	ARTICLE	IF	CITATIONS
1781	Oxidative stress-induced epigenetic changes associated with malignant transformation of human kidney epithelial cells. <i>Oncotarget</i> , 2017, 8, 11127-11143.	0.8	59
1782	Extrachromosomal HPV-16 LCR transcriptional activation by HDACi opposed by cellular differentiation and DNA integration. <i>Oncotarget</i> , 2016, 7, 75526-75538.	0.8	3
1783	A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma. <i>Oncotarget</i> , 2017, 8, 9123-9133.	0.8	8
1784	A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis. <i>Oncotarget</i> , 2017, 8, 14748-14758.	0.8	14
1785	Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat. <i>Oncotarget</i> , 2017, 8, 56210-56227.	0.8	17
1786	Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. <i>Oncotarget</i> , 2017, 8, 56110-56125.	0.8	64
1787	Epigenetic plasticity: A central regulator of epithelial-to-mesenchymal transition in cancer. <i>Oncotarget</i> , 2014, 5, 2016-2029.	0.8	109
1788	Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy. <i>Oncotarget</i> , 2017, 8, 67891-67903.	0.8	4
1789	Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo. <i>Oncotarget</i> , 2017, 8, 70828-70840.	0.8	11
1790	Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6. <i>Oncotarget</i> , 2017, 8, 103087-103099.	0.8	16
1791	Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. <i>Oncotarget</i> , 2015, 6, 5735-5748.	0.8	16
1792	The histone deacetylase inhibitor SAHA induces HSP60 nitration and its extracellular release by exosomal vesicles in human lung-derived carcinoma cells. <i>Oncotarget</i> , 2016, 7, 28849-28867.	0.8	56
1793	Impact of negative lymph nodes on colon cancer survival and exploring relevant transcriptomics differences through real-world data analyses. <i>Annals of Translational Medicine</i> , 2019, 7, 525-525.	0.7	5
1794	Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics. <i>Current Medicinal Chemistry</i> , 2019, 26, 1328-1350.	1.2	13
1795	Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. <i>Current Medicinal Chemistry</i> , 2020, 27, 2449-2493.	1.2	85
1796	HDAC as a Therapeutic Target for Treatment of Endometrial Cancers. <i>Current Pharmaceutical Design</i> , 2014, 20, 1847-1856.	0.9	22
1797	Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2015, 18, 693-700.	0.6	4
1798	Molecular Modeling Used to Evaluate CYP2C9-Dependent Metabolism: Homology Modeling, Molecular Dynamics and Docking Simulations. <i>Current Drug Metabolism</i> , 2011, 12, 533-548.	0.7	8

#	ARTICLE	IF	CITATIONS
1799	Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions. <i>Current Cancer Drug Targets</i> , 2019, 19, 368-381.	0.8	9
1800	Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives. <i>Current Cancer Therapy Reviews</i> , 2013, 9, 97-110.	0.2	10
1801	Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies. <i>Current Computer-Aided Drug Design</i> , 2019, 15, 145-166.	0.8	8
1802	1,3,5-Triazine Analogs: A Potent Anticancer Scaffold. <i>Current Signal Transduction Therapy</i> , 2019, 14, 87-106.	0.3	8
1803	Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2007, 2, 119-134.	0.8	51
1804	Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 223-232.	0.9	23
1805	Three Amino Acid Derivatives of Valproic Acid: Design, Synthesis, Theoretical and Experimental Evaluation as Anticancer Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 984-993.	0.9	5
1806	HDAC2 Cytoplasmic Sequestration Potentiates Keratinocyte Terminal Differentiation. <i>The Open Cell Development & Biology Journal</i> , 2008, 1, 1-9.	1.0	3
1807	SETDB1 in Early Embryos and Embryonic Stem Cells. <i>Current Issues in Molecular Biology</i> , 2015, , .	1.0	10
1808	The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment. <i>Future Oncology</i> , 2020, 16, 2457-2469.	1.1	15
1809	Zinc-Containing Metalloenzymes: Inhibition by Metal-Based Anticancer Agents. <i>Frontiers in Chemistry</i> , 2020, 8, 402.	1.8	29
1810	Protein acetylation and deacetylation: An important regulatory modification in gene transcription (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 2923-2940.	0.8	46
1811	Therapeutic integration of new molecule-targeted therapies with radiotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 89-94.	1.3	16
1812	Vorinostat-An overview. <i>Indian Journal of Dermatology</i> , 2015, 60, 419.	0.1	83
1813	In vitro cytotoxic activities and molecular mechanisms of angelica shikokiana extract and its isolated compounds. <i>Pharmacognosy Magazine</i> , 2015, 11, 564.	0.3	16
1814	Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers. <i>Advanced Biomedical Research</i> , 2019, 8, 63.	0.2	84
1815	Histones: Controlling Tumor Signaling Circuitry. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2013, 1, 1-12.	0.3	18
1816	Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 473.	0.8	25

#	ARTICLE	IF	CITATIONS
1817	Histone modifications: Targeting head and neck cancer stem cells. <i>World Journal of Stem Cells</i> , 2014, 6, 511.	1.3	31
1818	Deacetylase inhibitors - focus on non-histone targets and effects. <i>World Journal of Biological Chemistry</i> , 2010, 1, 55.	1.7	55
1819	Synthesis and Biological Evaluation of N-(Aminopyridine) Benzamide Analogues as Histone Deacetylase Inhibitors. <i>Bulletin of the Korean Chemical Society</i> , 2012, 33, 535-540.	1.0	5
1820	Cap-Modified Hydroxamate Analogues as Histone Deacetylases Inhibitors and Antitumor Agents. <i>Bulletin of the Korean Chemical Society</i> , 2014, 35, 129-134.	1.0	1
1821	Analysis of the Hox epigenetic code. <i>World Journal of Clinical Oncology</i> , 2012, 3, 48.	0.9	3
1822	Enhanced Cisplatin Response with Histone Acetyl Transferase Inhibitor, Anacardic Acid, in Malignant Pleural Mesothelioma Cell Line. <i>Turkiye Klinikleri Journal of Medical Sciences</i> , 2013, 33, 478-484.	0.1	1
1824	Selection of an improved HDAC8 inhibitor through structure-based drug design. <i>Bioinformation</i> , 2011, 7, 134-141.	0.2	18
1825	Molecular Mechanism of SAHA on Regulation of Autophagic Cell Death in Tamoxifen-Resistant MCF-7 Breast Cancer Cells. <i>International Journal of Medical Sciences</i> , 2012, 9, 881-893.	1.1	105
1826	PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma. <i>Journal of Cancer Therapeutics & Research</i> , 2013, 2, 21.	1.2	25
1827	HDAC inhibitors: applications in oncology and beyond. <i>HOAJ Biology</i> , 2013, 2, 1.	1.0	11
1828	Transport performance of coupled Brownian particles in rough ratchet. <i>Wuli Xuebao/Acta Physica Sinica</i> , 2019, 68, 240501.	0.2	4
1829	Optimization and Development of Selective Histone Deacetylase Inhibitor (MPT0B291)-Loaded Albumin Nanoparticles for Anticancer Therapy. <i>Pharmaceutics</i> , 2021, 13, 1728.	2.0	8
1830	The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?. <i>Frontiers in Oncology</i> , 2021, 11, 745187.	1.3	33
1831	The gold complex auranofin: new perspectives for cancer therapy. <i>Discover Oncology</i> , 2021, 12, 42.	0.8	48
1832	Can Post-Transcription Modifiers Change the Course of Prostate Cancer?. <i>Translational Medicine Series</i> , 2006, , 179-194.	0.0	0
1834	Histone Deacetylase Inhibitors in Multiple Myeloma. , 2008, , 379-392.		0
1835	Histone Deacetylase Inhibitors in Cancer Therapy. , 2008, , 381-398.		0
1836	Clinical Trials and Approved Drugs for Epigenetic Cancer Therapy. , 2008, , 415-425.		0

#	ARTICLE	IF	CITATIONS
1837	Proteins That Alter Histone Modifications in Cancer. , 2008, , 181-195.		0
1838	Blockade of mTOR Signaling Potentiates the Ability of Histone Deacetylase Inhibitor to Induce Growth Arrest and Differentiation of Acute Myelogenous Leukemia Cells.. Blood, 2008, 112, 1612-1612.	0.6	0
1839	Molecular Biology and Genetics of Cancer. , 2009, , 27-36.		0
1840	Contributions of Tumor Suppressors to the Epigenetic Regulation of Aging Cells. , 2010, , 227-255.		0
1841	Small Molecules as Versatile Tools for Activity-Based Protein Profiling Experiments. , 2010, , 603-639.		0
1842	New Agents for Patients with Hodgkin Lymphoma. , 2011, , 283-294.		0
1843	Viral Hepatitis B. Molecular Pathology Library, 2011, , 553-567.	0.1	0
1844	Transcriptional Modulation Using Histone Deacetylase Inhibitors for Cancer Immunotherapy. , 2011, , 307-322.		0
1845	Cancer Stem Cells in Ovarian Cancer. , 2011, , 151-176.		0
1846	Histone Deacetylases. , 2011, , 1698-1702.		0
1848	Epigenetic Therapy. , 2011, , 1287-1290.		0
1852	Epstein-Barr Virus-Associated Classical Hodgkin Lymphoma and Its Therapeutic Strategies. Biomolecules and Therapeutics, 2011, 19, 398-410.	1.1	0
1853	Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma. , 2012, , 87-108.		0
1854	Epigenetic Biomarkers in Melanoma. , 2012, , 89-112.		0
1855	The PI3K/PKB Signaling Module in Normal and Malignant Hematopoiesis. , 0, ,		0
1856	Hodgkin Lymphoma: From Molecular Pathogenesis to Targeted Therapy. , 2012, , 181-202.		0
1858	Epigenetic Regulation of Myeloma Within Its Bone Marrow Microenvironment. , 2013, , 255-282.		0
1859	Estado del arte: tumores de cresta neural, neuroblastoma fisiopatologÃa, diagnÃstico y tratamiento. Revista Med, 2012, 20, 38.	0.1	1

#	ARTICLE	IF	CITATIONS
1860	Pharmaco-epigenomics. , 2013, , 63-75.		0
1861	Hydroxamic Acid Derivatives as Potential Anticancer Agents. , 2013, , 173-204.		0
1862	Genetic and Epigenetic Basis of Myocardial Ischemia and Reperfusion Injury. , 2013, , 35-60.		0
1863	Therapeutic Significance of Chromatin Remodeling Complexes in Cancer. Cancer Drug Discovery and Development, 2014, , 399-422.	0.2	0
1864	New Developments in Targeted Analysis of Protein Posttranslational Modifications. Current Proteomics, 2013, 10, 98-119.	0.1	0
1865	The Fundamental Role of Epigenetic Regulation in Normal and Disturbed Cell Growth, Differentiation, and Stemness. , 2014, , 1-41.		0
1866	Epigenetics in Castration Resistant Prostate Cancer. Current Clinical Urology, 2014, , 277-295.	0.0	1
1870	A Novel SAHA-Bendamustine Hybrid Induces Apoptosis of Leukemia Cells. Blood, 2014, 124, 2227-2227.	0.6	0
1871	Epigenetic Therapy. , 2015, , 1-5.		0
1872	Epigenetic Therapy. , 2015, , 1581-1585.		0
1873	Mass Spectrometry for the Identification of Posttranslational Modifications in Histones and Its Application in Clinical Epigenetics. , 2016, , 195-214.		1
1875	Small Molecule Inhibitors. , 2017, , 771-795.		2
1876	Potential therapeutic effect of epigenetic therapy on treatment-induced neuroendocrine prostate cancer. Asian Journal of Andrology, 2017, 19, 686.	0.8	3
1878	HAT-HDAC System in Asthma. Translational Bioinformatics, 2018, , 243-275.	0.0	0
1879	Energy conversion efficiency of feedback pulsing ratchet. Wuli Xuebao/Acta Physica Sinica, 2018, 67, 190501.	0.2	3
1880	Histon-Deacetylase. , 2018, , 1-1.		0
1881	Implications of the HDAC6-ERK1 feed forward loop in immunotherapy. Journal of Immunological Sciences, 2018, 2, 59-68.	0.5	2
1882	Emerging Epigenetic Targets and Their Implications in Cancer Therapy. , 2019, , 157-188.		0

#	ARTICLE	IF	CITATIONS
1883	Histon-Deacetylase. Springer Reference Medizin, 2019, , 1121-1122.	0.0	0
1886	Searching for Potential HDAC2 Inhibitors: Structure-activity Relationship Studies on Indole-based Hydroxamic Acids as an Anticancer Agent. Letters in Drug Design and Discovery, 2020, 17, 905-917.	0.4	5
1888	Î ² -Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies. Bioorganic Chemistry, 2021, 117, 105461.	2.0	13
1889	Genome-wide identification, classification, and expression analysis of the JmjC domain-containing histone demethylase gene family in birch. BMC Genomics, 2021, 22, 772.	1.2	10
1891	Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors. European Journal of Medicinal Chemistry, 2022, 227, 113893.	2.6	13
1892	Intranasal curcumin and sodium butyrate modulates airway inflammation and fibrosis via HDAC inhibition in allergic asthma. Cytokine, 2022, 149, 155720.	1.4	24
1893	Transcriptional and epigenetic regulatory mechanisms in glioblastoma stem cells. , 2020, , 231-255.		1
1894	Chronic respiratory diseases: An introduction and need for novel drug delivery approaches. , 2020, , 1-31.		10
1895	3D-QSAR Research and Molecular Design of Coumarin Benzamide Histone Deacetylase Inhibitor Based on omoper CoMFA Method. Journal of Advances in Physical Chemistry, 2020, 09, 38-50.	0.1	0
1896	Combination Cancer Chemoprevention by Targeting the Epigenome. , 2020, , 577-612.		1
1897	Strong Involvement of Classical Histone Deacetylases and Mechanistically Distinct Sirtuins in Bellicose Cancers. , 2020, , 75-95.		2
1898	Apoptosis Activation in Thyroid Cancer Cells by Jatrorrhizine-Platinum(II) Complex via Downregulation of PI3K/AKT/Mammalian Target of Rapamycin (mTOR) Pathway. Medical Science Monitor, 2020, 26, e922518.	0.5	5
1899	Do Histone Deacetylase Inhibitors Target Cell Cycle Checkpoints that Monitor Heterochromatin Structure?. , 2008, , 291-309.		0
1900	Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 2114-2124.	0.9	4
1901	Activity-Based Imaging and Biochemical Profiling Tools for Analysis of the Cancer Degradome. , 0, , 101-135.		2
1902	Histone deacetylase inhibitors as novel anticancer therapeutics. Current Oncology, 2008, 15, 237-43.	0.9	63
1905	Gene expression patterns in myelodysplasia underline the role of apoptosis and differentiation in disease initiation and progression. Translational Oncogenomics, 2008, 3, 137-49.	1.7	13
1906	Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. American Journal of Translational Research (discontinued), 2011, 3, 166-79.	0.0	291

#	ARTICLE	IF	CITATIONS
1907	Potential non-oncological applications of histone deacetylase inhibitors. American Journal of Translational Research (discontinued), 2011, 3, 454-67.	0.0	18
1908	An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis. American Journal of Translational Research (discontinued), 2012, 4, 24-43.	0.0	14
1909	RNAi screening identifies KAT8 as a key molecule important for cancer cell survival. International Journal of Clinical and Experimental Pathology, 2013, 6, 870-7.	0.5	9
1911	A Functional Proteomics Perspective of DBC1 as a Regulator of Transcription. Journal of Proteomics and Bioinformatics, 2013, Suppl 2, .	0.4	14
1913	New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Current Pharmaceutical Design, 2013, 19, 734-44.	0.9	23
1916	Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma. Annals of Translational Medicine, 2016, 4, 50.	0.7	8
1917	Molecular basis of differentiation therapy for soft tissue sarcomas. Trends in Cancer Research, 2010, 6, 69-90.	1.6	6
1919	Histone deacetylase inhibitory and cytotoxic activities of the constituents from the roots of three species of. Iranian Journal of Basic Medical Sciences, 2019, 22, 93-98.	1.0	3
1920	Effect of Sodium Butyrate on mRNA Expression as a Transcription Factor of HDAC8 in Human Colorectal Cancer Cell Lines. Avicenna Journal of Medical Biotechnology, 2019, 11, 317-324.	0.2	5
1921	Effect of sodium butyrate on HDAC8 mRNA expression in colorectal cancer cell lines and molecular docking study of LHX1 - sodium butyrate interaction. EXCLI Journal, 2020, 19, 1038-1051.	0.5	1
1922	Promoter Demethylation Upregulates STEAP1 Gene Expression in Human Prostate Cancer: In Vitro and In Silico Analysis. Life, 2021, 11, 1251.	1.1	5
1923	From natural products to HDAC inhibitors: An overview of drug discovery and design strategy. Bioorganic and Medicinal Chemistry, 2021, 52, 116510.	1.4	21
1924	Glycocalyx mechanotransduction mechanisms are involved in renal cancer metastasis. Matrix Biology Plus, 2022, 13, 100100.	1.9	5
1925	Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 810387.	1.3	7
1926	LEAD IDENTIFICATION OF HYDROXAMATE DERIVATIVE AS SELECTIVE HDAC2 INHIBITOR USING COMPUTATIONAL APPROACHES. Indian Drugs, 2020, 57, 26-39.	0.1	0
1927	Evaluation of histone deacetylase inhibitor substituted zinc and indium phthalocyanines for chemo- and photodynamic therapy. RSC Advances, 2021, 11, 34963-34978.	1.7	5
1928	c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation. Cancers, 2022, 14, 457.	1.7	6
1929	Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?. International Journal of Molecular Sciences, 2022, 23, 546.	1.8	16

#	ARTICLE	IF	CITATIONS
1930	Diverse Roles of F-BoxProtein3 in Regulation of Various Cellular Functions. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 802204.	1.8	4
1931	Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors. <i>Clinical and Translational Oncology</i> , 2022, 24, 1262-1273.	1.2	12
1932	Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188676.	3.3	7
1933	Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, 835103.	2.2	5
1934	Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 422.	7.1	57
1935	A fluorogenic probe targeting two spatially separated enzymes for selective imaging of cancer cells. <i>Chemical Communications</i> , 2022, 58, 4079-4082.	2.2	3
1936	SMARCA2 deficiency in NSCLC: a clinicopathologic and immunohistochemical analysis of a large series from a single institution. <i>Environmental Health and Preventive Medicine</i> , 2022, 27, 3-3.	1.4	2
1937	ROS Modulatory Role of HDAC Inhibitors in Cancer Cells. , 2022, , 1-28.		1
1938	Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5149-5183.	2.9	28
1939	Identifying the Potential Role and Prognostic Value of the Platelet-Derived Growth Factor Pathway in Kidney Renal Clear Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	0
1940	Discovery of Potent and Isoformâ€selective Histone Deacetylase Inhibitors Using Structureâ€based Virtual Screening and Biological Evaluation. <i>Molecular Informatics</i> , 2022, , 2100295.	1.4	3
1941	Enhanced Cytotoxic Effects in Human Oral Squamous Cell Carcinoma Cells Treated with Combined Methyltransferase Inhibitors and Histone Deacetylase Inhibitors. <i>Biomedicines</i> , 2022, 10, 763.	1.4	3
1942	The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells. <i>Frontiers in Oncology</i> , 2022, 12, 855570.	1.3	1
1943	Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer. <i>Cancer Cell International</i> , 2022, 22, 160.	1.8	1
1963	Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse. <i>Heredity</i> , 2022, 129, 64-74.	1.2	4
1966	Histone Acetylation Defects in Brain Precursor Cells: A Potential Pathogenic Mechanism Causing Proliferation and Differentiation Dysfunctions in Mitochondrial Aspartate-Glutamate Carrier Isoform 1 Deficiency. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 773709.	1.8	0
1968	Recent Advances in Epigenetics of Age-Related Kidney Diseases. <i>Genes</i> , 2022, 13, 796.	1.0	6
1969	Histone Modification on Parathyroid Tumors: A Review of Epigenetics. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5378.	1.8	3

#	ARTICLE	IF	CITATIONS
1970	Targeting EZH2 for cancer therapy: From current progress to novel strategies. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114419.	2.6	33
1971	High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
1972	Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	10
1973	Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis. , 2022, 13, 773.		9
1974	Histone Deacetylase Inhibitory Activity and Antiproliferative Potential of New [6]-Shogaol Derivatives. <i>Molecules</i> , 2022, 27, 3332.	1.7	4
1976	Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines. <i>International Journal of Oncology</i> , 2022, 61, .	1.4	3
1978	Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	76
1979	RGS10 suppression by DNA methylation is associated with low survival rates in colorectal carcinoma. <i>Pathology Research and Practice</i> , 2022, 236, 154007.	1.0	8
1980	Integrative genome-wide chromatin accessibility and transcriptome profiling of diffuse large B-cell lymphoma. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	0
1981	Transcriptional Repression of Aerobic Glycolysis by OVOL2 in Breast Cancer. <i>Advanced Science</i> , 2022, 9, .	5.6	6
1983	An Epigenetic Role of Mitochondria in Cancer. <i>Cells</i> , 2022, 11, 2518.	1.8	57
1984	Porcine Deltacoronavirus Infection Cleaves HDAC2 to Attenuate Its Antiviral Activity. <i>Journal of Virology</i> , 2022, 96, .	1.5	6
1985	Polypharmacology in Clinical Applicationsâ€”Anticancer Polypharmacology. , 2022, , 73-132.		0
1986	Role of histone deacetylase CsHDA8 in regulating the accumulation of indole during the oolong tea manufacturing process. <i>Beverage Plant Research</i> , 2022, 2, 1-9.	0.6	1
1987	ROS Modulatory Role of HDAC Inhibitors in Cancer Cells. , 2022, , 3259-3286.		2
1988	Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	9
1989	Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis. <i>European Journal of Medicinal Chemistry</i> , 2022, 243, 114705.	2.6	5
1990	Evaluation of Small-Molecule HDAC Inhibitors Through In Vitro and In Cellulo Approaches. <i>Methods in Molecular Biology</i> , 2023, , 157-177.	0.4	0

#	ARTICLE	IF	CITATIONS
1991	Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy. <i>Hematological Oncology</i> , 2023, 41, 301-309.	0.8	5
1992	Novel bioactive hybrid Celecoxib-HDAC Inhibitor, induces apoptosis in human acute lymphoblastic leukemia cells. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 75, 117085.	1.4	3
1994	The role of histone deacetylases in embryonic development. <i>Molecular Reproduction and Development</i> , 2023, 90, 14-26.	1.0	2
1995	Azumamides A-E: Isolation, Synthesis, Biological Activity, and Structure-Activity Relationship. <i>Molecules</i> , 2022, 27, 8438.	1.7	2
1996	Switching the Mode of Cell Death between Apoptosis and Autophagy by Histone Deacetylase 6 Inhibition Levels. <i>ChemMedChem</i> , 2023, 18, .	1.6	2
1997	Rationally designed donepezil-based hydroxamates modulate Sig-1R and HDAC isoforms to exert anti-glioblastoma effects. <i>European Journal of Medicinal Chemistry</i> , 2023, 248, 115054.	2.6	3
1998	Epigenetic mechanisms in cardiovascular diseases. , 2023, , 393-421.		0
1999	YF343, A Novel Histone Deacetylase Inhibitor, Combined with CQ to Inhibit- Autophagy, Contributes to Increased Apoptosis in Triple- Negative Breast Cancer. <i>Current Medicinal Chemistry</i> , 2023, 30, 4605-4621.	1.2	1
2000	Inhibitory effect of parthenolide on peripheral nerve degeneration. <i>Anatomical Science International</i> , 0, , .	0.5	0
2001	Acetylation stabilizes the signaling protein WISP2 by preventing its degradation to suppress the progression of acute myeloid leukemia. <i>Journal of Biological Chemistry</i> , 2023, 299, 102971.	1.6	0
2003	HDACs as an emerging target in endocrine tumors: a comprehensive review. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 143-154.	1.2	1
2004	Current and emerging therapeutic strategies in adult T-cell leukemia-lymphoma. <i>International Journal of Hematology</i> , 2023, 117, 512-522.	0.7	6
2006	Disruption of mitochondrial oxidative phosphorylation by chidamide eradicates leukemic cells in AML. <i>Clinical and Translational Oncology</i> , 2023, 25, 1805-1820.	1.2	1
2007	FOXO signaling pathway participates in oxidative stress-induced histone deacetylation. <i>Free Radical Research</i> , 2023, 57, 47-60.	1.5	1
2008	Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from <i>l</i> -elemene scaffold. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2023, 38, .	2.5	2
2009	Design, Synthesis, and Biological Evaluation of Histone Deacetylase Inhibitors Derived from Erianin and Its Derivatives. <i>ChemMedChem</i> , 2023, 18, .	1.6	1
2010	Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic. <i>Aging</i> , 2023, 15, 2373-2394.	1.4	4
2013	Targeting Proteins in Nucleus through Dual-Regulatory Pathways Acting in Cytoplasm. <i>Nano Letters</i> , 2023, 23, 5811-5821.	4.5	0

#	ARTICLE	IF	CITATIONS
2029	Histone deacetylases and other epigenetic targets. , 2024, , 265-281.		0